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Obesity has become one of the major health problems worldwide, due to modern 
eating habits and an increase in sedentary lifestyles. Dietary strategies represent one 
among different therapeutic approaches employed to ameliorate, treat or prevent the 
obesity epidemic. 
In this thesis, we focused on bovine whey protein, selected for their ability to influence 
energy balance, satiety hormones production and glucose tolerance. In particular, 
using male C57BL/6 mice fed with high-fat diet (HFD), we investigated the effect of 
whey protein isolate (WPI) and the whey protein component alpha-lactalbumin (LAB) 
on body weight, adipose tissue, intestinal-related functions and gut microbiota. 
LAB given with HFD increased energy intake without affecting body weight. We 
observed that this energy mismatch was, in part, due to a change in the gene expression 
of nutrient transporters within the small intestine. This was accompanied by an 
increase in relative abundance of Parabacteroides, Bifidobacterium, Parvibacter and 
Lactobacillus in the gut. 
We next investigated the effect of HFD supplemented with WPI given at two different 
ages and with different WPI intake durations. We observed that, only in younger mice, 
WPI decreased body weight and adiposity, which might be caused by an increase of 
adipose tissue catabolism. In addition, the gut microbiota of younger mice fed with 
HFD-WPI showed a different gut microbiota composition, including an increased 
relative abundance of Lactobacillus murinus. 
In another experiment, we observed that, even during microbiota depletion, WPI still 
caused a decrease in HFD-induced body weight gain, adiposity and tissues 
inflammation. On the contrary, the beneficial effect of WPI on HFD-induced gut 
permeability disruption is abolished during gut microbiota depletion. 
 
Overall, these results provide novel insight on the effects of whey protein on energy 











According to the most recent World Health Organization (WHO) estimation, 1.9 
billion adults (over 18) worldwide were overweight, of which nearly 600 million were 
obese (WHO 2016). Obesity is a multifactorial condition which primarily arises as a 
result of a long-term positive energy balance, whereby the energy extracted from the 
food consumed is greater than what is used by the body. This leads to an increase of 
adipose tissue mass and, consequently, weight gain. Importantly, obesity leads to a 
chronic low-grade inflammation and insulin resistance. For these reasons, obesity can 
be also considered as a metabolic disease.  As such, it is considered as one of the major 
health problems in the world because it increases the risk of development of several 
clinical conditions, including cardiovascular disease, stroke, hypertension, 
steatohepatitis, type 2 diabetes and different kind of cancers such as colon-rectal, 
breast, pancreas, liver, gallbladder and gastric (Calle & Kaaks 2004, O'Neill & 
O'Driscoll 2015).  
During the last 25-30 years, the incidence of obesity has risen dramatically (WHO 
2016). While there are many reasons for this, there is a growing recognition that the 
main driver of obesity is the change in our dietary habits, which have impacted on our 
ability to regulate the balance between energy intake and energy expenditure. Notably, 
in the last century, there has been a growing trend towards an increased intake of high 
energy diets coupled with an increasingly sedentary lifestyle. Alongside this, obesity 
is characterized by deregulation of the production or action of many hormones, some 
produced by the gut and others by internal organs such as the adipose tissue (e.g., 
leptin). This, coupled with increased tissue growth (including the intestine) and altered 
intestinal nutrient absorption, affects the gut-hypothalamic-adipose cross-talk in the 
control of appetite and energy balance regulation (Klok et al 2007). In the last few 
years, it was shown that the composition, diversity and the functions of the gut 
microbiota can also play important roles in the aetiology of obesity (Cani 2013, Clarke 
et al 2012, Torres-Fuentes et al 2017). Despite continuous medical and scientific 
effort, long-term strategies aimed at attenuating or reversing the obesity epidemic are 
still to be developed. Hence, there is a growing interest to identify safe therapies, in 
particular those involving nutrients, such as proteins, which can reduce weight gain 
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and prevent the development of obesity or help already obese people to lose weight 
and sustain this effect long term. 
 
In the following sections, I will provide an overview of the structure and functions of 
the above named key tissues important for energy balance regulation, the role of gut 
microbiota, and how each of these are affected during the progression of weight gain 
towards and/or following development of obesity. In this regard, the focus would be 
on the impact of high-fat diet (HFD). In the final part of the introduction, I will provide 
the background to a potential dietary solution tested in this thesis with a view to the 
management of HFD-induced weight gain (rather than weight loss), namely whey 
protein, which is a dietary protein sourced from milk. Ultimately, I will highlight 
unanswered questions that formed the basis for undertaking the project. In essence, 
the research project uses mouse models to better understand the impact of whey 
protein on the gut environment including the microbiota, and their influence on energy 
balance with specific reference to changes in adipose tissue and the hypothalamus. 
 
 
1.1 Energy balance homeostasis: organs and hormones 
involved  
Energy balance is defined as the difference between energy absorbed by the intestine 
following ingestion of food (assimilated energy) and energy used by the body tissues 
to carry out any kind of activity. The main factors that influence energy balance are, 
indeed, energy intake, intestinal energy absorption, energy expenditure and energy 
storage. Through the routinely consumption of macronutrients (such as fats, 
carbohydrates and proteins), the mammalian body gets energy that serves as fuel to 
execute all the processes that maintain the body alive. For instance, the energy from 
food is consumed by metabolic activities, including the resting metabolic rate (RMR), 
thermogenesis and physical activity (Hill et al 2012). RMR is the largest component 
of energy spent daily, accounting for 60% of daily energy expenditure in humans. It 
corresponds to energy expended by the body during a rest condition, in order to 
maintain vital organ functions and for thermogenesis. Thermogenesis is the autonomic 
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process that uses energy to produce and release heat (McMurray et al 2014, 
Rosenbaum & Leibel 2010). Under the influence of environmental and dietary factors, 
energy intake, intestinal energy absorption, energy expenditure and energy storage 
fluctuate and change dynamically, resulting in positive or negative energy balance, 
and where they match, energy homeostasis is achieved. A situation of positive energy 
balance derives from an energy intake and assimilation that surpasses the energy 
requirements of physical and physiological energy expenditures. The excess of energy 
is deposited within the body fat, which is the primary energy store in humans (and 
other mammals) and, consequently, the body weight and body fat mass of the 
individual increase. Conversely, a negative energy balance comes from an excess of 
energy expenditure over intake or following a reduction in intake below basal energy 
requirements such as during food deprivation or restriction, leading to body weight 
loss (Hill et al 2013). A long-term disruption of energy homeostasis leads to the 
development of chronic disorders including obesity (long-term positive energy 
balance) but also anorexia and undernutrition (long-term negative energy balance) 
(Kurpad et al 2007, Uauy & Diaz 2005). A practical way to determine energy balance 
dynamics both in humans and rodents involves carrying out different metabolic 
measurements. For rodents, a special cage equipped with several chambers and 
analysers, called metabolic cage, is widely used. Some important metabolic 
parameters detected are: oxygen consumption (VO2) carbon dioxide production 
(VCO2), respiratory exchange ratio (RER, VCO2/VO2) and locomotor activity 
(Speakman 2013). 
 
To impede energy imbalance and its consequences, there are some strategies that the 
organism adopts. The most important one is the control of satiety, defined as the 
physiological state at the end of a meal when further eating is inhibited by 
‘fullness’(Amin & Mercer 2016). In this context, there exists a fine regulation of 
hunger and fullness state based on energy availability of the individual. This is brought 
about by organs cooperating and communicating within each other to maintain energy 
homeostasis. The protagonist organs in this process are: gastrointestinal tract (GIT), 
adipose tissue and the brain, followed by liver, pancreas and skeletal muscle 
(Boguszewski & van der Lely 2014, Roh et al 2016). They establish a crosstalk with 
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each other through the production of hormones and neuropeptides and, consequently, 
act through specific receptors expressed on the cellular surface. These receptors 
activate a specific cascade of regulation in response to molecules produced by other 
organs. 
 
1.1.1 Brain and hypothalamic control of energy balance  
In general, energy balance-related hormones produced in the periphery communicate 
with the brain through a variety of mechanisms; most notably by the activation of 
receptors on the vagus nerve and by directly activating brain circuits, especially in the 
hypothalamus where there is a relatively permeable blood brain barrier (BBB) 
(Owyang & Heldsinger 2011). Once in the brain, the satiety-related hormones 
stimulate a specific area of the hypothalamus, the arcuate nucleus (ARC). Notably, the 
ARC neurons are in close proximity to the circulatory system, and thus can sense not 
only levels of hormones but also nutrients and thereby coordinates hunger and fullness. 
The neurons in the ARC are orexigenic (appetite-increasing) or anorexigenic 
(appetite-decreasing). Under peripheric satiety hormonal stimulation, ARC neurons 
produce other neuro-hormones, such as the orexigenic neuropeptide Y (NPY) and 
agouti-related peptide (AgrP), and the anorexigenic pro-opiomelanocortin (POMC) 
and cocaine- and amphetamine- regulated transcript (CART) (Fig. 1.1). POMC is the 
precursor of all melanocortin peptides, including α-melanocortin stimulating hormone 
(α-MSH), one of the most important mediators of the catabolic response. To exert its 
function, α-MSH binds the hypothalamic melanocortin receptors 3 and 4 (MC3/4R) 
(Shimizu et al 2007). In turn, the hormones produced by ARC stimulate other 
hypothalamic areas (such as paraventricular nucleus and lateral hypothalamus) and 
higher centers (such as amygdala, limbic system and cerebral cortex) in order to 
control feeding behavior (Camilleri 2015). Specifically, second order neurons are 
activated and, via sympathetic neurons, directly control catabolic and anabolic 
reactions in the peripheral tissues (Roh & Kim 2016). In summary, in the CNS, 
multiple inputs from the periphery are integrated and, as a response, outputs are 
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elaborated and directed back to the periphery. This process regulates energy intake 
and energy expenditure in order to maintain energy homeostasis. 
 
 
Figure 1.1 Neuroendocrine control of food intake. Role of the hypothalamic arcuate nucleus 
in regulating food intake. Leptin and insulin circulate in the blood at concentrations 
proportional to body fat mass. They decrease appetite by inhibiting neurons that produce the 
molecules NPY and AgRP, at the same time stimulating α-MSH (POMC) and CART neurons 
in the arcuate nucleus. NPY and AgRP stimulate eating, and α-MSH inhibits eating, via other 
neurons (top). Activation of NPY/AgRP-expressing neurons inhibits POMC neurons, either 
directly through NPY receptors or by AgRP blocking the effects of α-MSH. The hormone 
ghrelin stimulates appetite by activating the NPY/AgRP-expressing neurons. PYY3-36 and 
GLP-1, released from the small intestine, inhibit these neurons, and thereby decrease appetite. 
Abbreviations: AgRP, agouti-related peptide; CART, cocaine- and amphetamine-regulated 
transcript; CCK, cholecystokinin; GI, gastrointestinal; GLP-1, glucagon-like peptide-1; 
MSH, melanocyte-stimulating hormone; NPY, neuropeptide Y; POMC, proopiomelanocortin; 




1.1.2 Small intestinal morphology and nutrient absorption  
The gastrointestinal tract (GIT) is responsible for the ingestion and digestion of foods 
and liquids and, subsequently, for the absorption of nutrients important for individual 
survival. Food digestion starts in the mouth, continues in the stomach, and concludes 
in the small intestine. 
 
The small intestine is the portion of the GIT where nutrient absorption primarily 
occurs. The small intestine is divided into duodenum, jejunum and ileum, forming, 
respectively, the proximal (just after the stomach), central and distal parts (before the 
colon). The duodenum receives chyme from the stomach and contributes to digestion 
by the action of pancreatic enzymes and bile acids from the liver. The jejunum and 
ileum are the regions in which the absorption of nutrients (i.e., fats, amino acids, 
sugars, vitamins and minerals) mainly occurs (Collins & Badireddy 2020). The 
intestinal epithelium contains a large variety of transporters (active and passive) that 
are responsible for the translocation of the nutrients into the bloodstream (Kiela & 
Ghishan 2016). The density of these transporters changes across the small intestine 
(Spiller 1994), reflecting the diverse nutrient absorptive capacities of the intestinal 
regions. 
 
This intestinal tract is composed of three layers. The external layer, serosa, is constitute 
mainly by mesothelium and endothelium. The middle layer, muscularized, consists of 
two smooth muscle layers, a thin outer longitudinal layer that shortens and elongates 
the gut, and a thicker inner circular layer of smooth muscle which causes constriction 
(Collins et al 2020). Nerves belonging to the enteric nervous system (ENS) are located 
between the two muscle layers (Nezami & Srinivasan 2010). The inner layer, divided 
into submucosa and mucosa, is composed by innervated connective tissue irrorate by 
blood vessels and, on the lumen side, it accommodates different cell types: 
 
- Enterocytes: cells organized in a monolayer that forms a polarized epithelium. 
Their plasma membrane is characterized by basal, lateral and apical domain. 
Microvilli with a brush border appearance protrude from the apical domain and 
facilitate nutrient absorption. The enterocytes plasma membrane is equipped 
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with different enzymes and transporter proteins that control metabolism, 
absorption and/or secretion of nutrients, metabolites and electrolytes (Overeem 
et al 2016). A comprehensive list and description of all nutrient transporters 
within the small intestine is provided in the work of Kiela and Ghishan (Kiela 
& Ghishan 2016). 
 
- Goblet cells: cells organized in exocrine glands able to secrete mucins, which 
are large molecular weight glycoproteins. Mucins are the main component of 
the mucus, which provides mucosal protection from dehydration and 
mechanical damage. In addition, it constitutes a physical barrier between the 
intestinal epithelium and luminal contents, including pathogenic microbes 




Table T1.1 Enteroendocrine cells (ECCs): location within the gastrointestinal tract (GIT) 
and hormones secreted. Abbreviations: CCK, cholecystokinin; 5-HT, serotonin; GIP gastric 







EECs kind Location within the GIT Hormones secreted 
A (X-like)  Stomach Ghrelin 
G Stomach, Duodenum Gastrin 
D Stomach, Small intestine Somatostatin 
I Proximal small intestine CCK, 5-HT 
K Proximal small intestine GIP, 5-HT 
L Distal small intestine, colon GLP-1, GLP-2, PYY, 5-HT 




- Crypts of Lieberkühn: glands lined with the intestinal epithelium. They are 
home to: 
• Stem cells: cells in charge of epithelial layer renewal every few days. 
• Paneth cells: specific cells that assist undifferentiated columnar cells 
and rapidly amplify cells in the regeneration of absorptive and 
secretory cell types. In addition, Paneth cells are the primary producers 
of antimicrobial peptides in the intestinal tract (Bevins & Salzman 
2011). Thus, they are involved in shaping the composition of the gut 
microbiota (Gassler 2017). 
• Enteroendocrine cells (EECs): cells able to secrete specific hormones 
in response to stimuli. They are present also in the stomach and in the 
colon. The EECs are divided in subcategories detailed in table T1.1 
(Latorre et al 2016). 
- Peyer’s patches: aggregations of lymphoid follicles which represent the gut-
associated lymphoid tissue. In the Peyer’s patches are present B-cells, T-cells, 
macrophages and dendritic cells (DCs). They are considered the immune 




1.1.3 The gastrointestinal tract controls energy balance via 
communication with the brain 
The GIT acts as an essential regulator of energy homeostasis in response to the 
availability or demand of food. This is facilitated by the presence of diverse cell types 
mentioned above, which regulate nutrient absorption and production of several satiety 
and metabolism-related hormones, such as ghrelin (produced by the stomach), 
cholecystokinin (CCK, produced by duodenum and jejunum), glucagon-like peptide 1 
and peptide YY (GLP-1 and PYY respectively, both produced by distal ileum and 
colon) (Fig. 1.1) (Boguszewski & van der Lely 2014, Castagneto Gissey et al 2019, 
Murphy & Bloom 2004). Such hormones produced by GIT are defined as “short-term 
energy balance signals”, which relay a sense of fullness or starvation in order to limit 
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the size of individual meal and change the time of intake of the next meal through the 
communication with the brain in a short period of time (Havel 2002). 
1.1.3.1 Ghrelin 
Ghrelin is a small protein composed of 28 amino acids, which is produced mostly by 
endocrine cells in the stomach and, in small part, by the small intestine cells and 
pancreas (van der Lely et al 2004). Ghrelin is encoded by the same gene (i.e., Ghrl) 
that encodes obestatin, another satiety-related hormone, functions of which are still 
under investigation (Grönberg et al 2008). Initially, the Ghrl gene is translated into a 
longer peptide, called preproghrelin that undergoes cleavage, becoming proghrelin. 
After a proteolysis process, proghrelin is converted to ghrelin through a post-
translational modification at a serine residue with an octanoyl group, a specific kind 
of acylation (Sato et al 2011). The addition of octanoyl groups is essential because it 
allows ghrelin to be active, to bind its receptor and to exert its function. Ghrelin is 
denominated the “hunger hormone” for its ability to stimulate appetite and increase 
food intake and fat storage. It is secreted before a meal, during fasting, and its 
production decreases after feeding (Ibrahim Abdalla 2015). After secretion, both blood 
circulation and vagus nerve afferent neurons have been identified as routes for 
conveying ghrelin’s signal from the periphery to the brain (Date et al 2002, Schaeffer 
et al 2013). Once in the brain, ghrelin is able to cross the BBB and bind a specific 
isoform of growth hormone secretagogue receptor (GHSR) expressed in the 
hypothalamus and in the pituitary gland (Howard et al 1996). The activation of GHSR 
in the ARC neurons of the hypothalamus stimulates the production of the orexigenic 
neuropeptides NPY and AgRP (Guan et al 2010), promoting food intake and 
suppressing thermogenesis (Wren et al 2000, Yasuda et al 2003). It was shown that 
the orexigenic effect exerted by ghrelin is impeded in mice with a deletion or mutation 
in Ghsr. Moreover, antagonists of this receptor have been designed to regulate food 
intake as a possible strategy to ameliorating eating disorders (Howick et al 2017, 




Cholecystokinin (CCK) is produced mainly by intestinal I cells in the duodenum and 
jejunum and, in a small part, in the CNS. Different active CCK isoforms (with a 
specific number of amino acids) can be obtained by processing of pro-CCK, the CCK 
precursor (Rehfeld 1998). CCK is released during food ingestion and the principal 
stimulators of its secretion are dietary protein and fats. CCK has an anorexigenic effect 
and acts as a satiety-stimulator in two ways: by suppressing gastric emptying and 
transit through a direct action on the stomach and by inhibiting food intake through 
the communication with the brain (Beglinger 1994, Matzinger et al 1999). The CCK-
1 receptors are present on the afferent fibres of the vagus nerve as well as in the nucleus 
of the solitary tract (NTS) in the hind brain and in the hypothalamus (Wank 1995). 
The NTS is a region in the brain considered as gateway for meal-related signals 
entering the brain from the periphery. An increase of post-prandial CCK stimulates 
the NTS region and the upregulation of CART in the hypothalamic neurons, promoting 
an anorexigenic response (D'Agostino et al 2016, Maletínská et al 2008). Vagotomy 
or the removal of the NTS region abolishes CCK satiety effects downstream (Edwards 
et al 1986, Shillabeer & Davison 1985). Agonists of CCK receptors have been 
developed and have been demonstrated to have different beneficial effects, such as 
increase of insulin-sensitivity and regulation of adipokines production in the adipose 
tissue (Cawston & Miller 2010, Lin et al 1990, Plaza et al 2019). 
1.1.3.3 Glucagon-like peptide 1 
Glucagon-like peptide 1 (GLP-1) is a 30 amino acids hormone produced by intestinal 
L cells found in the distal ileum and colon. In response to a meal, intestinal L cells are 
promoted to activate proglucagon gene expression, which is the same gene that 
encodes glucagon in the pancreas. Following the cleavage of proglucagon, GLP-1 and 
GLP-2 are the two isoforms produced (Donnelly 2012, Janssen et al 2013). GLP-1 
secretion is higher in the presence of a meal rich in carbohydrates and fats (Gibbons 
et al 2013, Yoder et al 2009). Recently, it was showed that GLP-1 release is also 
controlled by intestinal intraepithelial lymphocyte (IEL) within the intestine (He et al 
2019). GLP-1 is considered an incretin hormone due to its ability to stimulate the 
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proliferation of the insulin-secretor β-pancreatic cells and, thus, to enhance the 
secretion of insulin. In addition, GLP-1 inhibits the pancreatic secretion of glucagon 
(Ramracheya et al 2018). Accordingly, GLP-1 secretion is correlated with a decrease 
of blood sugar levels (Ramracheya et al 2018, Shigeto et al 2015). In parallel, GLP-1 
acts as an anorexigenic molecule, able to reduce food intake. As in the case of other 
satiety-regulator hormones, GLP-1 exerts its anorexic function by binding its specific 
receptor (i.e., GLP-1R) present on the vagus nerve, NTS and in hypothalamic ARC, 
both on POMC and NPY/AgRP neurons (Baggio & Drucker 2014). Here, 
simultaneously, GLP-1 stimulates the activation of POMC neurons and inhibits 
NPY/AgRP neurons and, then, those anorexogenic signals are integrated to elaborate 
the output (Bugarith et al 2005, Seo et al 2008). From a study conducted in humans, it 
was shown that GLP-1 can also influence energy expenditure in that GLP-1 injection 
in healthy humans resulted in decreased diet-induced thermogenesis and carbohydrate 
oxidation during the post-prandial period (Flint et al 2000). In rats, GLP-1 receptor 
has been observed to be involved in the control of energy expenditure during chronic 
HFD-feeding (Krieger et al 2018). 
1.1.3.4 Peptide YY 
Peptide tyrosine tyrosine (PYY) is a 36 amino acids protein secreted by L-type 
endocrine cells along the GIT, found at a higher concentration in the terminal ileum 
and colon. PYY belongs to pancreatic polypeptide-fold family of peptides, together 
with NPY and the pancreatic peptide PP. Like GLP-1 and CCK, PYY is an 
anorexigenic hormone and is secreted as PYY (1-36) in response to calorie increase. 
PYY (1-36) becomes active, termed PYY(3-36), after a cleavage performed by the 
enzyme dipeptidyl peptidase IV (DPPIV) (Ballantyne 2006). The active form PYY(3-
36) has satiety effects. A peripheral administration of  PYY(3-36) results in a strong 
food intake inhibition both in human and rodents (Batterham et al 2003, Batterham et 
al 2002). PYY(3-36) binds Y2 receptor, which is expressed both in the periphery and 
in different areas of the brain, such as the NTS, hypothalamic ARC, medial nucleus of 
the amygdala, substantia nigra, and parabrachial areas (Dumont et al 1998). In the 
hypothalamus, PYY stimulates and represses the expression of POMC and NPY, 
respectively (Challis et al 2003). In addition, considering that Y2 receptors are 
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expressed in parts of the limbic system, including the amygdala, it is possible that PYY 
participates in the modulation of hedonic pathways involved in food intake control 
(Münzberg et al 2016). Regarding energy expenditure, it was observed that mice 
overexpressing PYY showed an enhanced lipogenic capacity, and an increase in 
thermogenesis and post-prandial insulin action as well as a reduction in food intake 
(Shi et al 2012, Sloth et al 2007). 
1.1.3.5 Regulation of gastrointestinal hormones by nutrient availability: an 
overview  
GIT hormones in charge of the regulation of energy balance are primarily regulated 
by the nutrients that are present in the intestinal tract. The response of EECs, which 
result in hormone production, can be various, depending on which nutrient is more 
available and its capacity to stimulate different EECs. 
 
- Proteins are broken down by stomach proteases into oligopeptides and amino 
acids. It was demonstrated that I and L cells secrete CCK and GLP-1, 
respectively, in response to oligopeptides availability. Indeed, those cells 
express the proton-coupled oligopeptide transporter PEPT1 (Diakogiannaki et 
al 2013, Liou et al 2011a). In addition, single amino acids can stimulate gut 
hormone release, specifically through the activation of different G protein-
coupled receptors (GPCRs). Different amino acids stimulate the production of 
different gut hormones. The I cells express the calcium sensor receptor CaSR 
and the taste receptor T1R1/T1R3 on their surface, which bind tryptophan and 
leucine, respectively (Liou et al 2011b, Tian et al 2019). Thus, tryptophan and 
leucine stimulate CCK secretion. The CaSR is present also on L and K cells, 
promoting the production of GLP-1 and GIP, upon tryptophan stimulation 
(Diakogiannaki et al 2013, Mace et al 2012). In addition, GIP production is 
stimulated by arginine and lysine, which activate the basic amino acid sensor 
GPRC6a present on K cells (Wellendorph et al 2005).  
It was shown that dietary proteins can control gut hormone biosynthesis, such 
as GLP-1 and ghrelin, through the activation of mTOR, a key regulator of 
cellular anabolism (Li et al 2019b, Xu et al 2015).  
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- Lipids are present in the intestinal lumen as free fatty acids (FFAs) and 
monoacylglycerols (MAG) after completion of digestion (paragraph 1.2.1). 
There are evidences that show the presence of FFAs receptors (FFARs) on 
different EECs, which stimulate CCK, GLP-1 and GIP secretion upon lipids 
ingestion (Isaacs et al 1987). Moreover, a intraduodenal lipid injection 
enhanced the expression of FFAR1 in K cells, which was positively correlated 
with GIP secretion (Cvijanovic et al 2017). Interestingly, it was observed that 
L cells express FFAR1, which is located on the basolateral membrane of the 
cells and not on the apical side, as previously thought (Christensen et al 2015). 
In addition, through the interaction with the lipid amine receptor GPR119, 
MAG is able to stimulate the production of GLP-1 and GIT, but not CCK or 
PYY (Chu et al 2008, Hansen et al 2011, Parker et al 2012).  
 
- Carbohydrates are sensed by most of EECs. In the presence of glucose, ghrelin 
secretion is suppressed and 5-HT, CCK, GIP and GLP-1 secretions are 
increased (Gribble & Reimann 2016, Muller et al 2015). Specifically, it was 
shown that GLP-1 secretion by L cells is driven by glucose uptake from 
SGLT1 transporter and fructose uptake by GLUT5 (Gorboulev et al 2012, 
Reimann et al 2008). Enterochromaffin cells (ECs) are able to sense glucose 
and fructose, and consequently, produce 5-HT, through the expression of 
different glucose transporters such as SGLT1, GLUT2, GLUT5 and the sweet 
taste receptor T1R2/T1R3 (Martin et al 2017a, Martin et al 2017b, Young et al 
2018). In addition, K cells are also able to sense glucose via metabolism-
dependent mechanism and produce GIP but, despite their ability to express 
GLUT5 on their surface, there are no evidence in vivo that GIP is produced by 





1.1.4 Adipose tissue control of energy balance  
The adipose tissue, despite its simple cellular structure compared to other organs, is 
involved in different important functions such as storage, thermogenesis and endocrine 
capability, because of its ability to secrete different metabolically active components 
important for the energy homeostasis (Booth et al 2016). In humans and rodents, the 
two most important kinds of adipose tissues are: white adipose tissue (WAT) and 
brown adipose tissue (BAT).  
 
The WAT is subcategorized based on its location: it can be found underneath the skin 
(subcutaneous) and all around the internal organs (mesenteric, retroperitoneal, 
perirenal, omental, and epidydimal in rodents). The BAT is localized in the cervical-
scapular zone in rodents, and in the clavicular-paravertebral zone in humans (Choe et 
al 2016). WAT is responsible for fat storage regulation in response to dietary fat 
supply. Excess of fat is stored in the adipocytes mainly as triacylglycerol (TAG). The 
synthesis or breakdown of TAG within the WAT is dynamic: they are assembled from 
lipoproteins into the adipocytes and hydrolyzed and released into the bloodstream as 
free fatty acids (FFAs) with different chain length and degree of saturation (detailed 
description of adipose tissue metabolism: paragraph 1.2) (Fernandez-Quintela et al 
2007).  
In the meantime, based on the fat deposition, adipose tissue growth and peripheric 
hormonal network, WAT releases specific hormones denominated adipokines. The 
adipokines are involved in the regulation of energy balance, metabolism and 
inflammation through the communication with the CNS and peripheric organs (Khan 
& Joseph 2014). Leptin and adiponectin are two hormonal adipokines involved in 
energy homeostasis (leptin description: paragraph 1.1.4.1). The production level of 
adiponectin, encoded by the gene Adipoq, is inversely correlated with adiposity, leptin 
levels and insulin resistance (Robinson et al 2011) and mainly affects liver, endothelial 
cells, blood vessels and skeletal muscle (de Oliveira Leal & Mafra 2013). In addition, 
other adipokines involved in inflammation are secreted by the adipose tissue, such as 
resistin, chemerin, apelin, visfatin, plasminogen activator inhibitor 1 (PAI1), 
monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor alpha (TNFα) and 
interleukin 6 (IL6) (Fasshauer & Blüher 2015).  
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BAT is a particular type adipose tissue able to dissipate energy (heat) to ensure correct 
thermoregulation, using glucose and fat as metabolic fuels. This ability relates to the 
fact that BAT adipocytes are enriched in mitochondria that express uncoupling protein 
1 (UCP1). This protein, present in mitochondrial inner membrane, allows the 
production of non-shivering heat by uncoupling the fatty acids oxidation from 
adenosine triphosphate (ATP) synthesis in order to dissipate energy (Nicholls et al 
1978, Zhang & Bi 2015). UCP1 expression depends on brown adipocytes state of 
differentiation and on the different peripheral induction or inhibition signals 
(Villarroya et al 2017). Despite the two different approaches, both BAT and WAT 
participate in the regulation and maintenance of energy balance.  
1.1.4.1 Leptin 
The gene encoding for leptin (i.e., Ob) was observed for the first time by chance in the 
Jackson Laboratory in 1950. Mice with a mutation in Ob gene, in homozygosis, 
manifested in obesity with rapid progression, increased energy intake, infertility, 
diabetes and neuroendocrine dysfunctions (Ingalls et al 1950). Later on, through the 
examination of two severely obese children, a homozygous frame-shift mutation in 
the gene encoding for leptin was identified. These individuals had a very low level of 
circulating leptin despite the large amount of fat mass. This finding is considered to 
be the first genetic evidence to establish leptin as an important regulator of energy 
balance in humans (Friedman 2019, Montague et al 1997). Leptin is a protein 
composed of 167 amino acids and is secreted into the bloodstream mainly by the WAT 
in proportion to the fat mass and based on the nutritional state. For instance, after a 
meal or during fasting, circulating leptin increase and decrease, respectively, and it is 
considered as a long-term acting energy balance-related signal (Ahima et al 1996). 
Additionally, leptin secretion can be controlled by insulin and glucocorticoids 
(Lewandowski et al 2001). Leptin was found both in circulation and in cerebrospinal 
liquid and, thanks to its ability to cross the BBB, is able to directly target the CNS, 
specifically the hypothalamic ARC (Peng et al 2015). Here, leptin binds the long form 
of the leptin receptor (LepRb), which belongs to the JAK-Stat family. LepRb is 
regulated by different signalling proteins such as a suppressor of cytokine signalling 3 
(SOCS3). In the presence of leptin, SOCS3 is activated and, with a negative feedback 
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action, decreases the leptin signalling cascade (Mori et al 2004). Leptin signalling 
activates anorexigenic neurons expressing POMC and CART and inhibits orexigenic 
neurons expressing AgRP and NPY. Downstream signalling then results in a satiety 
effect (Park & Ahima 2015). In addition, leptin was reported to act on the 
hippocampus, where it seems to exert an antidepressant effect (Lu et al 2006). BAT is 
mainly innervated by the sympathetic nervous system (SNS) and it was shown that 
leptin signalling through the hypothalamus is able to increase BAT sympathetic tone, 
regulating thermogenesis (Enriori et al 2011). In addition, SNS activation by leptin 
modulates energy expenditure by elevating heart rate and arterial pressure (Haynes et 
al 1997, Shek et al 1998). Finally, leptin has a critical role in the control of glucose 
homeostasis and insulin sensitivity. For this reason, it is not surprising that the two 
metabolic diseases, obesity and diabetes, are very frequently related to each other 
(Amitani et al 2013). Obesity-related leptin dysfunctions and consequences are 
detailed in the paragraph 1.3.1. 
 
1.1.5  Pancreatic control of energy balance 
Energy homeostasis is also controlled by the endocrine compartment of the pancreas, 
called the islets of Langerhans. These areas are composed of different cell types, which 
are able to secrete different hormones: β-cells for insulin, α-cells for glucagon, δ-cells 
for somatostatin, ε-cells for ghrelin and PP-cells for pancreatic peptide (Mastracci & 
Sussel 2012). The exocrine portion of the pancreas, populated by acinar cells, plays a 
role in the digestion through the production of digestive enzymes (Pandiri 2014). In 





Insulin, together with leptin, is considered a long-term acting signal as its secretion is 
related to blood glucose level and to the adipose tissue mass within the body. Since 
1886, it was noticed that a total pancreatectomy caused severe diabetes and, in the 
following years, insulin was identified as the hormone directly involved in this 
metabolic disease (Bliss 1993, Vecchio et al 2018). Insulin is encoded as pre-
proinsulin, that becomes proinsulin after the cleavage of the signal peptide. Proinsulin 
undergoes other modifications by the action of endopeptidases and, after the formation 
of three disulphide bonds and the cleavage of C-peptide, insulin is complete and active 
(Fu et al 2013). During a meal, insulin is secreted into the bloodstream as a 51 amino 
acids dimer by β-cells of the pancreas in response to glucose uptake and through the 
action of the intestinal incretin hormones GLP-1 and glucose-dependent insulinotropic 
peptide (GIP) (Yabe & Seino 2011). Subsequently, insulin reaches its target organs 
(liver, adipose tissue, CNS and skeletal muscle) and binds insulin receptor (IR) 
(Escribano et al 2017). This activates a signal cascade, which promotes membrane 
expression of glucose receptors (GLUT) (Furtado et al 2002). For instance, insulin 
promotes the uptake of glucose into the adipocytes through the transporter GLUT4. 
Once in the adipocytes, glucose is converted to TAG by de novo lipogenesis 
(paragraph 1.2.2) (Smith & Kahn 2016). In the skeletal muscle, insulin promotes the 
conversion of glucose into glycogen and, in the liver, promotes the biosynthesis of 
TAG, through glycolysis and lipogenesis (Jensen et al 2011, Saltiel & Kahn 2001). 
Additionally, insulin crosses the BBB and interacts with areas in the CNS that express 
IR, such as the hypothalamus, cerebral cortex, cerebellum and the hippocampus. In 
the hypothalamus, insulin stimulates POMC neurons and inhibits NPY signalling in 
related neurons, inducing an anorexigenic response downstream (Benoit et al 2002, 






1.2 White adipose tissue metabolism: dietary fatty acids 
absorption, lipogenesis and lipolysis 
1.2.1  Dietary fatty acids absorption 
The digestion of dietary fat occurs in the duodenum (Fig. 1.2). Initially, dietary fats 
are present in the small intestine mainly as TAG and phospholipids, which are 
insoluble. The combined action of hepatic bile acids and pancreatic lipases solubilizes 
TAG in micelles. Subsequently, intestinal lipases break down TAG-soluble micelles 
into free fatty acids (FFAs) and monoacylglycerols (MAG) (Wang et al 2013). FFAs 
and MAGs are imported into the enterocytes by passive diffusion or by protein 
transporters (i.e., fatty acids transporter proteins, FATPs and cluster of differentiation 
36, CD36) present on the brush border of the enterocytes. FFAs and MAGs uptake can 
occur along the entirety of the small intestine (Abumrad & Davidson 2012). Once in 
the cytoplasm of the enterocytes, acyl-CoA synthetase converts FFAs into the active 
form: FFA-CoA. Meanwhile, MAGs are converted into diacylglycerol (DAG). 
Subsequently, FFA-CoA and DAG are used to re-form TAGs (Mansbach & Nevin 
1998). If the level of TAGs is high, they are temporary stored within the enterocytes 
as cytoplasmatic lipids droplets. Otherwise, from the cytoplasm, TAGs are 
translocated to the endoplasmic reticulum (ER) and, here, they are assembled with 
proteins and cholesterol and surrounded by phospholipids. These circular and 
hydrophilic structures, called chylomicrons, are transported through the Golgi to the 
basolateral side of the enterocytes and, then, secreted into the lymphatic system and 
into the bloodstream (Mansbach & Siddiqi 2010). Through the circulation, the 
chylomicrons reach the organs provided with fat storage or fat oxidation system, such 
as WAT, BAT, liver, skeletal muscle and the heart.  
In this thesis, I will focus on fat uptake, lipogenesis and lipolysis by WAT. 
1.2.2  White adipose tissue anabolism 
Once chylomicrons and very-low-density lipoproteins (VLDLs; TAG-carrier 
structures that come from the liver) arrive in the blood vessels in proximity of WAT, 
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TAGs within those structures are hydrolysed into FFAs by an enzyme called 
lipoprotein lipase (LPL), which is anchored to the capillary endothelium. Long-chain 
fatty acids (LCFAs) are part of the FFAs released after LPL action. LPL is encoded 
and produced by WAT and its activity is very important for fat uptake regulation. In 
light of this, it is not surprising that LPL is finely regulated at transcriptional and post-
transcriptional level (Kersten 2014). On the adipocyte membrane, several transporters 
involved in FFAs uptake into the cell are present. These are FATPs, CD36, plasma 
membrane fatty acid binding protein (FABPpm) and caveolin-1 (Thompson et al 
2010). The FFAs in the adipocytes are re-converted into TAGs through diacylglycerol 
acyltransferase enzyme (DGAT), which causes the esterification of FFAs. By this 
process, TAGs are formed and stored within the adipocytes (Harris et al 2011) (Fig. 
1.2). The FFAs from dietary fat are not the only FFAs source that results in TAG 
production within the adipocyte. FFAs can be synthetized also starting from 
carbohydrates through a metabolic process called de novo lipogenesis. Briefly, after a 
meal, insulin released from the pancreas binds IRs that promote adipocytes intake of 
glucose through GLUT4. In the cell, glucose is converted in acetyl-coenzyme A 
(acetyl-CoA) by glycolysis and tricarboxylic acid cycle (TCA cycle). Glycolytic 
metabolites activate carbohydrate response element-binding protein (ChREBP), which 
translocates into the nucleus and upregulates the expression of enzyme involved in the 
lipogenesis, such as ATP-citrate lyase (ACLY), acetyl-CoA carboxylases 1 (ACC1), 
fatty acid synthase (FASN) and stearoyl-CoA desaturase-1 (SCD1). All these enzymes 
contribute to the conversion of acetyl-CoA in FFAs (Song et al 2018). Together, FFAs 
from dietary fat and from de novo lipogenesis contribute to the TAG stock in the 
adipocytes, even if the first case is the most important in normal healthy conditions. 
 
1.2.3  White adipose tissue catabolism 
When the energy supply to the organs is not enough, for example during fasting, a 
metabolic process called lipolysis is activated in the WAT (Fig. 1.2). Lipolysis ensures 
TAGs breakdown into glycerol and FFAs, which will be transported through the 
bloodstream to the organs in energy deficit. During fasting, different hormones are in 
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charge of lipolysis activation, such as pancreatic glucagon and catecholamines from 
the SNS (Carmen & Victor 2006). The catecholamines stimulate β-adrenergic 
receptors (β-AR). These molecules enhance the production of adenosine 3’,5’-cyclic 
monophosphate (cAMP) and guanosine 3,5-cyclic monophosphate (cGMP), which 
activate cAMP-dependent protein kinase (PKA) and cGMP-dependent protein kinase 
(PKG). In turn, the kinases promote the phosphorylation and, thus, the activation of 
the enzymes involved in the lipolytic cascade (Langin 2006). In order of action, the 
lipolytic enzymes are: adipose TAG lipase (ATGL), which converts TAG into 
diacylglycerol (DAG), hormone-sensitive lipase (HSL), which converts DAG into 
monoacylglycerol (MAG),  and monoglyceride lipase (MGL), which converts MAG 
into FFAs and glycerol (Fredrikson et al 1986, Haemmerle et al 2002a, Zimmermann 
et al 2004). Other factors that can promote lipolysis are glucocorticoids, growth 
hormones and TNFα (Hansen et al 2002, Ryden et al 2002, Xu et al 2009). On the 
other hand, insulin production and action inhibits this process (Jensen & Nielsen 2007, 
Nielsen et al 2014).  
 
In the adipose tissue, catabolism also includes oxidation of FFAs. This specific 
reaction occurs within the mitochondria in aerobic conditions. Through β-oxidation, 
FFAs (mainly LCFAs) transported within the adipocytes are metabolized into acetyl-
CoA units (Houten & Wanders 2010). From the cytoplasm, FFAs are conjugated to a 
CoA group by fatty acyl-CoA synthase (FACS). At this point, carnitine 
palmitoyltransferase 1 (CPT1) converts FFA-acyl-CoA into FFA-acylcarnitine (Qu et 
al 2016). In this form, FFAs can translocate into the mitochondria. Within the 
mitochondrial inner membrane, carnitine palmitoyltransferase 2 (CPT2) re-converts 
FFA-acylcarnitine into FFA-acyl-CoA. This molecule undergoes different 
biochemical reactions that result in the production of acetyl-CoA. Subsequently, 
acetyl-CoA units join the TCA cycle, promoting the production of nicotinamide 
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) which, in 
turn, are used by electron transport chain (ETC) to produce the energy carrier ATP 
(Adeva-Andany et al 2019). In addition, ACC enzyme plays an important role in the 
regulation of FFAs β-oxidation. The ACC catalyses the reaction that converts acetyl-
CoA into malonyl-CoA, which is an intermediate of FFA biosynthesis described in the 
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paragraph 1.2.2.. Moreover, malonyl-CoA can interfere with β-oxidation of FFAs by 
inhibiting CPT1 (Munday & Hemingway 1999). 
 
 
Figure 1.2 White adipose tissue metabolism. In the small intestine, dietary TAGs are broken 
down into FFAs and MAG by the action of hepatic bile acids and pancreatic lipases. FAs 
absorption: FFAs and MAG are transported inside the enterocytes by FATPs and CD36 
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transporters. Here, FFAs and MAG are converted into FFAs-CoA and DAG, respectively. 
Both FFAs-CoA and DAG are re-converted into TAGs and translocated into ER, in which they 
are assembled into chylomicrons. Chylomicrons are secreted into the lymphatic system and 
then into the bloodstream, by which they can reach different organs and tissues. Lipogenesis: 
in the blood vessels that irrorate the adipose tissue, both chylomicrons and VLDV (from the 
liver) are converted into FFAs by LPL, an enzyme produced by the adipocytes. These FFAs 
are translocated into the adipocyte by CD36, FATP4, FABP, CAV1 transporters. FAAs within 
the adipocytes can derive from de novo lipogenesis in the presence of carbohydrates. Insulin 
binds IRs that promote the adipocytes’ intake of glucose through GLUT4. In the cell, glucose 
is converted in acetyl-CoA by glycolysis and TCA cycle. Glycolytic metabolites activate 
ChREBP, which upregulates the expression of ACLY, ACC1, FASN and SCD1. All these 
enzymes contribute to the conversion of acetyl-CoA in FFAs.  Both dietary- and de novo 
lipogenesis-derived FFAs can be converted into TAGs by DGAT or they undergo β-oxidation. 
FFAs β-oxidation: FFAs are conjugated to a CoA group by FACS. Then, CPT1 converts FFA-
acyl-CoA into FFA-acylcarnitine. In this form, FFAs can translocate into the mitochondria. 
Within the mitochondrial inner membrane, CPT2 re-converts FFA-acylcarnitine into FFA-
acyl-CoA. This molecule undergoes different biochemical reactions that result in the 
production of acetyl-CoA. Subsequently, acetyl-CoA units join the TCA cycle and the NADH 
and FADH2 produced are used by ETC to produce ATP. Lipolysis: it is stimulated by 
glucagon and catecholamines binding to their receptors, GR and β-AR, respectively. This 
enhances the production of cAMP and cGMP, which activate PKA and PKG. In turn, the 
kinases promote the phosphorylation and, thus, the activation of ATGL, which converts TAG 
into DAG, HSL which converts DAG into MAG, and MGL which converts MAG into FFAs 
and glycerol. 
Abbreviations (in order of appearance): TAG, triacylglycerol; FFA, free fatty acid; MAG, 
monoacylglycerol; FA, fatty acid; FATPs, fatty acid transporters; CD36, cluster of 
differentiation 36; CoA, coenzyme A; DAG, diacylglycerol; ER, endoplasmic reticulum; BAT, 
brown adipose tissue; VLDL, very low-density lipoprotein; LPL, lipoprotein lipase; FABP, 
plasma membrane fatty acid binding protein; CAV1, caveolin-1; GLUT4, glucose transporter 
4; ChREBP, carbohydrate response element-binding protein; ACLY, ATP-citrate lyase; 
ACC1, acetyl-CoA carboxylases 1; FASN, fatty acid synthase; SCD1, stearoyl-CoA 
desaturase-1; DGAT, diacylglycerol acyltransferase; FACS, fatty acyl-CoA synthase; CPT1 
and 2, carnitine palmitoyltransferase 1 and 2; NADH, nicotinamide adenine dinucleotide; 
FADH2, flavin adenine dinucleotide; ETC, electron transport chain; ATP, adenosine 
triphosphate; GR, glucagon receptor; β-AR, beta-adrenergic receptor; cAMP, adenosine 
3’,5’-cyclic monophosphate; cGMP, guanosine 3,5-cyclic monophosphate; PKA, cAMP-
dependent protein kinase; PKG, cGMP-dependent protein kinase; ATGL, adipose TAG lipase; 










1.3 Obesity: a metabolic and endocrine dysregulation of 
energy balance 
Obesity is a chronic, relapsing, progressive disease. It is characterized by genetic or 
diet-induced dysfunctions in several tissues, including the adipose tissue, the gut and 
the hypothalamus (Halsted 1999, Williams 2012) (Fig. 1.3). As there hasn’t been a 
substantial evolutionary pressure to change the human gene pool in the last century 
alongside the gradual rise in prevalence of obesity, there is a growing recognition that, 
instead, the change in the dietary habits and how they impact on the existing gene pool, 
underlie the basis for the obesity problem. This simplistic view is further complicated 
by the discovery that diet induced changes in the composition of the gut microbiota 
may also impact on our ability to regulate energy balance. The reason why not all 
humans develop obesity in the current obesogenic environment appears to be due to 
the inter-individual variation (polymorphisms) in the existing genes and how they 
respond to the diet and the microbiota. 
 
 
1.3.1 Obesity-induced adipose tissue dysfunction and leptin 
resistance 
The physiological and endocrine functions of the adipose tissue are highly 
compromised during obesity. High fat mass affects centre of gravity, posture and 
balance of the body, leading to an exaggerated lumbar spine curve, difficulties in 
movements and asymmetries that predispose to injuries (Maciałczyk-Paprocka et al 
2017). High amount of adipose tissue also causes organ compression, which leads to 
high pressure and, because of an enlargement of adipocytes, bringing about hypoxia. 
For these reasons, the adipose tissue in obese individuals is more susceptible to 
inflammation and insulin resistance (Ye 2009) (Fig. 1.3). Once the adipose tissue 
becomes saturated with fat, the excess fat gets deposited ectopically in other tissues 
including the liver, heart and skeletal muscle. Ectopic fat deposition exacerbates the 
disease by increasing the risk of hepatic steatosis and by decreasing muscular oxygen 
metabolism, followed by loss of muscular strength (Snel et al 2012). In addition, 
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during obesity, BAT activity and mass decrease (Seale & Lazar 2009). It has been 
shown that a short-term HFD exposure is sufficient to induce BAT whitening (i.e., 
BAT transition in a WAT-like phenotype), which implies a reduction of mitochondrial 
oxidation and dynamics, together with an increase of inflammation (Kotzbeck et al 
2018, Kuipers et al 2019) (Fig. 1.3). In light of this, a rational approach to combating 
obesity can be through the restoration of BAT activity (Seale & Lazar 2009).  
 
1.3.1.1 White adipose tissue lipogenesis dysregulation 
In a situation of excess energy, the morphology, size and organization of adipocytes 
change. Higher fat intake, as expected, causes a higher TAG accumulation within the 
adipocytes, which become hypertrophic. In turn, they secrete more paracrine factors 
that induce the transit from premature adipocytes to mature adipocytes, causing an 
increase of the adipose mass and, thus, an adipose tissue remodelling (Choe et al 2016, 
Pellegrinelli et al 2016). This situation over long-term can lead to ectopic fat deposits 
in other organs, exacerbating metabolic syndrome. It was demonstrated that during 
HFD feeding, the FFA uptake into the adipocytes from the circulation increases, 
together with a dysregulation of factors involved in lipid uptake, such as FABP and 
FATP1 (Berk et al 1999, Wu et al 2006). In parallel, an upregulation of DGAT enzyme 
was observed (Tinahones et al 2010). With the abnormal increase of TAG storage 
within the adipocytes during HFD feeding, it is not surprising that de novo lipogenesis 
is, in turn, affected. Indeed, obesity is characterized by an inhibition of de novo 
lipogenesis, mainly through a downregulation of ACC. This phenomena is even more 
evident if obesity is accompanied by insulin-resistance (Marcelino et al 2013, 
Tinahones et al 2010). 
1.3.1.2 White adipose tissue lipolysis and β-oxidation dysregulation 
HFD and obesity lead to an imbalance in lipogenesis and, also, in lipolysis rate. In 
rodents, HFD feeding showed a decrease in the lipolysis within the adipose tissue 
(Tepperman et al 1986). The same scenario was observed in obese individuals (Arner 
et al 2011). In contrast, an increase in the lipolytic rate of the subcutaneous abdominal 
adipose tissue has been shown in obese humans consuming HFD (Howe et al 2011). 
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This excess of FFAs released from the adipose tissue was linked with ectopic fat 
deposition and insurgence of insulin-resistance and non-alcoholic fatty liver diseases 
(NAFLD) (Samuel & Shulman 2012). Accordingly, targeting lipolysis with 
compounds able to inhibit enzymes involved in this metabolic process, such as ATGL, 
can ameliorate HFD-induced complications (i.e., insulin-resistance and NAFLD) 
(Schweiger et al 2017). However, genetic deletion of ATGL, HSL and MGL lead to 
different physiological outcomes, making the role of lipolysis in the pathogenesis of 
obesity still unclear. For instance, a lack of ATGL and HSL caused an exacerbation of 
obesity compliance (Haemmerle et al 2006, Haemmerle et al 2002b). Conversely, lack 
of MGL attenuated HFD-induced insulin-resistance (Taschler et al 2011). In light of 
this, further investigations are required to fully understand the role of lipolysis during 
different phases and degrees of metabolic disorders.  
On the other hand, it is well established that WAT β-oxidation is enhanced during 
obesity (Serra et al 2013). An increase in β-oxidation rate during HFD feeding was 
also observed in skeletal muscle and the heart. This is due to an upregulation of FATP, 
CD36 and PPARγ gene expression (Cameron-Smith et al 2003, Sikder et al 2018). An 
enhancement of β-oxidation causes electron transport chain overactivation, which 
results in a surplus of ATP and reactive oxygen species (ROS). The oxidative stress 
induced, due to ROS increase, leads to mitochondrial disfunction and inflammation. 
In general, HFD-induced derangements lead to metabolic syndrome exacerbation, 
mainly causing insulin-resistance (Lee et al 2015, Serra et al 2013). 
1.3.1.3 Leptin resistance 
In addition to an adipose tissue dysfunction, a deregulation of hormone production 
also occurs during obesity. One of the most important hormones in the pathogenesis 
of obesity is leptin (Fig. 1.3). In humans and rodents without mutations in Ob gene, 
the concentration of circulating leptin correlates with body mass index (BMI): higher 
BMI corresponds to a higher circulating leptin (Maffei et al 1995). A chronic high 
leptin level in the circulation might results in leptin resistance phenomena, which leads 
to a further aggravation/exacerbation of obesity and other metabolic complications. 
Myers and colleagues defined leptin resistance as “the failure of endogenous or 
exogenous leptin to promote anticipated salutary metabolic outcomes in states of over-
27 
 
nutrition or obesity, although the hormone's inability to promote desired responses in 
specific situations results from multiple molecular, neural, behavioural, and 
environmental mechanisms” (Myers et al 2012). Leptin resistance can have different 
causes other than hyperleptinemia such as chronic inflammation, ER stress and 
defective autophagia within the hypothalamus. Many mechanisms seem to be involved 
in the development of leptin resistance. Among those, the most important are: decrease 
of leptin transport across the BBB, impairment in LepRb signalling cascade 
components (which lead to a downregulation or, in general, a desensitization of 
LepRb) and deficiency or impairment downstream signalling components including 
melanocortin system (which orchestrate the hypothalamic neural circuit in charge of 
the control of energy balance) (Zhou & Rui 2013).  
Many studies have been carried out, both in humans and rodents, with the aim to assess 
the efficacy of leptin injection for treating obesity in individuals with leptin deficiency. 
The results are contrasting: in some studies no amelioration in hyperphagia and body 
weight loss in Ob/Ob mice was observed upon leptin administration and, in others, 
there are evidences of energy balance and body weight improvement in mice and 
humans (Cummings et al 2011, Dardeno et al 2010, Hamann et al 1997, Heymsfield 
et al 1999, Mistry et al 1997). Thus, it is still unclear if leptin can be employed for 
obesity therapy.  
A very recent study carried out using several mutant murine models and anti-leptin 
antibodies showed that a partial reduction in circulating leptin levels can restore 
hypothalamic leptin sensitivity with a long-term reduction in weight gain, with further 
improvement of insulin sensitivity. Moreover, it was confirmed that hyperleptinemia 
is one of the main driving forces for metabolic disorders (Zhao et al 2019). This can 
be another starting point for the development of new therapeutic strategies in the 




1.3.2 Obesity-induced gastrointestinal dysfunction 
1.3.2.1 Gut hormone dysfunction  
Part of the comorbidities that come from obesity are due to a dysregulation of the 
hormones produced by the GIT, in particular those involved in the control of energy 
balance, glucose homeostasis and appetite (Fig. 1.3). Circulating levels of PYY were 
found to be inversely correlated with markers of adiposity. In obese individuals, both 
the basal fasting levels of PYY3-36 and its postprandial response after meals were 
significantly lower in obese subjects relative to lean ones. This led to a reduction of 
satiety (Karra et al 2009). Chronic PYY administration in rodents, as well as transgenic 
mice that overexpressed PYY, decreased body weight and caused resistance to HFD-
induced obesity (Boey et al 2008, Chelikani et al 2007, Vrang et al 2006). 
 
Similar to PYY, CCK satiety-signalling and sensitivity to lipids is disrupted during 
HFD feeding. In these animals, a significant downregulation of CCK receptors was 
observed in a specific zone of the vagus nerve called the nodose ganglia (Covasa et al 
2000, Duca et al 2013). Furthermore, HFD interferes with the capacity of CCK to 
induce gastric emptying (Covasa & Ritter 2000). Unlike for PYY, therapeutic 
approaches targeting CCK signalling were not successful and there were no advances 
in clinical practice (Kim et al 2011). 
 
Regarding GLP-1, how it changes during HFD feeding is still unclear since different 
studies are in disagreement with each other. In human subjects, it was reported that 
postprandial GLP-1 was lower in obese/overweight individuals compared to normal 
weight individuals (Adam & Westerterp-Plantenga 2005, Verdich et al 2001). 
Conversely, in another study, postprandial GLP-1 was higher in obese versus lean 
subjects (Bowen et al 2006a). Despite this discrepancy, liraglutide, a GLP-1 receptor 
agonist has been tested in different clinical studies that demonstrated its efficacy in the 
short-term reduction of body weight by 10% and in the improvement of insulin 




Unexpectedly, ghrelin was found to be lower in obese humans and rodents (Gomez et 
al 2012, Tschöp et al 2001). In mice fed with HFD, a lower expression of Ghsr was 
observed in both the hypothalamus and vagus nerve nodose ganglion, together with 
higher inflammation in the same sites. This is a possible cause of ghrelin signalling 
disruption during HFD-induced obesity (Naznin et al 2015).  During diet-induced 
weight loss, ghrelin resistance is reversed and its circulating levels are higher than 
during a normal situation. This possibly suggests that the brain senses a reduced food 
availability or the rapid loss of body weight (negative energy balance) and responds 
accordingly by enhancing the ghrelin system to prevent further weight loss. Ghrelin 
may take months to return to a normal level after weight loss (Zigman et al 2016). 
 
1.3.2.2 Nutrient absorptive defects within the gut 
Diets enriched in fat affect intestinal fat absorption (Fig. 1.3). During HFD 
consumption in rats, an elongation of the intestinal villi was observed, which caused 
an increase of the intestinal absorptive surface (Thomson et al 1986). In humans, the 
gene expression of fatty acids transporters, such as FATP4 and CD36, were 
upregulated and, additionally, the expression of genes involved in re-conversion of 
FFAs into TAG within the enterocytes were dysregulated in the presence of HFD 
(Tremblay et al 2013). Moreover, HFD causes the upregulation of factors involved in 
chylomicrons synthesis and release (Hernández Vallejo et al 2009). 
In other studies, it has been observed that obesity causes an elevated abundance of 
dietary fat availability in the enterocytes, which interfere with nutrient transporter 
expression (Uchida et al 2011, Zhou et al 2018). Accordingly, HFD exposure in 
rodents decreases the abundance of sodium glucose transporter protein (sodium-
dependent glucose transporter, SGLT1), cluster of differentiation 36 (fatty acids 
importer, CD36), peptide transporter 1 (PEPT1), Niemann-Pick C1-Like 1 (sterol 
transporter, NPC1L1) and glucose transporter 2  (GLUT2) (Betters & Yu 2010, 
Cifarelli & Abumrad 2018, Losacco et al 2018, Roder et al 2014, Wang et al 2017). 
At the gene expression level, it was shown that genes encoding CD36 and other lipid 
transporters are overexpressed during HFD feeding, creating a discrepancy between 
protein and gene expression level (Primeaux et al 2013, Torelli Hijo et al 2019). The 
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mechanism that regulates these changes and the explanation of the gene expression-
protein disconnection is still to be elucidated.  
Moreover, many studies carried out in obese patients showed that these individuals are 
deficient of several micronutrients (D, B12 vitamins, minerals and proteins) (Daniel 
et al 2015, Lespessailles & Toumi 2017, Via 2012). In conclusion, obesity status and 
long-term exposure to fat-enriched foods lead to an alteration of nutrient transporters 
density, as well as a malabsorption of micronutrients, which are contributors to the 
progress of the disease. 
 
 
1.3.3 Obesity-induced inflammation 
Another consequence that comes from a long-term HFD exposure is a systemic 
chronic low-grade inflammation. The organs that are more likely to be inflamed are 
the hypothalamus within the CNS, together with the liver, intestine, adipose tissue and 
skeletal muscle in the periphery (Fig. 1.3). The excess of adipose tissue during obesity 
status causes the infiltration of activated immune cells which, once in the tissue, 
overproduce proinflammatory cytokines that are able to attract other immune cells, 
enhancing the inflammatory response. This status, which often proceeds silently, can 
cause the development of other chronic diseases that threaten the health and longevity 
of the individuals, exacerbating obesity condition (Duan et al 2018). 
In this thesis, the focus is mainly on intestinal and adipose tissue inflammation. 
1.3.3.1 Adipose tissue inflammation 
Other than adipocytes, adipose tissue contains stromal and vascular cells, such as 
inflammatory cells, vascular endothelial cells and fibroblasts (Murawska-Cialowicz 
2017). In obesity, the main cause of increased adipose mass is adipocyte enlargement. 
In this situation, the extracellular space between adipocytes, where the other resident 
cell types and vasculature are present, decreases, thus provoking hypoxia. Chronic 
hypoxia causes cell death and fibrosis, together with an activation of the resident 
immune cells. These cells increase the production of cytokines, also considered as 
adipokines (paragraph 1.1.4) (Lee et al 2014). In particular, in HFD-induced obese 
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rodents, an increase in IL6, TNFα and MCP-1 was observed (Morin et al 1997, Poret 
et al 2018). To aggravate the situation, macrophages infiltration within the tissue was 
observed in both rodents and humans, which contributes to the humoral mediators and 
cytokine production (Hotamisligil 2006). Obesity-related macrophage infiltration has 
been shown several times through adipose tissue histological staining 
(immunohistochemistry), flow cytometry and by CD68 gene expression. CD68 is a 
protein highly expressed by the macrophages (Morgan-Bathke et al 2017, Todoric et 
al 2006). The recruitment of macrophages in the adipose tissue is abolished when IL6-
trans-signalling is blocked in mice, confirming the chemotactic properties of IL6. 
However, IL6 blockage did not prevent the onset of inflammation-induced insulin 
resistance (Kraakman et al 2015). Despite increased MCP-1 in obesity, disruption of 
MCP-1 signaling did not confer resistance to diet-induced obesity (DIO) in mice or 
reduce adipose tissue macrophage infiltration (Chen et al 2005). In contrast, Kanda et 
al showed that MCP-1 homozygous KO mice extensively reduced insulin resistance, 
hepatic steatosis, and macrophage accumulation in adipose tissue induced by HFD 
(Kanda et al 2006). These findings might suggest that MCP-1 is an important 
contributor to HFD-induced macrophage infiltration but is not the only one involved. 
Thus, a strategy to efficiently block HFD-induced macrophages infiltration within the 
adipose tissue might be to simultaneously disrupt the signaling of different cytokines 
and chemokines. 
1.3.3.2 Intestinal inflammation 
The GIT is the part of the anatomy that is most exposed to dietary components, and it 
is not surprising that diets enriched in fat have a direct effect on this site. A prolonged 
exposure to HFD has been shown to impact on the inflammatory status of the intestine. 
More specifically, HFD causes a decrease in differentiation of goblet cells, which are 
particular cells located on the surface of the respiratory and intestinal epithelium 
(Gulhane et al 2016). Their main function is to secrete mucus that contain mucin, anti-
microbial proteins, cytokines and chemokines, which protect the intestinal barrier 
from luminal microbes. In addition, goblet cells have the ability to deliver luminal 
substances to antigen-presenting cells (APCs) present in the lamina propria of the 
epithelium and, in this manner, they contribute to the modulation of the immune 
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response (Knoop & Newberry 2018). Additionally, a significantly higher expression 
of cytokines such as interleukin 1 beta (IL1β), TNFα and interleukin 17 alpha (IL17α) 
was observed within the intestinal epithelium after both, short- and long-term HFD 
feeding (Ding et al 2010, Gulhane et al 2016). High expression level of TNFα in the 
intestine has been associated with weight gain and increase of glucose and insulin in 
the bloodstream (Ding et al 2010). 
 
 
1.3.4 Obesity-induced insulin resistance 
A chronic inflammation status, created by a long-term energy disequilibrium, 
facilitates the development of insulin resistance. The overactivation of inflammatory 
pathways within the adipose tissue causes a defect in TAG storage and stimulates FFA 
release. This FFAs excess contributes to insulin resistance within the liver and the 
muscle (Guilherme et al 2008). Additionally, inflammation can cause the development 
of insulin resistance through other mechanisms, particularly in the adipose tissue and 
in the liver (Fig. 1.3). Obesity-induced low-grade inflammation is able to inhibit IR 
and its signalling pathway, as well as the activity of peroxisome proliferator-activated 
receptor γ (PPARγ), a nuclear receptor, the main role of which is to regulate the 
transcription of genes involved in glucose homeostasis, fatty acids biosynthesis and 
fat storage (Gayet et al 2007, Kubota et al 2017). However, during obesity, insulin 
resistance can be triggered by inflammation-independent mechanisms. The excess of 
lipids causes an overactivation of fatty acid β-oxidation within the mitochondria 
which, in turn, leads to extra energy availability (ATP). This energy surplus activates 
a negative feedback that aims to reduce ATP levels by inhibiting insulin-induced 
glucose uptake (Ye 2013). Finally, insulin resistance can come from an imbalance 
between insulin production and insulin clearance that results in hyperinsulinemia, even 































Figure 1.3 Obesity-induced multi-organ dysfunctions. Obesity-induced liver, BAT, WAT, cardiovascular system, brain, skeleton, 
muscles, and GIT dysfunctions. Abbreviations: BAT, brown adipose tissue; WAT, white adipose tissue; GIT, gastrointestinal tract; PYY, 
peptide YY; CCK, cholecystokinin; ↑, increase; ↓, decrease.
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1.3.5 Obesity-induced hypothalamic energy balance-related 
signaling defects 
Obesity or HFD exposure results in hypothalamic inflammation. Both in humans and 
in rodents, a diet enriched in fats increases the expression of proinflammatory 
cytokines within the hypothalamus, with IL6, TNFα and nuclear factor kB (NF-kB) 
considered to be most important (Thaler et al 2012). A chronic hypothalamic 
inflammation is one of the main causes of leptin and insulin resistance (Milanski et al 
2009). This is partially due to a dysregulation of AgRP neuron signalling which, 
additionally, causes hyperphagia and impairment of POMC neurons to sense glucose 
sensing capacity (Parton et al 2007, Tsaousidou et al 2014). In addition, HFD induces 
the expression of SOCS3, which has an inhibitory activity of LepRb. This causes a 
drop in responsiveness of anorexigenic neurons following leptin and insulin 
stimulation (Ueki et al 2004). An impairment in Ca++ balance, important for 
mitochondrial functionality, has been observed in POMC neurons during HFD 
feeding. This leads to POMC neuronal desensitisation (Paeger et al 2017). Recently, 
it has been shown that a short-term HFD exposure causes a dramatic change in the 
hypothalamic proteome, which indicates an increase in cellular stress and 
derangements in synaptic plasticity and mitochondrial dysfunction (McLean et al 
2019).  
In conclusion, obesity causes derangements of hypothalamic energy balance control 








1.4 Gut microbiota: characteristics, functions and role in 
the pathogenesis of obesity 
Over the last 20 years, the scientific community has investigated the composition and 
the function of the gut microbiota in a greater depth than ever before. The trillions of 
microbes that inhabit our gut, together with its genetic repertoire (Qin et al 2010b, 
Tierney et al 2019), has been recently proposed to represent an organ in recognition 
of the wide variety of essential functions that it performs. The composition of the gut 
microbiota is characterized by a wide inter-individual variation, although there are a 
conserved set of metabolic functions that are shared between individuals known as the 
“core gut microbiome” (Turnbaugh et al 2009). This suggests that the overall 
functionality of the gut microbiota is of more importance to the host than its 
composition. Modulation of the host immune system, protection against opportunistic 
pathogens, metabolism of some xenobiotic and drugs and regulation of the harvest, 
storage and expenditure of energy obtained from the diet are among the most important 
functions encoded by the core gut microbiome (Jandhyala et al 2015). These functions 
are essential for the correct functionality of the gut. For this reason, it is not surprising 
that a chronic perturbation to the composition and function of the normal gut 
microbiota have been frequently associated with the pathogenesis of several 
gastrointestinal diseases such as obesity and inflammatory bowel disorders (Delzenne 
et al 2019, Harsch & Konturek 2018, Nishida et al 2018). In addition, in the last few 
years, it has been established that there exists a communication link between the gut 
microbiota and the CNS through neural, endocrine and immune pathways important 
for brain function and behaviour (Cryan & Dinan 2012b). Therefore, new treatments 
that focus on the selective modulation of the gut microbiota have been considered 
recently as a means to address metabolism-related diseases and mental disorders. 
 
Bacterial colonization of the GIT occurs immediately after birth, but it is only after 2 
years of age that this becomes more stable, remaining relatively consistent until the 
elderly phase of life. The stable adult gut microbiota is primarily comprised of 
bacterial species that are members of the Firmicutes and Bacteroidetes phyla, with the 
remaining species being predominantly members of the Actinobacteria, 
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Verrucomicrobia, Proteobacteria, Fusobacteria and/or Cyanobacteria phyla (Qin et al 
2010a). The factors that most considerably influence gut microbiota composition 
throughout life include the method of delivery at birth, genetic makeup of the host, 
diet, antibiotic usage and ageing (Wen & Duffy 2017). Among these factors, diet is 
particularly important. Depending on the kind of diet consumed (i.e., quantity and type 
of carbohydrates, fats, proteins and fibres), the composition and functionality of the 
gut microbiota can be strongly affected. For example, diet-induced changes in the 
colonic gut microbiota responsible for the fermentation of carbohydrates and proteins 
results in the altered production of short-chain fatty acids (SCFAs) under anaerobic 
conditions (paragraph 1.4.2.1). The SCFAs, of which butyrate, propionate and acetate 
are the major components produced by the gut microbiota, can influence host 
metabolism by acting as an energy source, by influencing hosts’ energy intake 
(Morrison & Preston 2016, Ríos-Covián et al 2016) or by exerting anti-inflammatory 
effects on the host (Li et al 2018, van der Beek et al 2017). Thus, modulation of the 
gut microbiota by diet may provide a way to alter the host metabolism and, in turn, 
improve the metabolic deregulation seen in people with metabolic diseases. This, 
however, requires a more detailed understanding of the role of the gut microbiota in 
metabolic diseases and its interaction with the diet.  
 
1.4.1 How to analyse the microbiome? 16S rRNA-based and 
shotgun metagenomics: a brief description  
The emergence of the human microbiome (defined in Table T1.2) as a hot topic in 
science has been facilitated by the development of new methods that allow the detailed 
analysis thereof. For this purpose, the use of classical microbiological methods to 
classify and study the morphology and biochemistry of the microorganisms, such as 
Gram stain and culture-dependent techniques with different media, was not practical 
as many of the microbes within the gut cannot be cultured. Thus, the scientific 
community started to adopt culture-independent techniques, which involve in the 
extraction of DNA from the whole microbial community within a sample (referred to 
metagenomic DNA) and the determination of its composition and diversity and/or 
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microbial functional potential through high throughput DNA sequencing and 
subsequent bioinformatic analysis (Morgan & Huttenhower 2012). This relied on the 
use of the two most commonly used techniques, i.e., 16S rRNA-based and shotgun 
metagenomics (defined in Table T1.2). These approaches have been applied to the 
analysis of multiple microbial communities, such as those in human saliva, skin, lung 
and stool. In this thesis, I will focus on faecal samples only. During this process, 
detailed protocols describing how to collect samples for microbiota analysis have been 
developed in order to avoid contamination and ensure reliability (Kumar et al 2014, 
Ogai et al 2018, Wang et al 2018b). 
 
Table T1.2 Gut microbiota-related terminology and definitions (Behjati & Tarpey 2013, 





1.4.1.1  16S rRNA metagenomics 
Bacterial genomes generally consist of a single circular DNA molecule, typically 
under 10Mb in length, with smaller stretches of DNA contained on smaller circular 
plasmids (Bobay & Ochman 2017). Bacterial genomes contain marker genes, which 
allow one to distinguish different bacterial members within a population. Among 
them, the most ubiquitous and significant one is the small 16 ribosomal RNA subunit 
gene (16S rRNA gene). This particular gene, which is approximately 1500 bp long, is 
characterized by 9 separate hypervariable regions, called V1-V9 (Van de Peer et al 
1996). For 16S rRNA-based microbiota analysis, the hypervariable regions V1-V5 are 
most frequently used. Once bacterial DNA is extracted from samples and quantified, 
it is possible to create a 16S rRNA metagenomic library. This involves the completion 
of two PCR steps, required to amplify a region of the 16S rRNA using two highly 
conserved binding sites at either end of the variable region of interest and apply a 
sample-specific bar code at the extremity of each amplicon (Nurul et al 2019) (Fig. 
1.4). The 16S rRNA library is sequenced using different sequencing platforms, such 
as, Illumina MiSeq, Ion Torrent PGM, PacBio Sequel or Oxford Nanopore MinION. 
The sequencing platform choice depends on the sequencing depth, read length and 
number of samples required and the error rates that can be tolerate (Allali et al 2017). 
Subsequently, the reads are analysed using bioinformatic approaches that utilise 
different databases and tools, which are not detailed in this thesis. The outputs that 
result from the bioinformatic analysis are: taxonomical classification assignment 
(down to genus and OTU level; species level assignment is generally unreliable), α- 
and β- diversity at all the taxonomic levels and an inference of bacterial function 
profile (only an estimation through tools such as PiCrust) (Jovel et al 2016) (Table 








Table T1.3 16S rRNA-based metagenomics vs shotgun metagenomics (Callahan et al 2016, 
Jovel et al 2016, Langille et al 2013). 
 
 
1.4.1.2  Shotgun metagenomics 
The shotgun metagenomic approach does not target a specific gene within the bacterial 
genome but, instead, the whole genetic information contained in each sample is 
considered. The whole metagenome present within the microbial community is 
fragmented into small pieces of different length (through tagmentation or other 
approaches) (Quince et al 2017a). In contrast to 16S rRNA sequencing, this includes 
DNA from phages, viruses, bacteria, archaea, fungi and other eukaryotes genomes. 
Every fragment is bar coded and sequenced in an independent manner (Fig. 1.4). The 
reads are analysed using bioinformatic approaches that utilise different databases and 
tools packages, which are not detailed in this thesis (Morgan & Huttenhower 2012). 
In general, all the reads that result from the sequencing are aligned with DNA sequence 
databases. Consensus sequences will be informative with respect to the taxonomic 
profile and the functions encoded in the genome (Quince et al 2017b, Sharpton 2014). 
The outputs that result from the bioinformatic analysis are several and more complex 
compared to 16S rRNA-based approach. It is possible to detect taxonomical 
classification assignment (down to species and strain levels), α- and β- diversity at all 
the taxonomic levels and reliable data describing the functions (such as of metabolic 
and biochemical potential) characteristic of a sample. In addition, is possible to 
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recognise and annotate new genes (Ekblom & Wolf 2014, Morgan & Huttenhower 
2012) (Table T1.3). 
 
Figure 1.4 16S rRNA-based and shotgun metagenomics: methodology overview. DNA is 
extracted from a sample, such as stool. For the 16S rRNA-based approach, a region of the 
16S rRNA is amplified using two highly conserved binding sites at either end of the variable 
region of interest and applying a sample-specific bar code at the extremity of each amplicon. 
For the shotgun approach, the whole metagenome of the microbial community is fragmented 
into small pieces of different length (tagmentation), which are bar coded in an independent 
manner. For both approaches, the resulting libraries are sequenced and analysed with 
different bioinformatic tools. The outputs from the bioinformatic analysis will be a taxonomic 
profile for the 16S rRNA-based approach and a taxonomic and functional profile, as well as 
novel gene recognition, for the shotgun approach. 
 
 
1.4.2  Gut microbiota metabolites and their influence on the host 
The microbial community within the gut contributes to the regulation of the host 
metabolism through the production of metabolites. This crosstalk between microbiota 
and host is important for good health and good metabolic homeostasis. Different 
microbial taxa are associated with the production of a specific metabolites. For this 
reason, is not surprising that an alteration of the gut microbiota causes, not only an 
imbalance in the proportions of the microbes, but also in the metabolites produced by 
them. This can result in the development of health disorders (Canfora et al 2019b, 
Lavelle & Sokol 2020). In this thesis, an overview of some important metabolites, 
produced by gut microorganisms through fermentation of fibers and metabolism of 
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amino acids, carbohydrates, nucleotides and lipids, is provided (Oliphant & Allen-
Vercoe 2019). 
1.4.2.1  Short-chain fatty acids 
The fermentation of non-digestible fibres occurs in the colon, with the main products 
being SCFAs. Butyrate, acetate and propionate represent 95% of the total amount of 
SCFAs (Morrison & Preston 2016) (Fig. 1.5). Firmicutes, in particular 
Faecalibacterium prausnitzii and Clostridium spp. of the family Ruminococcaceae, 
and Eubacterium rectale and Roseburia spp. of the family Lachnospiraceae, are 
among the main SCFAs producing-bacteria within the human gut (Louis & Flint 2009, 
Louis & Flint 2017). Most of SCFAs are absorbed by the host, and just 5-10% are 
excreted in the faeces (Cummings et al 1987). In the past few years, several studies 
observed that SCFAs can influence the host metabolism by acting on different organs 
such as the liver, adipose tissue, brain and muscle. SCFAs interact with these different 
body regions by binding G protein-coupled receptor 41 and 43 (GPR41 and 43), also 
known as free fatty acid receptor 3 and 2, respectively (FFAR3 and 2) (Layden et al 
2013). In vitro and in rodents, it has been demonstrated that SCFAs stimulate the 
production of anorexigenic hormones GLP-1 and PYY within the intestine and leptin 
in the adipose tissue (Al-Lahham et al 2010, Larraufie et al 2018, Psichas et al 2015, 
Tolhurst et al 2012, Xiong et al 2004). In addition, an injection of acetate leads to a 
reduction in appetite through a modulation of anorexigenic hypothalamic 
neuropeptides (Frost et al 2014). Accordingly, SCFAs are actively involved in gut-
brain axis networking (van de Wouw et al 2018). Moreover, SCFAs have a role in 
attenuating body weight gain by increasing energy expenditure through promoting 
lipid oxidation in the WAT and thermogenesis in the BAT (Reynés et al 2019, Sukkar 
et al 2019). Additionally, SCFAs are involved in the development of immune system, 
increasing the number of myeloid precursors post-haematopoiesis, and participating 
in the amelioration of allergic reactions (Khosravi et al 2014, Trompette et al 2014). 
This evidence is consistent with a positive role for SCFAs against inflammatory and 
metabolic diseases such as obesity and diabetes and the importance of adopting 
beneficial dietary habits, including the consumption of large amounts of fibres.  
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1.4.2.2  Neurotransmitters 
An alteration of the gut microbiota is associated with behavioural disturbances and 
neurodegenerative diseases. This is partially due to the role of the microbes in the 
production of neurotransmitters, such as gamma-aminobutyric acid (GABA), 
serotonin (5-hydroxytryptamine; 5-HT) and catecholamines (adrenalin, nordrenalin, 
dopamine) (Fig. 1.5). GABA comes from glutamic acid metabolism and is produced 
by glutamic acid decarboxylase (GAD). It acts in the CNS, modulating pain, anxiety, 
depression and sleep, as well as in the ENS, regulating intestinal function and motility 
(Hyland & Cryan 2010, Ting Wong et al 2003). Bacteroides, Parabacteroides, 
Escherichia, Lactobacillus and Bifidobacterium are among the GABA producing 
genera in the gut (Strandwitz et al 2019, Yunes et al 2019). 
 
Serotonin is a molecule that acts both as a hormone and neurotransmitter and covers 
an important role in sleep regulation, anxiety, happiness, cognition and mood control 
(Jouvet 1999). It is thus not surprising that a decreased serotonin level is associated 
with mood disorders, such as anxiety and depression. In addition, serotonin plays a 
role in the gut through the modulation of gastrointestinal motility and is involved in 
the pathophysiology of irritable bowel syndrome (IBS) (Duval et al 2000). The 
conversion of tryptophan to serotonin requires two essential enzymes: the first, 
tryptophan hydroxylase, hydroxylates the tryptophan to produce 5-hydroxiltriptophan 
(5-HTP) and the second, L-aromatic amino acid decarboxylase, decarboxylates 5-HTP 
to generate 5-HT. The GIT is responsible for 90% of total 5-HT production, which 
occurs in ECs and gut bacteria. Escherichia, Streptococcus, Enterococcus, 
Akkermansia, Alistipes and Roseburia have been identified as potential serotonin-
producing taxa (Cryan & Dinan 2012a, Valles-Colomer et al 2019). Just 5% of total 
serotonin synthesis occurs in the CNS. Notably, germ-free (GF) mice have been shown 
to have a higher tryptophan/serotonin ratio in plasma compared to conventional mice 
(Jenkins et al 2016, Mohammad-Zadeh et al 2008). When bacteria that are able to 
metabolize tryptophan are added to the GF gut, levels of circulating tryptophan drop 
and levels of serotonin rise. At the same time, serotonin levels in the hippocampus 
increase and there is a reduction in anxiety-like behaviour (Clarke et al 2013). In a 
recent study, depression-like behaviour was further linked with the gut microbiota 
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using GF mice and specific pathogen-free (SPF) mice that underwent an acute 
tryptophan depletion procedure (Lukić et al 2019). These studies clearly indicate the 
importance of tryptophan intake and the effect that its conversion to serotonin, 
mediated by the gut microbiota, has on mood and behaviour. 
 
Dopamine is a neurotransmitter that controls reward-motivated behaviour, in 
particular affection, emotions, working memory, attention, motivation, reward, 
locomotor activity and neuroendocrine regulation (Baik 2013). This catecholamine is 
synthetized from phenylalanine and tyrosine and is the precursor of adrenalin and 
noradrenalin. The species within the gut involved in dopamine production are still 
under investigation. E. coli, E. coli K12 and Bacillus spp. are able to produce dopamine 
in vitro, together with Proteus vulgari, Serratia marcescens and Staphylococcus 
aureus (Clarke et al 2014a, Strandwitz 2018). In vivo, GF mice showed a lower levels 
of β-glucuronidase activity and, consequently, of free catecholamines both in the 
caecum and in other tissues and those levels are restored followed by colonization by 
either a faecal microbiota from SPF mice or a mix of Clostridium species. However, 
it is unclear if Clostridium spp. directly produce catecholamines or if this is an indirect 
effect (Asano et al 2012). 
1.4.2.3  Vitamins 
Gut bacteria provide the host with a range of vitamins important for the regulation of 
host metabolism. The most abundant vitamins produced by the intestinal bacteria are 
vitamin K and Bs, which include thiamine (B1), riboflavin (B2), niacin (B3), 
pantothenate (B5), pyridoxine (B6), biotin (B7), folate (B9) and cobalamin (B12) (Hill 
1997) (Fig. 1.5). Vitamin K is important for blood coagulation due to its role as a 
coenzyme in the reaction that is crucial for the production of clotting factors (Merli & 
Fink 2008). Notably, GF mice showed a lower prothrombin levels and high risk of 
haemorrhage (Gustafsson et al 1962). Among the main vitamin K producers bacteria 
there are E. coli, Mycobacterium phlei and Bacillus subtilis (Meganathan 2001, 
Walther & Chollet 2017, Walther et al 2013). It has been recently discovered that, 
within the human gut, at least 256 common human gut bacteria (based on their genome 
annotations alone) are involved in the synthesis of different kinds of B vitamins and 
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actively exchange B vitamins among each other. This evidence suggests that human 
gut microbiota has co-evolved relationships that are specific to the gut environment 
(Magnusdottir et al 2015). B vitamins produced by gut bacteria are directly absorbed 
in the colon, unlike food-derived B vitamins, which are absorbed in the small intestine 
(Said 2011). Those gut-derived vitamins have been shown to regulate important 
metabolism pathways within the host, among which the most important is 
immunoregulation (Hosomi & Kunisawa 2017). 
 
 
Figure 1.5 Metabolites produced by the gut microbiota. Gut microbiota produces SCFAs 
(from the fermentation of dietary fibers), serotonin, indoles and kynurenine pathway-related 
metabolites (from dietary tryptophan), and lithocholic acid and deoxycholic acid (from the 
metabolism of bile acids present in the intestinal lumen). In addition, gut microbiota can 
synthetize neurotransmitters, such as GABA and dopamine, as well as vitamins B and K.  
Abbreviations: SCFA, short-chain fatty acid; GABA, gamma-aminobutyric acid. 
 
1.4.2.4  Bile acids 
Bile acids derive from cholesterol metabolism and are synthesised within hepatocytes. 
Once conjugated with taurine or glycine, they are secreted into the duodenum, where 
they participate in fat digestion. Subsequently, almost 95% of the bile acids are 
reabsorbed in the distal ileum and return to the liver through the portal vein. The 
remaining 5% of bile acids are excreted within faeces (Chiang 2013). The microbes 
within the gut can modify bile acids. The microbial enzyme bile salt hydrolase (BSH) 
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dissociates taurine and glycine from the rest of the molecule. The taxa in which BSH 
activity has been observed include Bacteroides, Lactobacillus, Bifidobacterium, 
Clostridium and Enterococcus (Jia et al 2019). A second step in the bile acids 
metabolism occurs after BSH action. It consists in the production of deoxycholic acid 
(DCA) from cholic acid (CA) and lithocholic acid (LCA) from chenodeoxycholic acid 
(CDCA) (Ridlon et al 2006) (Fig. 1.5). The enzymes involved in these transformations 
are produced by anaerobic bacteria (Ridlon & Hylemon 2012). There exists an 
important interplay between the quantity and quality of bile acids and the composition 
and function of the gut microbiota (Golubeva et al 2017, Molinero et al 2019).  
1.4.2.5  Indole and kynurenine derivates 
Beside serotonin, tryptophan is a precursor of other classes of metabolites produced 
by intestinal bacteria. Two important such metabolites for bacteria-host crosstalk are 
indole and kynurenine derivates (Fig. 1.5). There is evidence that indole-derivate 
metabolites have positive effects on the host, particularly during bacterial infection, 
intestinal health and neurological, metabolic and inflammatory diseases (Beaumont et 
al 2018, Wikoff et al 2009). Since indole from gut bacteria leads to an increase in GLP-
1 levels in the small intestine and a diet high in sugar drastically decreases indole 
biosynthesis, indole metabolites can be beneficial to ameliorate metabolic diseases 
such as diabetes and obesity (Chimerel et al 2014, Isaacs et al 1994). It was shown that 
bacterial indoles are involved in the control of body weight and adiposity during HFD 
feeding. In particular, indole-3-carboxilic acid was demonstrated to be a key 
modulator of the expression of micro RNA miR-181 within the adipocytes. miR-181 
directly regulates a network of genes controlling adipose tissue function and 
development, energy expenditure and insulin signalling (Virtue et al 2019). In obese 
humans, a reduction in plasma indoles has been observed (Cussotto et al 2020). 
However, after gastric bypass surgery, microbiota‐derived indoles increase (Jennis et 
al 2018). In addition, indole-derivates, such as 7-hydroxyindole, have the capacity to 
improve intestinal permeability and integrity by increasing tight junction resistance 
and reducing the level of inflammatory markers in the colon. This is relevant for the 
amelioration of gut-related diseases such as cancer and IBS (Bansal et al 2010, 
Shimada et al 2013). Indole-3-propionic acid is a very interesting indole-derivate 
46 
 
metabolite. This compound exerts a variety of beneficial effects because of its potent 
anti-oxidant properties and its capacity to inhibit the formation of  β-amyloid fibrils in 
neurons (Chyan et al 1999, Poeggeler et al 1999).  
Tryptophan is also the precursor of kynurenine, from which other metabolites are 
synthetized (i.e., quinolinic acid, kynurenic acid and xanthurenic acid), all belonging 
to the “kynurenine pathway”. Gut bacteria have an impact on kynurenine-derived 
metabolism and this activity is influenced by the inflammatory status. For instance, 
the kynurenine pathway is upregulated by pro-inflammatory cytokines, such as 
interferon γ (INFγ) (Campbell et al 2014). Moreover, kynurenine metabolites 
contribute to gut-brain axis signalling (Kennedy et al 2017). Quinolinic acid was 
observed as a NMDA receptor agonist within the CNS and an increase or an injection 
of this specific metabolites causes neurodegeneration in mice (Lugo-Huitron et al 
2013). Kynurenine metabolites have also been linked with metabolic diseases. 
Accordingly, kynurenic acid controls energy metabolism by signalling to different cell 
types through the binding with its receptor, i.e., GPR35. GPR35 is expressed by 
adipocytes, immune cells, muscle fibres and enterocytes and it was recently considered 
as a good therapeutic target for obesity and diabetes treatment (Dadvar et al 2018). 
During obesity, kynurenine-derived metabolites are significantly higher in the plasma. 




1.4.3  The microbiota-gut-brain axis 
In the last few years, the existence of a gut-brain axis has been established, defined as 
a bidirectional crosstalk between the CNS and the gut. These anatomic parts are able 
to communicate via afferent and efferent routes. It has been shown that the intestinal 
microbial population can strongly influence the gut-brain axis structure and function 
(Cryan et al 2019). Indeed, the intestinal microbial population exploits the gut-brain 
link routes to, in turn, communicate with the brain.  
The vagus nerve and the bloodstream are considered the most important gut-brain axis 
communication routes. In paragraph 1.1.3, it was already noted that important appetite 
control-related hormones produced by the GIT (i.e., ghrelin, CCK, GLP-1) exert their 
regulatory function within the hypothalamus via both the vagus nerve and blood. In 
addition, as described in paragraph 1.4.2, intestinal bacteria produce a large number 
of metabolites in response to different physiological conditions, such as diet. Some of 
these metabolites, such as SCFA, neurotransmitters and tryptophan-derivate 
metabolites, take advantage of afferent routes to cross the BBB and act in specific 
regions of the brain (Cryan & Dinan 2012b, De Vadder et al 2014, Nicholson et al 
2012). The gut microbiota is also involved in the maturation of intestinal epithelial 
cells as well as in the maturation of the immune system (Edelman & Kasper 2008, 
Okumura & Takeda 2017). This relates not just to immune system within the intestine, 
but also systemically and in the CNS, suggesting a gut-brain interaction that is 
immune-system dependent (Fung 2020).  
In parallel, the brain is able to communicate with the gut through efferent signaling. 
The most important is the hypothalamic-pituitary gland-adrenal (HPA) axis. This 
specific signaling pathway is responsible for the production of corticosterone in 
rodents and cortisol in humans, which are defined as “stress hormones”. The activity 
of the HPA axis has been shown to impact on the immune system both in the periphery 
and in the gut, together with consequences on gut physiology mediated by the ENS 
(Bhatia & Tandon 2005, Savastano et al 1994). Gut microbes are able to influence the 
HPA axis activation, making the HPA axis-gut communication bidirectional 




Figure 1.6 The microbiota-gut-brain axis. These routes include the vagus nerve, production 
of SCFAs, immune activation with production of immune mediators, production of 
neurotransmitters and tryptophan. The gut microbiota is also able to convert primary bile 
acids into secondary bile acids, which activate receptors on EECs and stimulate the secretion 
of gut peptides. Neuroactive compounds produced by gut microbiota enter the circulation and 
reach the brain, subsequently affecting neuroendocrine function. Abbreviations: 5-HT 
serotonin, CCK cholecystokinin, DC dendritic cell, EEC enteroendocrine cell, ENS enteric 
nervous system, GABA ɣ-aminobutyric acid, GLP-1 glucagon-like peptide-1, IL interleukin, 
LPS lipopolysaccharide, NTS nucleus tractus solitarii, PYY peptide YY, SCFAs short chain 




1.4.4  The role of gut microbiota in obesity 
An alteration in the gut microbiota composition, with a concurrent reduction in overall 
diversity, has been suggested to be among the changes associated with obesity status 
(Turnbaugh et al 2008, Turnbaugh & Gordon 2009). The two most dominant phyla in 
the human gut are the Bacteriodetes and the Firmicutes. In studies conducted both in 
obese mice (Ley et al 2005a, Turnbaugh et al 2006b) and in humans (Ley 2006), the 
proportion of the phylum Firmicutes was observed to increase with decreases in the 
Bacteroidetes in the obese condition compared to their normal weight counterparts. 
These studies gave rise to the idea that an increased Firmicutes:Bacteroidetes (F/B) 
ratio could be used as an obesity biomarker. However, other findings contradict this 
notion (Schwiertz et al 2010). Thus, the precise alteration in the microbial composition 
that contributes to obesity remains the subject of debate. Despite this doubt, several 
important studies demonstrate an important role for the enteric microbiota in the 
pathogenesis of obesity. 
 
Backhed et al showed that GF mice have 40% less total body fat than conventional 
mice, although they ingest 29% more calories than their conventionally raised 
littermates (Backhed et al 2004). GF mice also gain less weight than conventionally 
raised mice and they were protected against diet-induced glucose intolerance and the 
development of insulin resistance (Piya et al 2013). In addition, faecal microbiota 
transplanted from conventionally raised mice to GF mice triggered a 57% increase in 
the amount of body fat and a dramatic increase in hepatic triglyceride levels and insulin 
resistance without modifying the amount of food consumed (Backhed et al 2004). The 
expression of host genes involved in energy homeostasis, lipid metabolism and 
mitochondrial metabolism in different parts of the gut, as well as in the liver and 
adipose tissues, is markedly different in GF mice and conventionally raised mice 
(Larsson et al 2012). These data highlight the role played by the gut microbiota in 
energy harvest and storage in host tissues.  
Recent studies have further defined the potential bacterial candidates for the above 
effects. Fei et al have demonstrated that the opportunistic pathogen, Enterobacter 
cloacae B29, isolated from the gut of an obese human, causes obesity and insulin 
resistance in GF mice (Fei & Zhao 2013). In another study, using gnotobiotic mice fed 
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a HFD or low-fat diet (LFD), the authors assigned a role for Clostridium ramosum in 
the upregulation of glucose and fat transporters in the intestine, as well as increased 
body fat deposition (Woting. A et al 2014). In addition, Staphylococcus aureus, 
Halomonas and Sphingomonas have been associated with an obese phenotype 
(Kalliomaki et al 2015), accompanied by low Bifidobacterium numbers when 
compared to lean individuals. On the other hand, other bacterial members in the gut 
can have a protective role against obesity and adiposity both in rodents and in humans. 
Among them, Akkermansia muciniphila, a mucin-degrading bacteria, is present in 
significantly lower levels in obese Ob/Ob mice (i.e., mice with a mutation in the gene 
encoding leptin). The oral administration of A. muciniphila reverses HFD associated 
metabolic disorders including fat mass gain and insulin resistance in these mice 
(Everard. A et al 2013). Other commensal enteric bacteria such as Enterococcus 
faecalis FK-23, Lactobacillus gasseri SBT2055 and the family Christensenellaceae 
have been shown to exert anti-obesity and anti-adiposity effects (Kadooka et al 2010, 
Motonaga. C  et al 2009). Christensenellaceae, a bacterial family present in lean 
individuals, has been shown to promote a lean host phenotype and has an impact on 
the diversity of the bacterial community when transplanted to mice (Goodrich et al 
2014). Considering these results together, a targeted modulation of specific gut 
microbiota components may prove a viable alternate target in the treatment of obesity, 
that can be adjusted in order to resemble as much as possible a healthy configuration. 
 
1.4.5 Strategies of gut microbiota manipulation 
To investigate and to understand the role of the gut microbiota in different 
circumstances, for example during diet intervention, drug administration or disease 
progression, several methods are commonly employed in in vivo studies. All those 
methods aim to disturb or manipulate the gut microbiota in order to assess the 
consequent amelioration or worsening of the original phenotype in the animal model.  
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1.4.5.1  Prebiotics 
Prebiotics are defined as selectively fermented non-digestible food ingredients that 
result in specific changes in the composition and/or activity of the gastrointestinal 
microbiota, thus conferring benefits upon the host health (Bindels et al 2015, Gibson 
et al 2010). Prebiotics include different kinds of food components such as fructans 
(inulin), galacto-oligosaccharides, starch and glucose-derivate oligosaccharides and 
non-carbohydrate oligosaccharides (Davani-Davari et al 2019). The main products of 
prebiotics fermentation/degradation by the gut microbiome are SCFAs and other 
molecules used by other intestinal microbial population (cross-feeding) (Belenguer et 
al 2006). Several studies in rodents and humans have shown that different kind of 
prebiotics have beneficial effects on gastrointestinal diseases, immunity and on the 
nervous system through the gut-brain axis (Davani-Davari et al 2019). Moreover, 
specific prebiotics consumption, for example inulin, showed several beneficial effects 
against metabolic syndrome-related comorbidities (Hiel et al 2018, Rodriguez et al 
2020). 
1.4.5.2  Probiotics 
Probiotics are defined as live microorganism that, when they are present in adequate 
amounts, confer a health benefit to the host (Hill et al 2014). The majority of 
commercially used probiotics belong to the genera Lactobacillus and Bifidobacterium, 
with L. acidophilus, L. casei, L. plantarum, L. rhamnosus, L. reuteri, L. brevis, L. 
johnsonii, L. plantarum, B. infantis, B. adolescentis, B. animalis B. lactis, B. longum, 
and B. bifidum among the most important species (Fijan 2014). Probiotics can help to 
maintain a balanced proportion of bacteria that are important for a correct gut 
microbiota functionality (Oelschlaeger 2010). In addition, they counteract the action 
of pathogenic bacteria within the gut by impeding their growth (Fijan 2016). For these 
reasons, a probiotic therapy is recommended after antibiotic treatment. In addition, in 
recent years, some probiotics have demonstrated positive effects with respect to 
different GIT-related diseases, metabolic syndrome, immunity, oral health, 
hypercholesterolemia and the gut-brain axis modulation (Markowiak & Śliżewska 
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2017, Salazar et al 2019). Moreover, a prebiotic-probiotic mix (i.e., synbiotic) have 
also been employed in order to improve gut health (Markowiak & Śliżewska 2017). 
1.4.5.3  Antibiotic treatment 
Antibiotics are antibacterial molecules. They are classified as bactericidal, which 
directly kill the bacteria, or bacteriostatic, which inhibit bacterial growth (Nemeth et 
al 2014). Different antibiotics target and inhibit/interfere with a specific function 
essential for the bacterial cell, such as DNA replication, RNA synthesis, protein 
synthesis and cell wall biosynthesis (Kohanski et al 2010). Moreover, antibiotics can 
be broad-spectrum, which act on different bacterial taxa, and narrow-spectrum, which 
are able to target just specific taxa. Broad-spectrum antibiotic usage can have the 
generally undesirable effect of also impacting on non-pathogenic bacteria (Melander 
et al 2018). However, for scientific research, when compared to GF mice, antibiotic 
treatment offers a more rapid, cheap and manageable method to study the depletion of 
the gut microbiota. The main advantages in the usage of antibiotics versus GF mice 
are (Kennedy et al 2018): 
- possibility to deplete the gut microbiota in any mouse genotype or condition; 
- possibility to deplete the gut microbiota in mice that were normally colonized 
since birth. Accordingly, mice that start an antibiotic treatment would have 
normal metabolism and neurodevelopment since birth. In GF mice, many 
metabolic, immunological, physiological and neurodevelopmental parameters 
are impaired since birth. 
 
A single antibiotic or an antibiotic cocktail, usually broad-spectrum, are given to the 
rodents dissolved in drinking water or placed directly into the GIT using oral gavage 
(Kennedy et al 2018). However, this gut microbiota depletion method has some 
disadvantages: 
 
- 100% of the bacteria are not killed by antibiotic treatment and antibiotic 




- the antibiotic treatment is not always localized within the intestine, but many 
antibiotics have a systemic effect, thus, they can influence other organs and 
eukaryotic cells. This leads to antibiotic-induced side effects, such as problems 
in the immunomodulation, metabolism and digestion (Blaser 2016, Langdon 
et al 2016). 
 
1.4.5.4  Faecal microbiota transplantation 
Faecal microbiota transplantation (FMT) involves the administration in the upper part 
of the GIT, or the placement directly in the colon, of faecal material from a healthy 
donor to a recipient with an altered gut microbiome (Kim & Gluck 2019). This practice 
is increasingly being used in the clinic to treat patient with Clostridium difficile 
infection, a pathogenic bacterium that cause gastrointestinal disturbances such as 
diarrhoea, fever and general sickness. C. difficile infection often happens after 
antibiotic usage (Ofosu 2016). FMT is also employed in rodent studies. To assess if 
the gut microbiota is implicated in the development or amelioration of certain 
conditions, FMT can be carried out from a donor rodent with a certain disease to a 
recipient healthy rodent, or vice versa (Backhed et al 2004, Ellekilde et al 2014, Lai et 
al 2018). Moreover, through FMT, it is possible to create so-called humanized rodents, 
by placing stool from a human donor in a rodent recipient. Despite the important 
discoveries carried out in rodents in understanding the crosstalk between the gut 
microbiota and the host, it is still difficult to translate these findings to humans, which 
have important differences compared to mice and rats. The use of humanized rodents 
provides one means to try to reduce these differences (Hugenholtz & de Vos 2018, 










1.5 Intestinal integrity and permeability: an overview 
The intestinal epithelium is an important barrier. Beyond its role as a physical 
protective barrier, one of the most important roles of the single layer of epithelial cells 
that clothe the intestinal tract is in nutrient and fluid absorption, together with 
bidirectional electrolyte flux. Moreover, the intestinal surface is enriched in cells from 
the innate and adaptive immune system such as B, T and DCs, macrophages as well 
as mucosal lymphocytes. They ensure intestinal protection from pathogens (Kagnoff 
2014). The enterocytes physically communicate and adhere to each other through 
different kinds of tight junction proteins (TJ). The most abundant in the intestinal 
epithelium are claudins, TJ-associated MARVEL proteins (TAMP, such as occludins 
and tricellulin), junctional-adhesion molecules (JAMs) and cytosolic plaques TJ 
proteins constituted by Zonula occlundes (ZO) proteins (Ivanov 2012). The quantity 
and, consequently, the functions of the TJs is controlled at different levels 
(transcriptional and post-transcriptional) by different factors, such as cytokines, 
growth factors, the gut microbiota, pathogens, and nutrients. This directly impacts on 
intestinal permeability.  Moreover, intestinal permeability is affected by different 
pathological condition, such as GIT diseases and metabolic syndrome, as well as 
during psychological stress, oxidative stress and ageing (Maeda et al 2010, Saunders 
et al 2002, Suzuki 2013, Thevaranjan et al 2017). 
 
1.5.1 Role of high-fat diet and gut microbiota in gut permeability 
modulation 
A growing body of evidence indicates that one of the side effects of obesity is an 
increase in gut permeability. Both genetically obese Ob/Ob and Db/Db mouse models 
showed an alteration in TJ assembly that leads to a disruption in intestinal barrier 
function (Brun et al 2007). Accordingly, HFD feeding causes disfunction at the 
intestinal barrier level through a decrease in abundance of occludin, claudin-1, 
claudin-3, and JAM-1 (Suzuki & Hara 2010). Gut permeability disruption in 
genetically obese mice or caused by HFD is associated with higher levels of circulating 
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cytokines such as IL1β, IL6 and TNFα (Al-Sadi et al 2009, Rohr et al 2019). It has 
been shown that HFD-induced gut permeability and altered plasma inflammatory 
markers are related to a gut microbiota alteration during HFD (Cani et al 2008, Cani 
et al 2009). Lipopolysaccharide (LPS) is a component of the outer membrane of Gram-
negative bacteria that starts an inflammatory reaction through toll like receptor 4 
(TLR4) interaction. HFD induces higher LPS levels in the plasma and a mild antibiotic 
treatment with ampicillin and neomycin abolished this phenotype, confirming the key 
importance of the gut microbiota in this phenomenon (Cani et al 2008). Moreover, this 
suggests that the composition of the gut microbiome influences intestinal permeability. 
Indeed, the gut microbiota is known to help the maturation of intestinal epithelial cells 
and it is not surprising that GF mice have a “leaky gut” due to TJ dysfunction. 
However, it has been shown that colonization of GF animals with a human microbiota 
results in a structural and functional intestinal barrier improvement, together with a 
reduced risk of intestinal injury (Hayes et al 2018). In line with this, a depletion of the 
gut microbiota with antibiotics induces TJs disruption and increase in gut permeability 
in vitro and in vivo (Feng et al 2019, Spiller 2018). FMT, probiotics and prebiotics, 
are among the approaches available to ameliorate intestinal permeability linked to a 
gut microbiota alteration (Yoon & Yoon 2018). Among probiotics, several species of 
Saccharomyces, Lactobacillus and Bifidobacterium, together with specific E. coli 
strains have been found to be efficient in addressing intestinal barrier disruption (Rao 
& Samak 2013, Terciolo et al 2019). 
 
1.5.2 Use of Ussing chamber as means to measure gut permeability 
In rodent studies, Ussing chamber provide a means to easily and reliably measure the 
permeability of some molecules and ions across the intestinal barrier (Thomson et al 
2019, Ussing & Zerahn 1951). Here, only the experimental procedure to measure 
molecules permeability is described. Primarily, an intestinal region is selected. Usually 
the permeability measurement is applied to the ileum or colon. Approximately one-
centimetre length of the intestinal zone selected is longitudinally cut and placed as a 
sheet between two parts of the apparatus, which together create a chamber (Fig. 1.7). 
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In this way, serosal (physiologically in contact with blood vessels) and mucosal 
(physically in contact with the intestinal lumen) parts of the intestinal portion are each 
facing one half of the chamber. Both halves of the chamber are filled with a carbonate 
sugar-enriched solution and a fluorescent macromolecule, 4KDa FITC-dextran, is 
added to the mucosal side. The chamber is attached to a gas source that maintains the 
flow of the solution within the chamber and, in the back part, the chamber is water 
jacketed to ensure a constant temperature of 37°C. Sampling is carried out at different 
timepoints, over 2 or 3 hours, in the chamber that faces the serosal side of the intestinal 
tissue. Subsequently, FITC-dextran abundance is detected by measuring its 
absorbance with a spectrophotometer at 485nm excitation / 535nm emission 
wavelengths. The timepoint zero (T0) absorbance of each tissue is subtracted from the 
following timepoints of the same tissue. The output is commonly a curve that describes 
the serosal concentration of FITC over time. Alternatively, it is also possible to 
calculate the total FITC flux that penetrates from the mucosal to the serosal side of the 
tissue surface in the total observation time. 
Figure 1.7 Measurement of macromolecules permeability using Ussing chamber apparatus. 
An intestinal region is mounted in the Ussing chamber and FITC-dextran is added to the 
mucosal chamber. Samples are collected from the serosal chamber at different timepoints, 
and levels of FITC-dextran are quantified by measuring its absorbance with a 
spectrophotometer at 485nm excitation / 535nm emission wavelengths. 
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1.6 Bovine whey protein and its action on energy balance, 
gut microbiota and mood 
Whey is the milk serum that has been separated from the milk during cheese 
manufacture. Specifically, whey is formed by the action of chymosin after casein curd 
formation. Whey is composed of vitamins, lactose, minerals, fat (in small amounts) 
and soluble proteins (Zadow 1994). In bovine milk, 80% of protein is in the form of 
casein, with whey protein (WP) accounting for the remaining 20%, which includes β-
lactoglobulin (LAG), α-lactalbumin (LAB), bovine serum albumin (BSA) and a small 
amount of,  lactoferrin (Lf), lactoperoxidase (Lp), immunoglobulin (Ig), 
glycomacropeptide (GMP) and lysozyme (Ly) (Morr & Ha 1993) (Fig. 1.8). However, 
the composition varies between species. For instance, human milk has more WP than 
casein (60% and 40%, respectively) (Zhu & Dingess 2019). The specific composition 
of WP also varies but, regardless, all are considered to represent high-quality protein 
sources because of their high content of essential amino acids. This includes high 
concentrations of branched-chain amino acids (BCAAs), such as leucine, isoleucine 
and valine, as well as tryptophan, which are all important for muscle growth and repair 
(Hulmi et al 2010, Millward et al 2008). Indeed, WP are well known for improving 
muscle building and health (Davies et al 2018). 
Moreover, WP and its components have been linked with other beneficial effects on 
health, such as lowering adiposity, lipid metabolism and cholesterol modulation, anti-
hypertensions, immunomodulation, wound healing, antioxidant, anticarcinogenic and 
glucose homeostasis (McAllan et al 2012, Pal & Radavelli-Bagatini 2013, Yalçin 
2006) (Fig. 1.9). 
WP The commercial sources of WP supplementation of diets exist in the form of whey 
protein concentrate (WPC), in which the amount of proteins varies between 50% and 
75%, or whey protein isolate (WPI), which contains a minimum of 90% protein (Morr 
& Ha 1993). 
Unlike casein, WP does not coagulate in the stomach. Instead, the components can 
rapidly enter the jejunum and be digested, releasing amino acids (Pal & Ellis 2010a). 
Thus, the absorption of digested WP components is faster than for caseins. A brief 





Figure 1.8 Bovine milk proteins: casein and whey. Bovine milk contains two kinds of 
proteins: casein (80% of the total) and whey protein (WP, 20% of the total). WP, in turn, 
includes different components at different percentages. Abbreviations: LAG, β-lactoglobulin; 
LAB, α-lactalbumin; BSA, bovine serum albumin; Lf, lactoferrin; Lp, lactoperoxidase; Ig, 






















Figure 1.9 Beneficial effects of whey protein. Among these, this thesis focuses on anti-




1.6.1 Whey protein components 
1.6.1.1 β-lactoglobulin  
LAG accounts for ~ 60-65% of the total WP content and ~ 12% of total bovine milk 
proteins. LAG consists of 162 amino acids residues in its primary structure and it has 
a globular structure, which is stable against the acids and enzymes present in the 
stomach. The molecular weight of the purified cattle LAG was measured as 17.44 KDa 
(Aich et al 2015). While LAG is the most abundant protein in bovine whey, it is absent 
from both human and rodent milk. Indeed, LAG is regarded as one the primary 
allergen in cow’s milk and its removal from whey has been suggested for the 
production of hypoallergenic food products such as milk formula (Chiancone; E 
1991). In addition, to providing a rich source of both essential amino acids and 
BCAAs, LAG has also been shown (in preruminant calves) to play an important role 
in the intestinal uptake of small hydrophobic ligands such as retinol, TAGs and LCFAs 
(Kushibiki et al 2001). Recent in vitro experiments using hybridoma cell models, 
demonstrated that LAG can influence human immunity and promote cell proliferation 
(Tai et al 2016). LAG is not heavily affected by gastric digestion in vivo and apparently 
remains mostly intact after its transition through the stomach (Ebeler et al 1990). For 
this reason, LAG has been proposed as a vehicle for the delivery of prebiotic 
compounds, viable probiotic bacteria and pH-sensitive drugs to the colon (Teng et al 
2015). 
1.6.1.2 α-lactalbumin 
Bovine LAB, which consists of 123 amino acid residues, is the second most abundant 
protein found in bovine whey (~20-25% of the total). It is a small Ca++ binding protein 
composed of a singular globular domain which is essential for the molecule stability 
and rigidity. Its ability to strongly bind Ca++ further enhances the stability of the folded 
state (Permyakov & Berliner 2000a). This specific WP is also able to bind other ions 
such as Mg++, Mn++, Na+, K+ and Zn++ and can interact with membranes, proteins, 
peptides and low molecular weight substrates (Permyakov & Berliner 2000b). There 
is evidence that LAB contributes to a reduced risk of incidence of some cancer types 
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through several mechanisms such as the anti-proliferative effects, as demonstrated in 
assays with colon adenocarcinoma cell lines (Sternhagen & Allen 2001). Indeed, 
BAMLET, which is a complex of bovine LAB and oleic acid, was shown to have the 
ability to kill tumour cells that are high resistant to apoptosis (Rammer et al 2010). 
Although when examined against several Gram-positive and Gram-negative bacteria, 
native bovine LAB did not exhibit any bactericidal activity (Pellegrini et al 1999). 
Pihlanto-Leppälä et al demonstrated that LAB reduced the metabolic activity of E. coli 
JM103 by 79% when pre-hydrolysed with pepsin or trypsin (Pihlanto-Leppala et al 
1999). Furthermore, Brück et al showed that a combination of LAB and GMP 
inhibited the association between CaCo-2 cells and the GIT pathogens 
enteropathogenic E. coli (EPEC), Salmonella typhimurium and Shigella flexneri. This 
suggests that the supplementation of milk with both LAB and GMP might be effective 
in the prevention of some GIT infections (Bruck et al 2006). In the GIT, LAB is able 
to exert other biological functions, such as an ability to protect against gastric mucosal 
injuries. This was demonstrated using two acute ulcer models in rats (Matsumoto et al 
2001). A recent review by Layman et al provides more information relating to LAB 
characteristics and the potential application of this WP for human health (Layman et 
al 2018a). 
1.6.1.3 Bovine serum albumin 
Unlike other WP, BSA is not synthesised in the mammary gland but, instead, joins the 
milk through its leakage from the bloodstream. For this reason, it may be considered 
a whey associated protein. BSA, which contains 583 amino acid residues, is involved 
in the maintenance of colloid osmotic pressure and acts as a carrier protein for FFAs, 
catecholamines and other hormones (Danon & Sapira 1972, Hankins 2006). In 
addition, BSA is also able to bind different kinds of drugs. More specifically, recent 
studies have explored the interaction between BSA and nitrofuran antibiotics, 
cephalexin, caffeic acid, the anticancer drug neratinib and the flavonoid compound 
astilbin (Hamishehkar et al 2016, Liu et al 2018, Precupas et al 2017, Wani et al 2018). 
Moreover, because of its chemical and physical properties, synthetic BSA 
nanoparticles that are able to efficiently carry and release drugs, such as salicylic acid, 
have been developed in vitro (Bronze-Uhle et al 2017). While known to be a good 
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source of essential amino acids, knowledge about the therapeutic potential of BSA is 
still limited. One notable property associated with BSA is its ability to inhibit tumour 
growth in a MCF-7 human breast cancer cell line (Laursen et al 1990).  
1.6.1.4 Lactoferrin 
Lf is a 80 KDa single chain iron-binding protein. It is a member of the transferrin 
protein family and accounts for ~1% of the total proteins in bovine whey. Lf is 
produced by mucosal epithelial cells in several mammalian species and is present in 
mucosal secretions such as tears, saliva and GIT fluids (Pierce et al 2009, van der 
Strate et al 2001). Of all the proteins contained within bovine whey, Lf is the most 
widely studied. Lf is a multifunctional protein whose properties include anti-bacterial 
activity and stimulation of beneficial intestinal bacteria (discussed in paragraph 1.6.4), 
as well as other functional properties such as anti-viral, immunomodulatory, anti-
cancer and anti-inflammatory activities (García-Montoya et al 2012, Jenssen & 
Hancock 2009). Briefly, the antimicrobial activity of Lf has been studied both in vitro 
and in vivo. Lf is effective against both Gram-positive and Gram-negative bacteria, 
exerting both bacteriostatic and bactericidal activity. Lf comprises two homologous 
lobes, each of which can bind one ferric ion (Fe2+ or Fe3+) (Baker et al 2003). Lf, 
therefore, exerts bacteriostatic activity through the sequestration of iron away from 
bacterial pathogens, thus limiting the use of this vital nutrient and down-regulating the 
expression of virulence factors (Parrow et al 2013). Lf also invokes bactericidal effects 
on pathogenic bacteria through direct interaction with bacterial surface proteins 
(Ellison et al 1988, Miyazawa et al 1991). For all these reasons, Lf may now be thought 
of as a nutraceutical protein and its use in nutritional and pharmaceutical application 
has been encouraged. 
1.6.1.5 Lactoperoxidase 
A member of the mammalian peroxidases family, the 78 KDa enzyme Lp accounts for 
0.25-0.50% of the total protein content of whey and is found in biological secretions 
such as tears, saliva and milk. It is a heme-containing chain glycoprotein and binds a 
covalently linked heme prosthetic group, a derivative of protoporphyrin IX, in its 
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catalytic centre (Sharma et al 2013). One of the most important enzymes in plain milk, 
Lp plays an important role in its preservation and has several commercial applications 
such as food and crop preservation and protection of the oral cavity against bacterial 
infection (Boots & Floris 2006, Reiter & Harnulv 1984, Seifu et al 2005). As well 
described by Köksal et al, antibacterial activity relies on the presence of both the 
thiocyanate anion (SCN-; which is present in significant levels in natural secretions 
such as saliva and milk) and hydrogen peroxide (H2O2) and is based upon the ability 
of Lp to catalyse the oxidation of SCN-  (Köksal et al 2016). This Lp-catalysed reaction 
results in the formation of short-life intermediary compounds, primarily 
hypothiocyante (OSCN-) and hypothiocyanous acid (HOSCN), which are thought to 
invoke anti-bacterial activity via the inhibition of the essential metabolic pathways 
such as glycolysis by the oxidation of sulfhydryl groups of bacterial proteins in both 
Gram-positive and Gram-negative bacteria (Bafort et al 2014, Tenovuo 2002). The 
formation of intermediary compounds from the Lp-catalysed oxidation of SCN- is pH 
dependant and may result in the formation of other bactericidal compounds such as 
cyanosulphuros acid (HO2SCN) and cyanosulphuric acid (HO3SCN). The Lp anti-
bacterial system plays an important role in the maintenance of oral health, where the 
Lp/SCN-/ H2O2 system was shown by Welk et al to have bactericidal activity against 
both Streptococcus mutans and S. sanguinis, which are associated with both dental 




1.6.2 Casein: a brief overview 
Bovine milk, the most popular animal milk consumed by humans, together with goat 
milk, contains four caseins: αS1, αS2, β and κ (Farrell et al 2004). Also present is γ-
casein, which is a product of degradation of β-casein (Andrews 1983). Caseins provide 
one of the best example of intrinsically or natively disordered (or natively unfolded) 
proteins, with very little secondary and tertiary structures, despite being functional 
(Thorn et al 2015). In raw milk, caseins are the most abundant proteins and they are 
responsible for the white colour of the milk. In addition, caseins can assemble into 
micelles, which are spherical colloidal structures that include all four casein species. 
These entities are stabilized by physiochemical properties, which allow them to bind 
calcium. For this reason, the key biological functions of caseins are to carry calcium 
and phosphate and to form a clot in the stomach for efficient digestion (Huppertz et al 
2018). 
These secretory calcium‐binding phosphoproteins possess high heat stability: only 
temperatures above 120˚C make caseins insoluble (Tamime 2007). Their content of 
non-polar amino acids amounts to 32 -42%, making these proteins high hydrophobic. 
However, the association with calcium and phosphates allow them to be soluble in 
aqueous solvents (Fox et al 2015).  
Once ingested, caseins coagulate in the acidic environment of the stomach, which 
delays its gastric emptying. When they reach the stomach, the proteolytic enzymes 
attack the external part of the micelles first, and then the hydrophobic subunits inside, 
which are insoluble. For this reason, caseins take a relatively long time to be digested, 
inducing a slow postprandial increase in plasma amino acids; this ensures a dietary 
amino acid availability that lasts for few hours (Boirie et al 1997).   
Caseins are essential for human growth and development and they contribute to 
functions related to nutrient and vitamins uptake (Hoffman & Falvo 2004). Many in 
vivo and in vitro studies have attributed anticarcinogenic, antibacterial activity and 




1.6.3 Whey protein effects on satiety, body weight, energy balance 
and inflammation 
Acquiring a better understanding of the fundamental mechanisms by which WP 
interventions affect mechanisms regulating energy balance would provide the basis 
for the development of enhanced health promoting food products for the consumer. 
The following provides an overview of what is known about the effects of dietary WP 
(both individual and collective proteins in the form of WPI or WPC) and the 
outstanding knowledge deficit in terms of developing these proteins or their bioactive 
components as food ingredients for the affected individuals. 
 
1.6.3.1 Whole and individual whey protein effects on satiety control 
WP can influence energy balance through appetite control via their satiety properties 
(Table T1.4). While it is generally accepted that dietary protein induces a greater 
satiety effect than other macronutrients such as carbohydrates or fats  (Tome et al 
2009), data from several studies have suggested that WP is more potent satiety inducer 
than other protein sources. A study by Hall et al reported that the intake of WP (48g) 
delayed the desire to consume a subsequent meal by 180 minutes when compared to 
casein in lean individuals (Hall et al 2003). In another human study it was shown that 
the consumption of a diet of protein, carbohydrate and fat, which provided 10%, 55% 
and 35% energy, respectively, reduced hunger more effectively when WP were 
included in the diet rather than casein or soy protein (Veldhorst et al 2009a). In a 
further study in lean subjects, Pal and Ellis reported significantly reduced mean energy 
intake and appetite during a subsequent buffet meal (4h later) in individuals who had 
consumed a blended drink containing WP, compared to those which had consumed a 
blended drink containing the same amount (50g) of either egg, tuna or turkey protein 
(Pal & Ellis 2010a). Later on, they showed that WP ingestion in the morning time has 
a stronger satiety effect and increased fullness just before lunch time (approximately 
4 hours later) compared to casein in overweight and obese humans (Pal et al 2014). It 
has been suggested that WP provides a greater satiety effect than other proteins due to 
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its higher content of BCAAs and, in particular, leucine (Sharp et al 2019). Leucine, 
which enters the brain more rapidly than any other amino acid (Yudkoff et al 2005), 
has been shown through intracerebroventricular injection to play an important role in 
appetite suppression, which suggests that WP invokes a central effect on energy intake 
(Morrison et al 2007). It is also possible that these effects are mediated by the high 
tryptophan content in whey. Tryptophan is a precursor of serotonin, an important 
appetite regulator (Sharma & Sharma 2012), thus the high tryptophan content of LAB 
may, in turn, increase satiety through an increase in serotonin production. Regardless, 
a study by Veldhost et al demonstrated that a breakfast diet where LAB provided either 
10% or 25% energy reduced lunchtime energy intake when compared to a breakfast 
diet deriving protein energy from casein, soy or whey (Veldhorst et al 2009b). This is 
consistent with the observations of Hursel et al who also reported that a LAB-enriched 
diet had a greater effect on appetite suppression than a whey diet (Hursel et al 2010). 
These results suggest a use for LAB in appetite control. Something to keep in mind is 
the extreme importance of amino acid quality in energy balance regulation. It has 
recently been shown that a long-term ingestion of an imbalanced quantity of amino 
acids, in particular BCAAs, leads to a dysfunction of appetite regulation and, 
consequently, to hyperphagia (Solon-Biet et al 2019).  
Another mechanism by which WP (or whey peptides resulting from gastric digestion) 
may influence energy intake is by the stimulation of hormones described in paragraph 
1.1.3, which are important regulators of energy intake. In support of this, it was shown 
that dietary WP intake (50g) decreased appetite in both lean and overweight 
individuals and this change was coupled with increased plasma levels of CCK and 
GLP-1 and reduced levels of ghrelin when compared to glucose intake (Bowen et al 
2006a, Bowen et al 2006b). The results of this study are in line with those of other 
studies in both humans and animal models (Hall et al 2003, Zhou et al 2011). Normal-
weight women that consumed a drink enriched in WP containing naturally present 
GMP showed an increase in plasmatic levels of CCK, GLP-1 and PYY at different 
timepoints after the drink administration, relative to women having a maltodextrin-
supplemented drink (Chungchunlam et al 2015). In obese male rats consuming a diet 
enriched in WP (WPI, LAB or Lf), an increase in plasma levels of PYY was noticed 
and, consequently, a stronger satiety effect compared to the control group (Zapata et 
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al 2018). These results suggest that WP or its associated bioactive peptides can reduce 
energy intake by the activation or suppression of important appetite regulating 
hormones within the gut. 
All together, these results suggest that, in lean individuals/animals, WP 
supplementation enhances satiety. However, some studies have suggested that the 
satiety effect of WP may be reduced in obese individuals/animals despite WP-induced 
reduction in body weight gain. In a study using diet-induced obese (DIO) rats, a similar 
energy intake pattern was observed in mice, which had whey supplemented drinking 
water (100g/L) compared with those provided with un-supplemented drinking water, 
despite the former group having significantly lower body weight (Eller & Reimer 
2010). This trend has also been shown in humans where supplementation reduced 
subsequent energy intake in normal weight but not obese individuals (Bellissimo et al 
2008). A few studies have demonstrated that, in addition to influencing the 
concentration of circulating satiety hormones, the presence of WPI had an impact on 
gene expression level of neuropeptides within the hypothalamic cells. It was shown 
that mice fed a LFD with a high or low sucrose dose that contained WPI as the main 
protein source showed a trend towards a decrease and increase in the genes encoding 
POMC and NPY, respectively, compared to the CAS counterparts (Nilaweera et al 
2017). In contrast, in Wistar rats, a phyto-oestrogen free (PF) diet given with WPC 
supplementation showed an increase in the hypothalamic expression of POMC, 
together with a decrease in energy intake relative to rats fed a PF diet without any 
supplementation (Andreoli et al 2016).  
 
Results from these studies suggest that the beneficial effects of WP on appetite 
suppression may be more significant and potent in lean than obese individuals. Based 
on this observation, it is possible that the presence of HFD might interfere with the 






Table T1.4 In vivo studies reporting whey protein (WP) effects on energy intake, satiety and 
satiety hormones and neuropeptides. Abbreviations: LAB, α-lactalbumin; BSA, bovine serum 
albumin; Lf, lactoferrin; Lp, lactoperoxidase; GMP, glycomacropeptide; HFD, high-fat diet; 
LFD, low-fat diet; HSD, high-sucrose diet; LSD, low-sucrose diet; CCK, cholecystokinin; 
GLP-1, glucagon-like peptide 1; PYY, peptide YY; PP, pancreatic polypeptide; POMC, 
proopiomelanocortin; NPY, neuropeptide Y; IL3, interleukin 3; INFγ, interferon gamma, 
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1.6.3.2 Whole whey protein effects on body weight, energy balance and 
inflammation 
With the current worldwide obesity epidemic, the anti-obesity properties associated 
with WP has attracted much attention in the recent years. Several studies have 
highlighted the anti-obesity effects of WP or, more specifically, its ability to reduce 
HFD associated increased body weight and fat mass accumulation (Table T1.5). Also 
casein, compared to other non-dairy proteins, is more efficient in preventing weight 
gain and accretion of adipose mass. In a recent study conducted in C57BL/LJ mice, 
Liisberg et al investigated the effect of a high-fat diet/high-protein diet using casein, 
soy, cod filets, chicken, beef, pork as protein sources. Casein was revealed to be the 
most efficient of these protein sources in obesity prevention and in lowering fat mass 
(Liisberg et al 2016). A decrease in body fat accretion and changes in the urinary 
excretion of phase II metabolites in the presence of hydrolysed casein were also 
demonstrated in obesity prone mice (Clausen et al 2015). However, in humans it was 
recently shown that casein consumption before sleep did not affect fat or glucose 
metabolism, RER, or suppress appetite in hyperinsulemic obese men, relative to the 
placebo control (Kinsey et al 2016). Notably, WP was not tested in this study. 
 
The reason why WP, and not casein, was selected in this thesis as a better candidate in 
the treatment of metabolic diseases is because this protein is more effective than casein 
in influencing body weight and energy balance. Pezhesky and colleagues recently 
demonstrate that WP and casein have a differential effect on energy balance, gut 
hormones and glucose metabolism in rats. A diet enriched in both CAS and WP caused 
a reduction in body weight, adiposity and food intake and an improvement of glucose 
tolerance but, in all cases, the effect of WP was more robust compared to CAS, without 
showing changes in energy expenditure (Pezeshki et al 2015). Another study showed 
that both WP and casein ameliorated energy balance, indices of renal inflammation 
and damage, and prevented morbidity associated with stroke in spontaneously 
hypertensive stroke-prone rats fed with HFD supplemented with 1% salt in drinking 
water for 12 weeks. However, only WP decreased fat mass and blood pressure (Singh 
et al 2016). In humans, WPI supplementation improves body composition by 
increasing lean mass in women without affecting changes in fat mass. The body weight 
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composition improvement was more evident if coupled with energy restriction (Bergia 
et al 2018). Several studies from our group aimed to extend the understanding of WP 
and energy balance regulations. The effect of WPI supplementations was investigated 
in the presence of a low/standard-fat diet (LFD; 10% fat by calories), high-fat diet 
(HFD; 45% fat by calories), low-sucrose diet (7% sucrose by calories) high-sucrose 
diet (HSD; 35% sucrose by calories) in male C57BL/J6 mice. Mice fed a LFD 
supplemented with 20% of WPI for 15 weeks showed a decrease in weight gain, 
cumulative energy intake and dark-phase VO2 compared with CAS-fed mice. In 
addition, a reduction in stomach and small intestine size was observed in mice that 
ingested WPI-supplemented diet, which had an additional decrease in the small 
intestinal expression of genes encoding PYY, FATP4 and IR compared to mice fed 
with LFD-CAS. Plasma leptin, insulin, TAG and GLP-1 remain unchanged between 
the two groups (McAllan et al 2015). In the same mouse strain, but in females, in 
which WPI was supplemented in drinking water, a decreased in hepatic lipid droplets 
and an increase in basal metabolic rates, respiratory quotient, glucose tolerance and 
insulin sensitivity were noticed (Shertzer et al 2011). Mice fed with HFD containing 
20% WPI for 8 weeks gained less weight and had an increase in the lean mass 
compared to their CAS counterparts (McAllan et al 2013). Interestingly, the change in 
energy intake could not account for the decrease in body weight gain, suggesting 
another mechanism was at play. A higher percentage of lean mass was observed also 
when the same diet was given for 21 weeks. Increasing the WPI portion in the HFD 
up to 40% (and proportionally reducing the carbohydrate content) caused a drastic 
drop in body weight gain, with observed values very similar for the low-fat diet control 
group. In addition, WPI reduced HFD-induced plasma leptin and liver TAGs 
(McAllan et al 2014). Again, in this study also, at moderate WPI content (20%), energy 
intake was not different to CAS-fed controls, but there was a trend towards a decrease 
in fat mass in the former group. Finally, in our recent study, we did observe differences 
in body weight gain but no changes in energy expenditure between mice fed with high-
sucrose diet (HSD)-WPI and HSD-CAS. However, the HSD-WPI showed a reduction 
in RER, adipose tissue weight and ileal gene expression of the amino acid transporter 
SLC6a19, glucose transporter 2 (GLUT2) and FATP4. In this study, it was noticed 
that the mice that were ingesting WPI, both in HSD and LSD, increased energy intake 
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compared to the CAS groups and yet they reduced weight gain (Nilaweera et al 2017), 
further strengthening the idea that there is a, so far unidentified mechanism through 
which whey affects energy balance that does not rely on energy intake. 
 
Pilvi et al have suggested several mechanisms by which WPI may reduce symptoms 
of obesity in a series of studies in C57BL/J6 mice consuming HFD (60% fat by 
calories). Initially, mice receiving HFD containing 18% WPI and 1.8% of calcium 
carbonate (CaCO3, which has anti-obesity properties) showed a significant decrease 
in body weight and fat coupled with significantly high levels of fat excretion when 
compared to mice in receipt of a similar diet where CAS was the protein source and 
which had a lower percentage of CaCO3 (0.4%). It was suggested that the reduction in 
weight gain and fat excretion results from the high leucine content of whey modulating 
insulin signalling, thus directing energy towards muscle biosynthesis rather than fat 
storage in adipose tissue (Pilvi et al 2007). In a follow-up study employing the same 
diet groups for the same 21-week study period, the authors observed the same 
inhibition of fat mass accumulation within the whey consuming cohort combined with 
a significant up-regulation of leptin and β-adrenergic receptor genes, leading the 
authors to suggest that WPI attenuates symptoms via improved leptin sensitivity and 
increased lipolysis (Pilvi et al 2008). Recently, WPI demonstrated a positive effect on 
cardiovascular derangements. A chronic 10% or 20% WPI supplementation (18 
weeks) improved high-fat/high-cholesterol diet-induced atherosclerosis in 
atherosclerosis-prone apolipoprotein E-deficient (ApoE null) mice. In particular, in 
the presence of WP, reductions in aorta lesions and cholesterol accumulation within 
the liver were observed along with an increase in serum high-density lipoprotein 
cholesterol levels. Moreover, serum IL6, a pro-inflammatory cytokine, and IL10, an 
anti-inflammatory cytokine, were decreased and increased, respectively, by WP 
supplementation (Zhang et al 2018). 
 
In summary, the above findings suggest that dietary WP can affect energy balance 




1.6.3.3 Specific whey protein effects on body weight, energy balance and 
inflammation 
All the aforementioned studies assessed the effect of whole WP components 
administered together. However, it is important to explore which specific effects can 
be attributed to WP components (Table T1.5). In a study from Pilvi et al, mice 
previously fed with HFD were placed on a low-calorie weight loss diet containing 
different WP components (LAB, LAG, WPI and Lf) for 50 days before being returned 
to ad libitum feeding. Mice which consumed the LAB diet showed a significant loss 
of fat mass during the calorie restricted period and a subsequent reduction in visceral 
fat gain during the weight recovery period compared to all other dietary groups (Pilvi 
et al 2009). In another study, Gao et al initially provided mice with HFD (60% fat by 
calories) and then, after 8 weeks, introduced hydrolysed LAB (LABH) in the diet for 
further 12 weeks. The presence of LABH in the HFD caused a decrease in the weight 
gain, blood glucose, serum insulin and downregulated the inflammation-related genes 
and the gene encoding insulin receptor substrate (Irs-1) in the adipose tissue. In 
addition, TNFα, IL6 and MCP-1 expression was downregulated within the adipose 
tissue in the presence of LABH. This suggests that LABH ameliorates adipose insulin 
resistance and inflammation in HFD-fed C57BL/6J mice (Gao et al 2018). Recently, 
in another study, LABH administration was shown to reduce inflammation and inhibit 
the destruction of the gut barriers through an upregulation of some TJs expression in 
the colon in HFD-induced endotoxemia and systematic inflammation in mice (Li et al 
2019a). In rats, Zapata et al, remarked on the importance of protein quantity and 
quality in energy balance improvement. DIO rats were randomized to isocaloric diets 
containing WPI, LAB, Lf or pair-fed to Lf. Both LAB and Lf led to a decrease in 
calories intake, body weight, plasma leptin and plasma insulin in the animals. 
Specifically, rats with Lf-supplemented diet decreased the energy expenditure and rats 
supplemented with LAB increased plasma PYY (Zapata et al 2017b). Recently, a study 
in pigs was performed, in which Caesarean-delivered preterm pigs were fed with 
bovine milk or bovine milk containing WPC enriched in LAB. The presence of WPC 
enriched in LAB improved organ growth and immunity parameters (Nielsen et al 
2020). A study conducted in humans reported that LAB had the same efficacy in 
reduction of body weight, fat mass and in the preservation of fat-free mass as similar 
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daily intakes of milk proteins during six months of calorie restriction (Soenen et al 
2011). 
 
A few studies have been focusing also on the role of bovine Lf in energy balance. A 
12-week Lf administration to HFD-induced obese mice decreased body weight gain, 
blood cholesterol and glucose concentration, and alleviated liver steatosis. Moreover, 
the HFD-Lf group showed a decrease in leptin and plasminogen activator inhibitor 
(PAI-I) expression in the adipose tissue, which could be attributed to a decreased LPS 
translocation and gut inflammation (Sun et al 2016). Conversely, we have shown that 
the body weight HFD-Lf-fed mice did not differ from their CAS counterparts. 
However, the Lf group had lower levels of leptin and corticosterone in the blood 
(McManus et al 2015a).  
 
There is evidence that BSA may also beneficially influence fat mass accumulation as 
noted in our study by McManus et al (McManus et al 2015b). In this study, C57BL/6 
mice fed with HFD, where BSA was the dominant dietary protein source, for 13 weeks 
had significantly reduced subcutaneous fat mass, plasma leptin and plasma 
corticosterone relative to animals that consumed a HFD where CAS was the dominant 
dietary protein source. Notably, BSA-fed mice had elevated energy intake but reduced 
body weight. 
 
There are no evidences for an impact by LAG or Lp on body weight and energy 
balance, but they have an influence on immunity. As already mentioned in paragraph 
1.6.1.1, LAG plays a role in enhancing the immune response and its enzymatic 
hydrolysis produces a higher yield of short bioactive peptides with potential 
antioxidant and anti-inflammatory effects (Bamdad et al 2017, Tai et al 2016). 
Similarly, in BALB/c mice, it was demonstrated that the oral administration of Lp 
causes a change in expression of several genes involved in metabolism, apoptosis and 
immunity (in particular the gene that encode the immunity-regulator FKBP5) in small 
intestinal epithelial cells (Wakabayashi et al 2007). Lp administration also ameliorates 
colitis by upregulating colonic anti-inflammatory cytokines and maintaining 
peripheral regulatory T cells (Shin et al 2009). Taking into account the link between 
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metabolic diseases, such as obesity, and increase in chronic low-grade inflammation 
(Saltiel & Olefsky 2017), it is not odd to think that LAG and Lp could have a positive 
effect on these diseases and have a co-adjuvant effect for other specific WPs within 
WPI.  
All of these findings suggest that WP modulate energy balance, lipid metabolism and 
body composition, even if it is still a challenge to precisely assign each WP component 
a specific role or mechanism of modulation. It is important to highlight that the activity 
of WP can vary according to quantity of protein intake, kind and quantity of micro 
(i.e., CaCO3) and macronutrients (i.e., fat, sucrose) present in the diet, the 
hydrolysation status and model used in the study (mice, rat or humans). 
 
Table T1.5 In vivo studies reporting whey protein (WP) effects on energy expenditure, body 
weight, metabolism regulation and inflammation. Abbreviations: LAB, α-lactalbumin; BSA, 
bovine serum albumin; Lf, lactoferrin; WPC, whey protein concentrate; DIO, diet-induced 
obesity; HFD, high-fat diet; LFD, low-fat diet; HSD, high-sucrose diet; LSD, low-sucrose 
diet; βAR, beta adrenergic receptor; TAG, triacylglycerol; VO2, oxygen consumption rate; 
FATP4, fatty acid transporter 4; IR, insulin receptor; RER, respiratory exchange ratio; 
SLC6a19, Sodium-dependent neutral amino acid transporter B(0)AT1 gene; GLUT2, glucose 
transporter 2; IL6, IL10, interleukin 6 and 10; IRS1, insulin receptor substrate 1; TNFα, 
tumour necrosis factor alpha, MCP-1, monocyte chemoattractant protein 1; TJ, tight junction; 
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1.6.4 Whole and individual whey protein effects on the gut 
microbiota 
The composition of the gut microbiota undergoes dramatic changes throughout the life 
cycle of the host. Protein components of whey appear to play important roles in the 
development of the infant gut microbiota by stimulating beneficial bacteria species 
such as members of the genera Bifidobacterium and Lactobacillus and providing 
protection against opportunistic pathogens, including pathogenic E. coli strains 
(Hascoet et al 2011, Mastromarino et al 2014, Subramanian et al 2014). However, the 
impact of dietary WP intake on the stable adult gut microbiota is currently poorly 
understood. Some promising results have been reported in the few studies examining 
the effect of dietary protein on the gut microbiota. Firstly, when compared to other 
dietary protein sources such as red and white meat, soy and casein, WP is shown to 
exert significantly less colonocyte DNA damage in rats (Toden et al 2007a, Toden et 
al 2007b). This result suggests that bacterial fermentation of WP does not result in a 
large array of the putrefactive metabolites traditionally associated with high dietary 
protein intake, and therefore WP represent potential novel candidates for beneficial 
gut microbiota modulation. Sprong et al reported that the consumption of a diet 
containing WP increased faecal Lactobacillus and Bifidobacterium counts in Wistar 
rats, when compared to those consuming the same diet but where the protein energy 
source was CAS (Sprong et al 2010). Similar results were reported by our group where, 
using 16S rRNA sequencing, we demonstrated significantly higher Lactobacillus and 
Bifidobacterium populations with a concurrent significant decrease in Clostridium 
populations in C57BL/6 mice consuming HFD-WPI compared to mice consuming a 
HFD-CAS (McAllan et al 2014). However, in a similar study, Tranberg et al did not 
observe any difference in the composition of the gut microbiota between two groups 
of C57BL/6 mice consuming HFD where the protein source was either casein or whey. 
Although, in the latter case, microbiota analysis was determined by less detailed, 
denaturant gradient gel electrophoresis (DGGE)-based, approach (Tranberg et al 
2013). In mice fed with WP-standard diet but with different percentages of sucrose, 
the proportion of Firmicutes was consistently lower, compared to the CAS 
counterparts, at different timepoints (Nilaweera et al 2017). Notably, another study 
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showed that, in comparison to a standard diet, an enteral whey-peptide based murine 
diet significantly increased concentration of cecal SCFAs (Tomoda et al 2015). While 
results from this study indicate that the microbial fermentation of WP or associated 
bioactive peptides promotes gut health through increased SCFA production, the 
authors did not examine the composition of the gut microbiota or the SCFA producing 
bacteria species (Tomoda et al 2015). In vitro gastrointestinal digestion following 
faecal batch culture fermentations (mimicking colonic fermentation), using faeces 
from normal-weight and obese donors, has been the basis of another study. Through 
this, the authors showed how a diet containing WP can selectively stimulate the growth 
of Bifidobacterium and Lactobacillus, enhancing SCFA production and contributing 
to improved intestinal health and reducing obesity (Sanchez-Moya et al 2017). 
 
There have been few human studies, focusing on assessing the effect of dietary WP 
coupled with exercise on gut microbiota composition. Clarke et al observed a 
significantly higher microbial diversity, which is a biomarker of good health, 
associated with the gut of professional rugby players relative to controls. The higher 
diversity was positively correlated with protein intake with, notably, whey protein 
supplements represented a significant proportion of the athletes’ total protein 
consumption (Clarke et al 2014b). The relationship between exercise and WP 
consumption was recently investigated also in healthy but sedentary adults that 
underwent short-term exercise and/or WP supplementation of their diets. During the 
exercise period the participants either consumed or refrained from consuming daily 
WP. The changes in gut microbial composition and function were modest following 
increases of physical activity but, in the whey protein-supplemented group, a 
significant change in the gut virome was evident. In this study, no differences were 
found in bacteria and archaea diversity following whey protein consumption (Cronin 
et al 2018).  While data from these initial studies suggest a potential use for WP in the 
beneficial modulation of the gut microbiota, more studies using specific component 





As mentioned in paragraph 1.6.1.4., bovine Lf is a growth promoter of several bacteria 
that colonize our gut, such as Bifidobacterium spp. (Oda et al 2014). In vitro, both apo-
Lf (iron free) and holo-Lf (iron saturated) exhibited bifidogenic activity with respect 
to several species of Bifidobacterium (i.e., B. infantis, B. breve, B. bifidum, B. longum) 
(Morshedur Rahman et al 2010, Saito et al 1996). Multiple in vivo studies have also 
established that Lf exerts bifidogenic effects. Hentges et al reported gnotobiotic mice 
associated with a human infant gut microbiota consuming a milk fortified with bovine 
Lf had increased counts of Bifidobacterium compared with mice consuming un-
supplemented formula (Hentges et al 1992). Furthermore, recombinant human Lf 
(rhLf) was shown to modulate the intestinal microbiota of piglets and increase ileal 
populations of Bifidobacterium spp. and Lactobacillus spp .(Hu et al 2012). Bovine Lf 
has also been shown to exert a positive effect on the gut microbiota also in HFD-
induced obese mice, increasing the Bifidobacterium spp. and modestly inhibiting the 
growth of Enterobacteriales (Sun et al 2016). These combined results suggest that the 
ingestion of Lf positively modulate the gut microbiota through exerting a probable 
prebiotic effect. 
 
While at the moment there is no data relating the specific effects of LAG, BSA and 
Lp on the modulation of the gut microbiota during normal or HFD, a few studies have 
focused on LAB. ln HFD-fed mice supplemented with LAB hydrolysates (LABH), 
there was an increase in the relative abundance of Lachnospiraceae and Blautia (Li et 
al 2019a). In addition, Cesarean-delivered preterm pigs fed with milk containing LAB-
enriched WPC showed an increase in Clostridiaceae, Streptococcus, 
Enterobacteriaceaea and Strepromyces within the gut microbiota, together with 
changes is some bacterial metabolites, such as acetic acid and butanoic acid (Nielsen 
et al 2020). 
 
In summary, in many cases, supplementation of WP in a normal diet or in a HFD have 
been show to positively modulate the gut microbiota by increasing the growth of 
beneficial taxa, such as Bifidobacterium spp. and Lactobacillus spp.. Based on results 
to date, the most important players would seem to be LAB and Lf. 
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1.6.5 Whole and individual whey protein effects on mood and 
behavioural control 
As mentioned in paragraph 1.6.3.1, bovine WP is rich in BCAAs and tryptophan. We 
have previously noted that the essential amino acid tryptophan is a precursor of 
serotonin. WP contains a higher percentage of tryptophan than other protein sources. 
Furthemore, LAB is known to have the highest proportion of tryptophan (approx. 6%) 
compared to other WP components (Madureira et al 2007). Due to its particularly high 
tryptophan contents, diets enriched in LAB were thought to have beneficial effects on 
mood and cognition. Several studies have been done in light of this hypothesis. Markus 
et al carried out three such studies. Initially, they recruited both highly stressed, 
vulnerable and relatively-stressed invulnerable subjects, which have been exposed to 
experimental stress after diet enriched in LAB or CAS intake. The supplementation 
with LAB resulted in an increase in plasma tryptophan levels in both groups and, 
through profile of mood states, measurement of skin conductance and peripheral pulse 
frequency, a reduction in depressive-like behavior and stress were recorded among 
stress-vulnerable subjects. These findings were coupled with a decrease in salivary 
cortisol, the “stress-hormone”, and an increase in plasma prolactin, which is an 
indication of stress reduction, and brain serotonin activity (Markus et al 2000). Again 
in stress-vulnerable subjects, the authors found increased ratio of plasma tryptophan, 
coupled with large neutral amino acids, and improved cognitive performance during a 
dietary intervention that included WP enriched in LAB (Markus et al 2002). A few 
years later, the same research group carried out another human study that included 
healthy subjects with or without sleep complaints. They demonstrated that LAB-
enriched diet intake in the evening caused, as expected, a dramatic increase in 
tryptophan in the blood before bedtime. In the morning, in both groups but especially 
in subjects with sleep complaints, subjects that had LAB-enriched diet were feeling 
“less sleepy” and their behavioral performance, together with brain sustained-attention 
processes, were improved (Markus et al 2005). Despite these encouraging findings, a 
human study carried out on unmedicated recovered depressed subjects showed that, 
although a diet enriched in LAB led to the expected rises in circulating tryptophan, 
only minimal effects were found on mood and cortisol response to experimental stress, 
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which is not sufficient to prevent a stress-induced mood deterioration in this specific 
category of subject (Merens et al 2005). However, a dietary LAB supplementation 
improved abstract visual memory in unmedicated recovered depressed subjects, 
suggesting a possible utilization of this WP component to mediate age- or decline-
related memory decline (Booij et al 2006). Notably, in these last two studies, the 
authors pointed out that one of the limitations of the studies is the effective exposure 
to LAB-enriched diet, discussing that the long-term effect of LAB intake should be 
investigated. In addition to the beneficial effects exerted by dietary LAB on stress, 
sleep control and memory, a study conducted in rats attributed an anxiolytic-like effect 
to LAB. Notably, Wistar rats were fed with LAB or CAS-enriched diets acutely (30 
minutes meal) or chronically (3 and 6 days). Animals fed with LAB-supplemented diet 
significantly increased the amount of serotonin produced by the hypothalamus, 
coupled with an increase in the time spent on the open arms of the elevated plus maze 
and increased number of visits to the center of the open field, indicating a less anxious 
status. Furthermore, a single LAB meal decreased sucrose consumption, reflecting an 
appetitive and/or rewarding action of this WP component (Orosco et al 2004). Further 
details on LAB applications in human nutrition are detailed elsewhere (Layman et al 
2018b).  
 
WP-derived peptides have also been investigated with respect to a potential role in 
mood and behavior. In a recent study, healthy humans received either whey peptide 
rich in tryptophan-tyrosine-related peptides (produce by enzymatic digestion of WP), 
or placebo supplements for 12 weeks. Notably, the whey peptide had been previously 
shown to have a positive effect on cognitive and memory performance in mice (Ano 
et al 2018). In agreement with the study conducted in rodents, this specific whey-
derivate peptide improved some cognitive functions in people with a high level of 
subjective fatigue. This study is in accordance with previous epidemiological and 
preclinical findings suggested that intake of whey peptide in daily life might 
experience benefit with respect to cognitive function (Kita et al 2018).  
In conclusion, WPs and, in particular LAB, thanks to their amino acid composition 
containing a high percentage of BCCAs and tryptophan, have a positive effect in 
ameliorating anxiety and stress, improving cognition and feeling refreshed after sleep. 
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The mechanism through which a protein source rich in tryptophan could modulate the 
cortisol levels and, thus, mood can be explained by two different scenarios: 
- a higher tryptophan availability results in a higher serotonin production. It has 
been shown that serotonin plays a role in the functionality of the HPA axis and, 
in turn, influences the production of cortisol. Moreover, a hyperproduction of 
cortisol have been shown to decrease the availability of tryptophan, increasing 
the risk of development of anxiety and depression (Fuchs & Flügge 2003, 
López et al 1998, Nuller & Ostroumova 1980). 
- The gut microbiota uses tryptophan to produce serotonin, indoles and 
kynurenine pathway-related metabolites. These metabolites, in turn, affect 
different functions in the host, including mental health. It could be, thus, there 
might be a link between tryptophan-derived gut metabolites and the 




1.7 Aims and Objectives 
Obesity has become one of the most prevalent health issues over the last decades, due 
to modern eating habits and an increase of sedentary lifestyle. Obesity is a 
multifactorial condition that comes from a long-term imbalance between energy intake 
and energy expenditure (paragraph 1.3). Despite the adoption of several therapies (i.e., 
pharmacotherapies, surgery and dietary therapies) for the prevention or amelioration 
of this metabolic disease, scientific effort is still required to expand therapeutic options 
(Ruban et al 2019). In this thesis, we aim to investigate the impact of a dietary strategy 
focused on bovine whey protein (WP) (paragraph 1.6). Our general goal was to better 
understand WP actions on adiposity, metabolism, energy balance, gut functionality, 
and gut microbiota in the presence of high-fat or low-fat diets. Further, we sought to 
provide mechanistic insight into the various WP-related effects (Fig. 1.10). 
 
1.7.1 Aim 1: Does alpha-lactalbumin influence energy balance, 
nutrient absorption, fat metabolism and gut microbiota 
during high-fat diet feeding? 
Bovine whey is composed by different protein types, present in different proportions. 
Previous studies in our group explored the effect of two WP components, BSA and 
Lf, on energy balance and metabolism (McManus et al 2015a, McManus et al 2015b). 
These studies had contrasting outcomes, confirming the fact that different WP 
components have different characteristics and influence differently energy balance and 
metabolism (paragraph 1.6.1). In this study, we sought to examine if the specific WP, 
LAB, countered the effects of a high-fat diet on gut-hypothalamic-adipose control of 
energy balance.  
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1.7.2 Aim 2: Does a high-fat diet containing whey protein 
differentially affect energy balance, nutrient absorption, fat 
metabolism and gut microbiota at different ages? 
Individuals’ gut microbiota and metabolism are influenced by diet throughout life 
(Conlon & Bird 2014, Drewnowski & Shultz 2001, St-Onge & Gallagher 2010). 
Adolescence is a particular period of development, marked by physical maturation, 
where dietary habits can have a health impact late in life (Das et al 2017, Joung et al 
2012). Thus, we sought to assess if an HFD containing WPI given at two different 
ages, before the adulthood period, would differentially affect energy balance, adipose 
tissue metabolism, intestinal nutrient absorption and gut microbiota configuration. In 
addition, we wanted to assess if WPI given before and during high-fat diet exposure 
would prevent or ameliorate HFD-induced metabolic syndrome. 
 
1.7.3 Aim 3: Does the gut microbiota mediate the effects of whey 
protein on adiposity, gut physiology and lipid metabolism 
during high-fat diet feeding? 
The aforementioned studies (described in Aim 1 and Aim 2) and paragraph 1.6.4 
showed that the gut microbiota configuration is affected by individual and whole WP 
supplementation within HFD. Notably, WPI had a positive effect on HFD-induced 
dysfunctions, such as body weight gain, adiposity, and metabolism-related changes in 
addition to gut microbiota changes. In light of these observations, we investigated if 
WPI-related changes in body weight and adiposity during were HFD mediated by the 
gut microbiota. To assess this, the microbiota of HFD-WPI-fed mice was depleted by 
treating with an antibiotic cocktail for 5 and 10 weeks. During this study, we had the 
opportunity to extend the knowledge of the effect of WP on inflammation, gut 





Figure 1.10 Diagram representing the general aim of the thesis. Top: the general aim of the 
thesis is to better understand WP action on adiposity, metabolism, energy balance, satiety 
control, intestinal physiology, and gut microbiota. In addition, this thesis aims to find a link 
among WP-related changes. Bottom: three aims of the thesis.  Abbreviations: HFD, high-fat 
diet; LAB, α-lactalbumin; WPI, whey protein isolate.
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Rationale Recently there has been a considerable rise in the frequency of metabolic 
diseases, such as obesity, due to changes in lifestyle and resultant imbalances between 
energy intake and expenditure. Whey protein is considered as potentially important 
component of a dietary solution to the obesity problem. However, the roles of 
individual whey proteins in energy balance remain poorly understood.  
 
Objectives This study investigated the effects of a high-fat diet (HFD) containing 
alpha-lactalbumin (LAB), a specific whey protein, or the non-whey protein casein 
(CAS), on energy balance, nutrient transporters expression, and enteric microbial 
populations. C57BL/6J mice (n = 8) were given a HFD containing either 20% CAS or 
LAB as protein sources or a low-fat diet (LFD) containing CAS for 10 weeks.  
 
Results HFD-LAB fed mice showed a significant increase in cumulative energy intake 
(P=0.043), without differences in body weight, energy expenditure, locomotor 
activity, respiratory exchange ratio or subcutaneous and epididymal adipose tissue 
weight. HFD-LAB intake led to a decrease in the expression of glucose transporter 
glut2 in the ileum (P=0.05) and in the fatty acid transporter cd36 (P<0.001) in both 
ileum and jejunum. This suggests a reduction of absorption efficiency within the small 
intestine in the HFD-LAB group. DNA from faecal samples was used for 16S rRNA-
based assessment of intestinal microbiota populations; the genera Lactobacillus, 
Parabacteroides and Bifidobacterium were present in significantly higher proportions 
in the HFD-LAB group.  
 
Conclusions These data indicate a possible functional relationship between gut 







Obesity has emerged as one of the most prevalent global health problems over the last 
30 years because of its association with comorbidities such as chronic inflammations, 
type II diabetes, cardiovascular disorders and certain types of cancer (O'Neill & 
O'Driscoll 2015). Whilst the aetiology of obesity is multifactorial, there is a growing 
recognition that high energy density diets (containing high levels of fat and sugar) are 
major contributors to long-term imbalance between energy intake and energy 
expenditure (Hu et al), with comparable effects seen in rodents including mice such as 
the C57BL/6J strain. Indeed, energy dense diets increase intestinal energy absorption 
and fat storage in adipose tissue (Galgani & Ravussin 2008). 
Additionally, these diets impair the hypothalamic regulation of hormones involved in 
the control of energy balance (Wang et al 2012). Thus, one approach to reducing 
weight gain or causing weight loss would be to devise interventions that affect the 
cross-talk between the gut, adipose tissue and the hypothalamic mechanisms 
regulating energy balance. 
Nutrient digestion and absorption provides the necessary energy for the survival of 
living organisms and the gastrointestinal (GI) tract has evolved to optimise these 
processes (Goodman 2010). In particular, nutrient absorption takes place in the 
duodenum, jejunum and ileum, through paracellular movements or by uptake through 
specific nutrient transporters, which are able to transport fats (i.e., Fatty Acid 
Transporter, FATP4; Cluster Differentiation 36, CD36), sugars (i.e., Glucose 
Transporter 2, GLUT2; Sodium-Glucose transporter Protein 1, SGLT1) and amino 
acids (i.e., L-type Amino acid Transporter 4, LAT4; neural amino acid transporter 1, 
B0AT1) into the blood stream (Ferraris & Vinnakota 1995). 
The complexity of nutrient absorption is further highlighted by the network of diverse 
intrinsic and extrinsic factors regulating this process. With regard to intrinsic factors, 
it is notable that deficiency of the anorexigenic hormone leptin in mice (Ferraris & 
Vinnakota 1995) increases energy ingestion leading to a greater adiposity and weight 
gain, coupled with associated hypothalamic-neuropeptide changes and chronic 
intestinal inflammation (Monteiro-Sepulveda et al 2015). Similarly, targeted deletion 
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of the gene encoding GLUT2, a key intestinal glucose transporter, also increases 
energy intake (Schmitt et al 2017).  
Of the extrinsic factors, the gut microbiota plays a key role in harvesting energy from 
ingested food and providing it for host metabolism (Cani 2013, Clarke et al 2012, 
Torres-Fuentes et al 2017, van de Wouw et al 2017). Hence, germ-free mice are 
protected against obesity despite consuming more calories than control mice, but this 
phenotype is reverted after faecal microbiota transplantation from conventionally 
raised mice (Backhed et al 2004). Using gnotobiotic mice fed a high-fat or low-fat diet 
(HFD and LFD, respectively), a role has been suggested for Clostridium ramosum in 
the upregulation of body fat deposition promoting factors (Woting. A et al 2014). 
These data, coupled with the observed impact of gut microbiota on brain formation, 
including hypothalamic micro-structures (JM. Fernandez-Real JM et al 2015), provide 
novel avenues for modulating the activity of the intestine, adipose tissue and 
hypothalamus, involving microorganisms. 
Αlpha-lactalbumin (LAB) is a globular protein well known as a source of peptides 
having beneficial properties such as antioxidant bioactivity and immune modulation 
ability (Mburu et al 2010). It constitutes around 25% of the bovine milk whey protein 
(Mburu et al 2010). Whey can be extracted during the manufacture of cheese and 
comprises also other protein types, varying in abundances, including β-lactoglobulin 
(~ 65%), bovine serum albumin (BSA, ~8%), lactoperoxidase (0.25-0.5%), lactoferrin 
(Lf, ~1%) as well as other minor proteins such as immunoglobulins (<1%) (Morr & 
Ha 1993). Recently, whole whey protein has been considered as a potential dietary 
solution to obesity in light of the discovery that this protein, as an isolate (WPI) or 
concentrate (WPC), acutely increases the production of hormones that are involved in 
satiety in both humans and rodents (Chungchunlam et al 2015, Zhou et al 2011). 
Moreover, intake of whey protein in humans reduces fat absorption (Stanstrup et al 
2014). This effect might be attributed to an altered composition of the gut microbiota 
involved in energy harvest, since other studies have shown that dietary whey protein 
can influence the composition of the gut microbiota (McAllan et al 2014, Nilaweera 
et al 2017, Sanchez-Moya et al 2017, Sprong et al 2010).  Indeed, we showed that WPI 
reduced the proportion of Firmicutes in the mouse gut microbiome (Nilaweera et al 
2017), and this was accompanied by a reduction in the expression of intestinal nutrient 
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transporters, specifically glut2 and fatp4. In addition, we showed that WPI reduced 
epididymal adipose tissue (eWAT) weight and overall body weight gain. Consistent 
with changes in the gut, WPI increased energy intake, which was reflected in the 
altered hypothalamic gene expression of neuropeptides, namely proopiomelanocortin 
(pomc), neuropeptide Y (npy) and ghrelin (Nilaweera et al 2017).  
While these data suggest a modulatory effect of WPI on the gut microbiome, 
hypothalamus and adipose tissue, it was not clear if the changes in energy intake were 
driven directly from the gut/hypothalamus axis or were secondary to the changes in 
adiposity. Indeed, previously it was shown that specific whey protein components, 
such as BSA and Lf, influenced in a different way body weight, energy intake and 
plasma leptin level (McManus et al 2015a, McManus et al 2015b). 
Given that, LAB has been shown to affect the energy balance but the underlying 
mechanism is still unclear (Gao et al 2018, Zapata et al 2017a), in the current study 
we sought to further investigate the link established previously between gut-
hypothalamic-adipose control of energy balance using LAB as the main protein 
source. The protein was given in a physiological amount (i.e., 20% calories) during 
HFD-induced weight gain phase in the C57BL/6J strain of mice, which was used as 
the model for humans. LAB was introduced early in development (5 weeks of age), 
given WPI specificity to influence weight gain during this period (Tranberg et al 
2013). As the control, we fed mice with LFD or HFD containing the same 
















The in vivo experiments were approved by the University College Cork Animal 
Experimentation Ethics Committee (2011/005) and were licensed under the European 
Directive 2010/63/EU. Twenty-four C57BL/6J three-week-old male specific pathogen 
free mice were purchased commercially (Harlan; UK) and were singly housed in each 
cage with enrichment (Litaspen 8/20 and alpha-dry Plus bedding; LBS-biotech, UK) 
on a 12 h light/dark cycle with humidity maintained at 45-60% and temperature 
between 19-22°C. The mice had ad libitum access to food and water throughout the 
study unless otherwise stated. The health of the animals and the environment 
parameters were checked and recorded daily. No adverse effects were observed by the 
dietary interventions or procedures detailed below. The mice were provided with a diet 
containing 10% (low) fat and 20% casein (LFD-CAS; #D12450Bi; Research Diets, 
USA) (all % values by energy) during the initial 2 week acclimatization period, and 
then weight matched mice were switched to a 45% (high) fat diet containing either 
20% casein (HFD-CAS; #D12451i) or alpha-lactalbumin (HFD-LAB; #D13081701i) 
(n=8 per group). The controls continued to receive LFD-CAS (n=8). The diets were 
OpenSource and were made by Research Diets, USA, with LAB sourced from Sigma, 
USA (diets composition details, Table 2.TS1). Body weight as well as food intake 
were measured weekly. The latter was converted to gross energy intake using the 
dietary energy density of the diets (HFD=19.79 KJ/g and LFD=16.11 KJ/g; Research 
Diets, USA). 
During weeks 8 and 9, mice were placed in TSE Phenomaster cages (Germany) for 3 
days to measure metabolic parameters, specifically, oxygen consumption (mL/h, 
VO2), carbon dioxide production (mL/h, VCO2), respiratory exchange ratio 
(VCO2/VO2, RER) and locomotor activity (X, Y and Z planes). The data were 
collected in the final 24h of the housing period as detailed previously (McAllan et al 
2013). 
At week 10, mice were fasted for 10-12h commencing at 22.00 in the dark phase, then 
anaesthetized (100mg/Kg Ketamine and 10 mg/Kg Xylazine) and blood samples were 
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collected. Mice were sacrificed by cervical dislocation and tissues were collected and 
samples were stored at -80˚C for subsequent analysis. The length of the small intestine 




Faecal samples were collected directly from the colon, homogenized and processed 
using mechanical and chemical lysis. The 16S rRNA gene (V3-V4 region) was 
amplified with Universal primers (PCR1 Forward and Reverse primer as to the 
Illumina 16S Metagenomic Sequencing Protocol) that facilitated sequencing on the 
Illumina MiSeq platform (2x250bp paired-end reads; V3 sequencing chemistry). The 
fastq files were filtered on the basis of quality (removal of low quality nucleotides at 
the 3' end) and length (removal of sequences with less than 200nt) with prinseq 
(Schmieder & Edwards 2011), and paired reads with a minimum overlap of 20 bp were 
joined using Fastq-join (Aronesty 2013). Sequences were clustered (97% identity) to 
obtain Operative Taxonomic Units (OTUs) using closed-reference usearch v7.0 
algorithm (Edgar 2010) and chimeric OTUs were removed through use of the GOLD 
database. The taxonomic assignment of OTUs was obtained using the Ribosomal 
database project (RDP) (Cole et al 2014). Alpha- and beta-diversity was determined 
using QIIME (Caporaso et al 2010), and additional analyses were performed with the 
R package phyloseq (McMurdie & Holmes 2013). 
To identify chow-associated microbes, total DNA was extracted from ~ 10 g of chow 
containing 20% fat and 20% casein (LFD-CAS; #D17052702; Research Diets, USA), 
and ~ 10 g of chow containing 40% fat and 20% casein (HFD-CAS; #D17052705; 
Research Diets, USA) using the Gene All Extragene SoilSV kit (GeneAll). The Qubit 
high-sensitivity DNA assay (Bio-Sciences, Dublin, Ireland) was used for accurate 
quantification of the total DNA. Whole-metagenome shotgun libraries preparation was 
performed following the Nextera XT DNA library preparation guide from Illumina 
(Clooney et al 2016) and sequencing was performed using the Illumina NextSeq 500 
with a v2 NextSeq 500/550 high-output reagent kit (300 cycles). 
The raw shotgun metagenomic sequences were filtered on the basis of quality (removal 
of low quality nucleotides at the 3' end and application of sliding window trimming, 
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cutting once the average quality within the window falls below a treshold quality of 
20 bp) and length (removal of sequences of less than 200nt) with prinseq (Schmieder 
& Edwards 2011). The filtered sequences were then converted to bam files using 
SAMtools (Li et al 2009), and duplicate reads were subsequently removed using 
Picard Tools (https://github.com/broadinstitute/picard). The quality of the sequences 
was tested using SAMtools in combination with Picard Tools, removing the low-




The small intestine samples, stored at -80˚C, were initially immersed in a RNAlater-
Ice frozen tissue transition solution and stored at -20˚C according to the instructions 
of the manufacturer (Ambion). This step allows untangling of the intestine while 
preserving the integrity of the RNA so that tissue samples, corresponding to the ileum 
(1 cm from the distal end of the small intestine) and jejunum (the central part of the 
small intestine), could be cut. Total RNA was extracted from the intestinal samples 
and hypothalamic blocks using RNeasy Minikit and QIAshredder columns (Qiagen), 
and from epididymal adipose tissue (eWAT) and subcutaneous adipose tissue (sWAT) 
using QIAzol Lysis Reagent (Qiagen). The extracted RNAs were treated with DNase 
(Qiagen, Ireland). Complementary DNA was synthetized from 600ng total RNA using 
SuperscriptTM II Reverse Transcriptase kit (Life Technologies, Ireland), and 
subjected to Real-Time PCR (Roche, Ireland) using SYBR Green Select Master Mix 
(Roche, UK) as detailed before (McAllan et al 2015). The gene expression was 
calculated using 2-ΔΔCp and normalized against the reference gene β-actin (intestine 
and adipose tissue) and YWHAZ (hypothalamus). The sequence of the primers can be 
found elsewhere (McAllan et al 2013, McAllan et al 2015, McManus et al 2015b). 
 
Plasma leptin, glucose and triglyceride levels 
Plasma leptin and glucose levels were determined using Mouse Leptin ELISA kit 
(Crystal Chem, USA) and Mouse Glucose Assay (Crystal Chem, USA) respectively. 
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Triglyceride (TAG) level in the plasma was measured using Triglyceride 
Quantification Assay Kit (abcam, UK). 
 
Statistical analysis 
For power calculation, the coefficient of variation was measured using data (body 
weight gain) from a previous study (McAllan et al 2015) and determined to be 8.8%. 
For a power of 80% and a significance level of 5%, this allows detection of a difference 
of 14% with a sample size of 8 mice per treatment. Body weight and energy intake 
differences over 10 weeks were analysed by a two-way repeated-measures ANOVA 
with Bonferroni’s post hoc pairwise comparisons. Statistical analysis of gene 
expression, cumulative energy intake, intestine weight/intestine length, plasma leptin 
and triacylglycerol data were performed using one-way ANOVA followed by pairwise 
comparison using Bonferroni’s post hoc test. Non-parametric data were compared by 
Kruskal-Wallis ANOVA followed by Mann-Whitney U test. Data were expressed as 
mean ± SEM and significance was set at P<0.05 using SPSS software version 24 (IBM 
Corp). VO2 and heat production was analysed by ANCOVA (SAS software version 
9.3), with total body weight being used as the covariant. 
Gut microbiota data were statistically analysed by Adonis and Anosim for beta-
diversity analysis. ANOVA was used to calculate significance for alpha-diversity-
related analyses (statistical significance established at P<0.05). Statistical differences 
across multiple samples were determined by Kruskal-Wallis and False discovery rate 
(FDR, qvalue) control based on the Benjamini-Hochberg procedure, used to correct 
for multiple testing with the R statistical package (https://www.r-project.org/). Test for 
association across all groups of samples were performed through correlation analysis. 
This was based on Spearman’s rank correlation test by the R function of cor.test, which 
aimed to examine similar expression association profiles between groups of samples 
(https://www.r-project.org/package=corrplot) and adjustment of the Pvalue by the 
Benjamini-Hochberg method. Statistical significance was established at P<0.05 (*), 




LAB increased cumulative energy intake but not weight gain  
Mice fed HFD-LAB and HFD-CAS had similar body trajectories (Fig. 2.1A) but 
differed from the LFD-CAS group in the time taken to increase weight. Notably, the 
HFD-CAS group had a significantly higher weight than LFD-CAS by week 3 
(P=0.033) while the weight of the HFD-LAB group did not significantly exceed that 
of the LFD-CAS group until week 6 (P=0.045) (F(8,160)=440.2, P<0.001 for the effect 
of the Time, F(2,20)=5.5, P<0.05 for the effect of the Diet, F(16,160)=11.6, P<0.001 for 
the effect of the Time x Diet interaction) (Fig. 2.1A). Despite having similar body 
weight trajectories, the energy intake of HFD-LAB showed a trend towards an increase 
at week 2 (P=0.053) (413±9 KJ in HFD-LAB, 383±8 KJ in HFD-CAS and 293± 8 KJ 
in LFD-CAS) and it was higher in HFD-LAB compared to HFD-CAS at week 4 
(P=0.037) (F(7,140)=7.2, P<0.001 for the effect of the Time, F(2,20)=81.7 , P<0.001 for 
the effect of the Diet, F(14,140)=1.3 , P>0.05 for the effect of the Time x Diet interaction) 
(Fig. 2.1B). The cumulative energy intake of HFD-LAB was significantly increased 
by week 10 relative to HFD-CAS (P=0.043) (Fig. 2.1C). The difference in energy 
intake was reflected in the hypothalamic expression of neuropeptides. Notably, at 
week 10, the expression of the anorexigenic neuropeptide pomc was reduced relative 
to the LFD-CAS control (P=0.043 compared to HFD-CAS and P=0.001 compared to 
HFD-LAB), without showing significant difference between the two HFD groups. 
(Fig. 2.1D). While the gene expression for the orexigenic neuropeptides ghrelin and 
npy remained unchanged, the gene expression of growth hormone secretagogue 
receptor (ghsr) was reduced in both HFD groups compared to LFD-CAS (P=0.012 
relative to HFD-CAS and P=0.001 relative to HFD-LAB) (Fig. 2.1D). Similar to pomc 
expression, the expression of ghsr between HFD-CAS and HFD-LAB groups did not 
change. There was no effect due to diet on the expression of the fatty acid synthase 
(fasn). The mismatch between energy intake and weight gain was unrelated to energy 
expenditure as both HFD-CAS and HFD-LAB groups had similar 24h VO2 levels (97 
±3 in HFD-LAB, 95±3 in HFD-CAS and 101±3 in LFD-CAS; all values in mL/h) and 
heat production (2.1±0.05 in HFD-LAB, 2.0±0.05 in HFD-CAS and 2.2±0.06 in LFD-
CAS; all values in KJ/h), where both parameters were measured during week 8 and 9 
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period. There were no differences between groups in terms of 24h locomotor activity 
(303±28 in HFD-LAB, 293±29 in HFD-CAS and 365±37 in LFD-CAS). While the 
HFD-CAS and the HFD-LAB groups had similar RER, the corresponding values were 
lower compared to LFD-CAS (both with P<0.001), consistent with increased fat 
consumption by former groups (0.816±0.014 in HFD-LAB and 0.809±0.014 in HFD-
CAS versus 0.916±0.008 LFD-CAS). 
 
Figure 2.1 HFD-LAB has an effect on energy intake without impacting body weight gain. 
Impact of HFD-CAS, HFD-LAB and LFD-CAS on body weight (A) and energy intake (B) 
trajectories during 10 weeks experiment. Also shown the cumulative energy intake (C) after 
10 weeks. In the hypothalamus were detected the level of expression of some genes involved 
in energy balance control (D) after 10 weeks of HFD-CAS, HFD-LAB or LFD-CAS intake 
relative to the control group LFD-CAS. Groups showing * are significant (* P<0.05 or ** 
P<0.01 or *** P<0.001; detailed statistical analysis in “supplementary statistic”). 
Abbreviation; POMC; proopiomelanocortin, NPY; neuropeptide Y, GHSR; growth hormone 
secretagogue receptor, FASN; fatty acid synthase. 
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LAB decreases the intestinal expression of glucose and fatty acid transporters 
To find an explanation for the apparent energy loss in the HFD-LAB group, the impact 
on gastro-intestinal size and related gene expression of several nutrient transporters 
were measured. The intestinal length was unaffected by the diet (33.2±0.61cm in 
HFD-LAB, 32.4±0.74 cm in HFD-CAS and 32.9±0.38 cm in LFD-CAS). While the 
intestinal weight expressed relative to the length and body weight was similar between 
HFD-CAS and HFD-LAB groups, this was significantly lower compared to LFD-CAS 
controls (P=0.039 relative to HFD-CAS and P=0.019 relative to HFD-LAB) (Fig. 
2.2A). The data from ANCOVA analysis showed that there was not significant effect 
of diet on intestinal weight/length when body weight was used as a covariant 
(0.024±0.001g in HFD-LAB, 0.025±0.001g in HFD-CAS and 0.026±0.001g in LFD-
CAS).  
In the ileum, we observed a significant decrease in the expression of the sodium-
glucose transporter protein (slgt1) in both HFD groups compared to the LFD-CAS 
(P=0.026 relative to HFD-CAS and P=0.029 relative to HFD-LAB), but glut2 gene 
expression was specifically reduced in the HFD-LAB compared to LFD-CAS 
(P=0.01) and it showed a trend towards a decrease, at the significance threshold, 
compared to HFD-CAS (P=0.053) (Fig. 2.2B). While fatp4 gene expression was 
unaffected in the ileum, the cluster of differentiation 36 (cd36; an integral membrane 
protein responsible for importing fatty acids into the cell) was reduced in the HFD-
LAB compared to the LFD-CAS (P=0.001) and HFD-CAS (P<0.001) (Fig. 2.2B). The 
expression of genes encoding the L-amino acid transporter, lat4, and the neutral amino 
acid transporter slc6a19 was not significantly affected (Fig. 2.2B). The same gene 
expression was measured in the jejunum. Similar to the ileum data, cd36 gene 
expression in the jejunum was reduced in the HFD-LAB group compared to the other 
two groups (P=0.001 relative to LFD-CAS and P<0.001 relative to HFD-CAS), 
whereas glut2 expression did not change across the groups (Fig. 2.2C). In addition, in 
the jejunum, the level of expression of fatp4 was significantly higher in the HFD-LAB 
group compared to the LFD-CAS control group (P<0.001) and the expression of lat4 
showed a trend towards an increase in the HFD-LAB fed mice relative to HFD-CAS 
fed mice (P=0.061) (Fig. 2.2C). 
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In light of the results obtained for glut2 and cd36 gene expression, we measured the 
levels of glucose and triglyceride in the plasma. We observed that the glucose in the 
plasma of HFD-LAB fed mice (311±23 mg/dL) was not significantly different to 
HFD-CAS (293±8 mg/dL) but was lower compared to LFD-CAS fed mice (364±8 
mg/dL, P=0.018). The level of triglyceride in the HFD-LAB (37±4 mg/dL), HFD-CAS 
(35±6 mg/dL) and LFD-CAS (36±5 mg/dL) groups was not significantly different. 
 
Figure 2.2 LAB influences 
the level of nutrient 
transporter expression 
within the small intestine. 
The data show the effect of 
LAB on intestine weight 
normalized by intestine length 
per 100g of body weight (A). 
The level of gene expression 
in the ileum (B) and in the 
jejunum (C) after 10 weeks of 
intake of LFD, HFD-CAS or 
LAB groups relative to the 
control LFD-CAS group has 
been reported. Groups 
showing * are significant (* 
P<0.05 or ** P<0.01 or *** 
P<0.001; detailed statistical 
analysis in “supplementary 
statistic”). Abbreviation; 
SGLT1; sodium-glucose 
transporter 1, GLUT2; glucose 
transporter 2, CD36; cluster of 
differentiation 36, SLCa19; 
methionine transporter, 
FATP4; fatty acid transporter 
4, LAT4; L type amino acid 







LAB does not affect leptin gene expression and plasma hormone availability  
Several tissues were harvested from the mice and their weights were recorded (Fig. 
2.3A). The weights of both the subcutaneous adipose tissue (sWAT) and the eWAT 
were greater in both the HFD groups compared to the LFD-CAS control group 
(sWAT: P=0.002 relative to HFD-CAS and P=0.056 relative to HFD-LAB; eWAT: 
P=0.001 relative to HFD-CAS and P<0.001 relative to HFD-LAB) but there were no 
differences in the adipose tissues weights between HFD-CAS and HFD-LAB (Fig. 
2.3A). Next, the expression of several genes involved in the catabolism and anabolism 
of fatty acids in the eWAT and sWAT was measured. In the current study, the 
expression in the eWAT of genes involved in fatty acid catabolism (carnitine 
palmoitoyltransferase I, cpt1; uncoupling protein, ucp; hormone-sensitive lipase, hsl; 
beta-3 adrenergic receptor β-3ar) and anabolism (acetylCoA carboxylase 1, acc1; fatty 
acid synthase, fasn; lipoprotein lipase, lpl) between HFD-LAB and HFD-CAS fed 
animals did not differ (Fig. 2.3B-C). There was also no change in the expression of 
genes involved in fatty acids transport, such as cd36, fatp1 and glut4 (Fig. 2.3C). 
However, consistent with the increased adiposity of the high fat fed groups, acc1 gene 
expression was down regulated in HFD-CAS (P=0.008) and HFD-LAB (P=0.002) 
compared to LFD-CAS (Fig. 2.3C). In addition, the inflammatory marker, cluster of 
differentiation 68 (cd68) expression showed a trend towards an increase in the HFD-
CAS group compared to the LFD-CAS (P=0.057), but for the HFD-LAB group, the 
increase was not significant relative to LFD-CAS (Fig. 2.3C). The unchanged adipose 
tissues weights, coupled with gene expression data in the eWAT, suggests an 
alternative mechanism of energy loss in the HFD-LAB group. We also measured leptin 
(ob) gene expression in the eWAT to assess if there is a specific effect of LAB in leptin 
regulation, similar to that attributed to the whey protein Lf (McManus et al 2015a). 
Consistent with the gain in body weight and adipose tissue weight, the expression of 
the ob gene in the HFD-CAS group increased compared to the control LFD-CAS 
(P<0.001) and, in the HFD-LAB group, it showed a trend towards an increase relative 
to the LFD control (P=0.059), without showing any differences between the two HFD 
groups (P=0.08) (Fig. 2.3C). 
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Figure 2.3 Effect of LAB on tissue weights and on the expression of genes involved in the 
catabolism and anabolism of adipose tissue. The data show the tissue weights normalized 
by 100g of body weight (A). Expression of catabolic (B) and anabolic (C) genes in the 
epididymal adipose tissue (eWAT) was investigate after 10 weeks of intake of LFD, HFD-
CAS or WPI groups relative to the control LFD-CAS group. Abbreviation; CPT1a and b; 
carnitine palmitoyltransferase I, HSL; hormone-sensitive lipase, UCP2 and 3; uncouplin  
protein, β3-AR; beta-3 adrenergic receptor, ACC; acetyl-CoA carboxylase, OB; leptin gene, 
CD68; cluster of differentiation 68, FASN; fatty acid synthase, FATP1; fatty acid transporter 
1, GLUT4; glucose transporter 4, LPL; lipoprotein lipase, CD36; cluster of differentiation 36. 
Again after 10 weeks, it was measured the level of plasma leptin (D) in the three groups of 
study. In the subcutaneous adipose tissue (sWAT), the expression of the genes ob, fasn and 
glut4 (E) has been reported. Groups showing * are significant (* P<0.05 or ** P<0.01 or *** 
P<0.001; detailed statistical analysis in “supplementary statistic”). 
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Similarly, no differences in ob expression were detected in the sWAT between the 
HFD groups (Fig. 2.3E), and the expression of fasn and glut4 genes were decreased 
compared with the LFD-CAS group (fasn: P=0.001 relative to HFD-CAS and P=0.001 
relative to HFD-LAB; glut4: P=0.021 relative to HFD-CAS and P=0.035 relative to 
HFD-LAB), with no difference between HFD-CAS and HFD-LAB groups (Fig. 
2.3E). 
The ob gene expression in eWAT and sWAT was reflected in the plasma availability 
of leptin, as the presence of LAB in the HFD did not influenced the plasma hormone 
level, relative to HFD-CAS (Fig. 2.3D).  
 
Beta-diversity and gut bacterial composition differs due to LAB intake. 
After quality filtration and length trimming an average of 182,494 high-quality 16S 
rRNA sequences per sample (i.e., faecal pellets collected from the colon) were 
obtained across two groups, i.e., HFD-CAS (n=8) and HFD-LAB (n=8). Analysis of 
this data revealed that, while alpha-diversity did not differ significantly across groups, 
a significant difference in beta-diversity (P=0.002) between the microbiota of the 
HFD-CAS and HFD-LAB animals was apparent, as represented by distinct clustering 
upon Principal Coordinates Analysis (PCoA) of all 16S rRNA reads (clustered at 97% 
similarity) (Fig. 2.4A).  
Differences in beta-diversity were reflected by taxonomic differences between the 
HFD-CAS and HFD-LAB groups. At the phylum level, a lower 
Firmicutes/Bacteroidetes (ratio F/B) was apparent in the HFD-CAS samples (ratio 
F/B=1.23) relative to the HFD-LAB equivalents (ratio F/B=1.42), though significance 
was not achieved (Fig. 2.4B). At the family level, two families differed significantly 
in a diet-associated manner. These were Lactobacillaceae (higher abundance in HFD-
LAB samples) and Streptococcaceae (higher abundance in HFD-CAS samples) 
(Table 2.T1). 
At the genus level, statistically significant differences were apparent in the abundance 
of Parabacteroides, Bifidobacterium, Parvibacter and Lactobacillus, all of which 
were present in higher proportions in the HFD-LAB sample groups, as well as 
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Lactococcus, Roseburia (P=0.021), Phascolarctobacterium (P=0.018) and 







Figure 2.4 Impact of LAB on the composition of the gut microbiota. Beta-diversity of the 
two groups (HFD-CAS: red, HFD-LAB: light blue) calculated using Principal Coordinate 
Analysis (PCoA) (A). Bar chart representing the phylum-level proportions in faecal samples 
of mice fed with HFD-CAS and HFD-LAB using Kruskal Wallis method (B). Heatmap 
illustrating Spearman’s rank correlations between the abundance of family and genus-level 
gut microbes and energy intake, glut2 expression and cd36 expression in both HFD-CAS and 
HFD-LAB groups. The pValue adjustment was done using Benjamini-Hochberg Method (C). 
Groups showing * are significant (* P<0.05 or ** P<0.005 or *** P<0.001). 
 
To assess the possibility that the presence of particular taxa within the chow containing 
CAS could be responsible for the associated increased proportion of Streptococcaeae 
in the gut, analysis of the microbiota of the CAS-containing chow was performed. This 
revealed that the family Streptococcaceae (99.6% and 99.8% in LFD-CAS and HFD-
CAS chow, respectively) and the associated genus, Lactococcus (99.6% and 99.8% in 
LFD-CAS and HFD-CAS chow, respectively), were dominant (Table 2.TS2). 
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Correlation and independent analyses of expression association profiles were 
conducted between cd36 and glut2 expression levels, as well as energy intake, against 
bacterial composition at the genus level. Dairy taxa potentially sourced from the food 
substrate were not considered. After adjustment for multiple testing (BH-corrected), it 
was noted that energy intake positively correlated within the group of HFD-CAS 
samples with Parabacteroides. Within the HFD-LAB group, Parabacteroides 
negatively correlated with cd36 expression. Glut2 expression was positively correlated 
with Parabacteroides in HFD-LAB samples (Fig. 2.4C). 
 
Table 2.T1 Relative abundance (%) of genera and families in which their abundance is 
significantly higher either in the HFD-CAS group or in the HFD-LAB group. Statistical 
differences across multiple samples were estimated by the bioinformatics methods “False 




Family HFD-LAB vs HFD-CAS Relative Abundance 
Streptococcaceae P=0.029 ↑ HFD-CAS 0.082895775 
Lactobacillaceae 
P=0.015 ↑ HFD-LAB 1.18133309 
Genus     
Lactococcus P=0.001 ↑ HFD-CAS 0.077810661 
       Turicibacter        P=0.024 ↑ HFD-CAS                   0.301261529 
Streptococcus P=0.001 ↑ HFD-LAB 0.148479572 
Parvibacter P=0.039 ↑ HFD-LAB 0.012092907 
Lactobacillus P=0.011 ↑ HFD-LAB 1.180503082 
Parabacteroides P=0.026 ↑ HFD-LAB 0.045986668 




In this study, we investigated the effects of a specific dietary whey protein (LAB) on 
intestinal-adipose-hypothalamic control of energy balance. We show that 
supplementation of LAB in a HFD reduced cd36 and glut2 gene expression in the 
small intestine and was associated with changes in the composition of the gut 
microbiota. These changes were accompanied by increased cumulative energy 
ingestion. This, coupled with the fact that targeted deletion of the glut2 gene increases 
energy intake (Schmitt et al 2017), suggests a potential link between gut microbiota, 
intestinal nutrient transporters and energy intake in response to LAB supplementation. 
These effects were unrelated to adiposity, as HFD-LAB-fed mice had similar weight 
gain, adipose tissue weight (both eWAT and sWAT) and plasma TAG.   
Previous studies have shown that diets rich in whey protein cause short-term satiety 
effects in mice and in humans (Lam et al 2009, MacKenzie-Shalders et al 2015, Yu et 
al 2009). Long-term effects on energy balance, however, do not involve the production 
of satiety hormones (Zhou et al 2011). On a background of HFD intake, which has 
been shown to reduce the brain sensitivity to satiety hormones (Westerterp 2006), the 
increased energy intake in mice fed with HFD-CAS compared to LFD and even higher 
(cumulative) energy intake in HFD-LAB is likely to involve another mechanism of 
regulation within the adipose tissue-gut-brain connection. 
Hypothalamic neuropeptide expression provided an insight into the regulatory effect 
of LAB on energy intake. Notably, the expression of the anorexigenic neuropeptide 
pomc gene expression was significantly lower in the HFD-CAS group in line with the 
higher energy intake compared to LFD-CAS, similar to that shown in previous studies 
(McAllan et al 2013, McManus et al 2015a). In the HFD-LAB group, while pomc 
expression remained low, the expression of the orexigenic neuropeptide, npy, did not 
change across the groups. We performed a t test analysis on npy gene expression data 
between HFD-CAS and HFD-LAB and we found a trend towards an increase (not 
significant) in the presence of LAB. This suggests that an increase in sample size might 
bring about a significant difference in hypothalamic npy expression. Since NPY has 
an orexigenic action, an increase in this neuropeptide would be in agreement with the 
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increased energy intake observed during LAB consumption. Significant effects on 
energy intake and on hypothalamic pomc and npy expression were previously found 
in mice fed with WPI compared to casein in a LFD (Nilaweera et al 2017). In addition, 
neither the expression of npy nor the cumulative energy intake changed in mice fed a 
HFD containing lactoferrin compared to casein (McManus et al 2015a). These data 
suggest that the whey protein LAB have bioactivity that influences energy intake and 
that is not mediated by the modulation of hypothalamic neuropeptide genes 
investigated in this study.  
In the current study, while the HFD-CAS group increased weight rapidly, reaching a 
significant increase relative to LFD values by week 3, it was a further 3 weeks before 
the mice fed HFD-LAB diet significantly increased body weight relative to LFD fed 
animals. The finding that the higher cumulative energy intake was not reflected in the 
increased body weight in the HFD-LAB group suggests a mechanism must exist to 
explain the missing energy from the supply. This is consistent with a rat study, which 
showed that HFD intake with LAB did not change energy intake but decreased 
adiposity (Zapata et al 2017a). The difference in energy intake between this study and 
our current study could be related to the fact that the rat study included both egg 
albumin and LAB as the protein sources in the same diet, whereas we used LAB as 
the only protein source. This apparent energy loss could be related to lipid oxidation, 
as a study showed that pre-exercise LAB-enriched whey protein meal preserved lipid 
oxidation alongside rapid delivery of amino acids to tissues for use during exercise, 
decreasing the adiposity in rats (Bouthegourd et al 2002). However, we did not observe 
this effect in the sedentary mice used in our current study, as RER was similar between 
HFD-LAB and HFD-CAS fed mice and adipose-specific gene expression linked to 
lipid catabolism also did not change. This, coupled with the similar sWAT and eWAT 
weights between HFD-LAB and HFD-CAS groups, suggests that the energy loss in 
the sedentary mice fed LAB occurs through another mechanism. 
It has been shown previously that WPI reduces fat absorption in humans and mice 
(Frestedt et al 2008b, Pilvi et al 2007, Tranberg et al 2013), and we showed that this 
effect could be related to decreased ileal fatp4 gene expression (Nilaweera et al 2017). 
In addition, we also showed a time course reduction of glut2 gene expression in the 
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same region with 17 weeks of WPI intake and this effect on intestinal gene expression 
was independent of sucrose content in the diet (Nilaweera et al 2017). In the present 
study, by feeding a constituent protein of WPI, i.e., LAB, to mice for a shorter time 
period (10 weeks) and by analyzing their intestinal gene expression, we now observed 
a reduction in the expression of sglt in both HFD groups relative to LFD groups. This 
can be a reflection of higher carbohydrate content in the LFD compared to the two 
HFDs (Table 2.TS1). In addition, we show a reduction of glut2 expression in the ileum 
exposed to HFD, specifically with LAB. The similar effects of LAB and WPI on 
intestinal glut2 expression in the ileum suggests that LAB may contributes to the 
bioactivity in WPI influencing glut2 expression and this bioactivity, whatever it may 
be, appears to be effective independent of sucrose or fat content in the diet (Nilaweera 
et al 2017). It was shown that the recruitment of apical GLUT2 in the small intestine 
is detrimental for health, i.e., it leads to an excess of glucose uptake with increased 
obesity and type 2 diabetes risk (Kellett et al 2008). Our study suggests a potential 
effect of a diet enriched in LAB in the control of intestinal glucose transporter-related 
transcripts, that could influence glucose absorption. In another in vitro study, using 
human intestinal Caco-2 cells, it was shown that polyphenols can also lead to a 
decrease in the abundance of apical GLUT2 (Alzaid et al 2013).  
In the current study, we also observed a reduction in cd36 gene expression within both 
ileum and jejunum. Thus, in combination, these data further support the hypothesis the 
whey protein LAB seems to affect different components of the mechanism involved 
in the absorption of glucose and fatty acids within the small intestine, at least at the 
gene expression level. This would explain, at least in part, the loss of energy that 
occurs in mice fed LAB. Further analysis aimed to look at the protein level and energy 
content in the faeces need to be done to confirm this hypothesis. Notably, differences 
in the level of cd36 and glut2 in the jejunum during LAB intake are in agreement with 
the fact that the modality and the degree of absorption can change along the intestinal 
tract. This is due to a different density of nutrient transporters across the three major 
regions of the small intestine (Spiller 1994). Based on the effect of LAB in a HFD on 
expression of nutrient transporters in the intestinal epithelium and associated energy 
loss, we speculate that mice compensate by increasing energy intake. In fact, in this 
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study we observed that the levels of glucose and triacylglycerol in the plasma did not 
show significant changes between HFD groups. 
Furthermore, the HFD groups consumed more energy than LFD. Since there were no 
differences in the energy expenditure, the energy surplus has been stored in the adipose 
tissue. Thus, the lower expression of acc and fasn in the adipose tissue, presumably 
reflects the reduced necessity to produce fat endogenously when there is an external 
supply of excess energy. A similar reduction in fasn gene expression has been noted 
in a previous study from our group (McAllan et al 2014). On the contrary, other studies 
show that HFD intake increases fasn and acc in the adipose tissue (de Oliveira Santana 
et al 2016, Jiang et al 2005, Morgan et al 2008). The reasons for these discrepancies 
are unclear, but we speculate that contributing factors can include different genetic 
background, age, diet (composition and duration) and different housing environment. 
Leptin, a hormone encoded by the ob gene, controls food intake and body weight 
through an interaction with specific receptors within the hypothalamus (Havel 2007). 
In obese humans and in mice fed an obesogenic diet the adipose tissue mass increases, 
enhancing significantly the level of plasma leptin and leading to metabolic 
dysfunctions (Myers et al 2010). In addition to the effect on intestinal nutrient 
transporters and energy intake, WPI in a LFD also reduced eWAT weight and plasma 
leptin, raising the possibility that the reduced adipose tissue and associated signals, 
including reduced leptin, could have stimulated the energy intake in mice. However, 
feeding mice with a HFD containing 20% of WPI for 8 weeks did not have an effect 
on plasma leptin levels, compared to mice fed a HFD containing CAS (McAllan et al 
2013). On the contrary, HFD containing Lf significantly reduced plasma leptin levels 
compared to the HFD-CAS controls (McManus et al 2015a). This is another 
demonstration of the distinct bioactivities that WPI-associated whey protein 
components can have. In this study, mice fed a HFD containing LAB as the sole 
protein source showed no significant decrease in plasma leptin, which was reflected 
in no change in eWAT and sWAT ob gene expression in the HFD-LAB group, 
compared to the HFD-CAS group. However, a t-test analysis on plasma leptin data 
between HFD-CAS and HFD-LAB showed a significant decrease in plasma leptin 
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during LAB consumption. Thus, an increased sample size might be important to show 
a significant effect of LAB on leptin availability. 
We also demonstrated that a HFD containing LAB has a strong influence on the 
composition of the gut microbiota. Beta-diversity data highlighted differences in the 
clustering of samples from the HFD-LAB group compared to the HFD-CAS group. 
Corresponding taxonomic analyses were also completed. In particular, we observed a 
significantly higher proportion of Parabacteroides in the HFD-LAB group, which is 
notable in that this genus showed a significantly positive correlation with the 
expression of nutrient transporters. Notably other studies have suggested that 
Parabacteroides protects the gut from inflammation and there have been reports of 
the apparent absence of this genus in the digestive tract of people affected by 
Inflammatory Bowel Diseases (Noor et al 2010, Zitomersky et al 2013). Moreover, 
Parabacteroides has been associated with anti-obesity effects. An increase in 
Parabacteroides goldsteinii was linked with the anti-obesity properties of a prebiotic 
polysaccharide isolated from the fungus Hirsutella sinensis (Wu et al 2019). A way 
through which Parabacteroides triggers its anti-obesity effects is by increasing the 
production of succinate and secondary bile acids (Wang et al 2019). These metabolites 
have been shown to be involved in central control of energy balance and glucose 
homeostasis (de Vadder & Mithieux 2018, Ma & Patti 2014).  
In this study, we also observed that the genera Bifidobacterium and Lactobacillus are 
significantly more abundant in the HFD-LAB group. In several human studies, an 
association between lower levels of Bifidobacterium and obesity was noted 
(Kalliomaki et al 2008, Million et al 2012b, Schwiertz et al 2010). In addition, higher 
levels of Bifidobacterium have been linked with an increase in SCFA production, an 
improvement of gut mucosal barrier and lower intestinal LPS levels (Pinzone et al 
2012, Schwiertz et al 2010). Furthermore, specific strains of Bifidobacterium and 
Lactobacillus spp. have been shown to exhibit anti-obesity effects (Torres-Fuentes et 
al 2015). It is worth highlighting the importance of species and strain level differences 
as, for example, human and animal studies have highlighted an association between 
different Lactobacillus species with weight gain or weight protection (Drissi et al 
2014, Million et al 2012a). For this reason, more accurate in-depth metagenomic 
109 
 
analyses, such as shotgun analysis, should be considered in the future to investigate 
the Lactobacillus species that populate the gut of HFD-LAB fed mice.  
A number of bacterial taxa typically associated with dairy products were also found to 
be altered in the gut. A recent human feeding study demonstrated that many 
bacteriophages and Streptococcus and Lactococcus genera, that were significantly 
altered in individuals whose diet was supplemented with whey protein, were present 
in high proportions within the whey protein supplement (Cronin et al 2018), and thus 
presumably originated from the food source. The family Streptococcaceae and the 
associated genus, Lactococcus, are significantly more abundant in the HFD-CAS 
group compared to the HFD-LAB group. This is consistent with our previous study 
that showed that Streptococcaceae proportion increased significantly in the CAS-fed 
mice compared to WPI-fed mice (Nilaweera et al 2017). However, this phenomenon 
is likely a reflection of the high proportion of Streptococcaceae and Lactococcus reads 
detected after analysis of both LFD-CAS and HFD-CAS chows.  
The changes in the gut microbiota in the presence of LAB, coupled with the reduced 
intestinal expression of genes for nutrient transporters, support and provide a potential 
scenario for the energy mismatch in the HFD-LAB group compared to the control 
group. However, the specific mechanism that connects these changes in intestinal 
transporters gene expression, gut microbiota and energy intake in the presence of LAB 
remains to be elucidated. Further studies are needed to assess if these effects are seen 
with different genetic background, sex, housing environment (group versus single 
housing) and dietary fat content and duration. In conclusion, this present study has 
demonstrated for what is to our knowledge the first time, how a HFD containing a 
specific whey protein, i.e., LAB, specifically affects the metabolism, microbiota and 
nutrient absorption regulation, without preventing weight gain and adipose tissue mass 








Table 2.TS1 Composition of the experimental diets: high-fat diet containing casein (HFD-













*Typical analysis of cholesterol in lard = 0.95 mg/gram. 










   HFD-CAS    HFD-LAB    LFD-CAS
Ingredients gm Kcal gm Kcal gm Kcal
Casein 200 800 0 0 200 800
α-Lactalbumin 0 0 200 800 0 0
Glycomacropeptide 0 0 0 0 0 0
L-Cysteine 3 12 3 12 3 12
Corn Starch 72,8 291 72,8 291 315 1260
Maltodextrin 10 100 400 100 400 35 140
Sucrose 172,8 691 172,8 691 350 1400
Cellulose, BW200 50 0 50 0 50 0
Soybean Oil 25 225 25 225 25 225
Lard* 177,5 1598 177,5 1598 20 180
Mineral Mix S10026 10 0 10 0 10 0
DiCalcium Phosphate 13 0 13 0 13 0
Calcium Carbonate 5,5 0 5,5 0 5,5 0
Potassium Citrate, 1 H2O 16,5 0 16,5 0 16,5 0
Vitamin Mix V10001 10 40 10 40 10 40
Choline Bitartrate 2 0 2 0 2 0
FD&C Yellow Dye #5 0 0 0,05 0 0,05 0
FD&C Red Dye #40 0,05 0 0 0 0 0
Total 858,15 4057 858,15 4057 1055,05 4057
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Table 2.TS2 Relative abundance (%) of families and genera in the LFD-CAS (20% fat, 20% 
CAS) and HFD-CAS (45% fat, 20% CAS) chows, using shotgun analysis approach. The 








Family Chow LFD-CAS Chow HFD-CAS 
Streptococcaceae 99.56243 99.78502 
Lactobacillaceae 0.43757 0.21498 
Genus     
Lactococcus 99.56243 99.76647 
Streptococcus 0 0.01855 





Statistical output related to Figure 1 (HFD-LAB has an effect on energy intake and 
hypothalamic gene expression without impacting body weight gain) 
Body weight F(8,160)=440.2, P<0.001 for the effect of the Time, F(2,20)=5.5, P<0.05 for the effect 
of the Diet, F(16,160)=11.6, P<0.001 for the effect of the Time x Diet interaction (A). Energy 
Intake F(7,140)=7.2, P<0.001 for the effect of the Time, F(2,20)=81.7, P<0.001 for the effect of 
the Diet, F(14,140)=1.3, P>0.05 for the effect of the Time x Diet interaction (B). Cumulative 
energy intake one-way ANOVA, F(2,22)=81.7, P<0.001 followed by Bonferroni’s post-hoc (C). 
Hypothalamic gene expression: one-way ANOVA, pomc F(2,22)=9.2, P<0.01; npy F(2,22)=2.8, 
P=0.079; ghsR F(2,22)=9.8, P<0.01; all followed by Bonferroni’s post-hoc except npy (D). 
 
 
Statistical output related to Figure 2 (LAB influences the level of nutrient transporter 
expression within the small intestine) 
Intestine weight/ Intestine Length per 100g of body weight one-way ANOVA, F(2,20)=5.5, 
P<0.05 followed by Bonferroni’s post-hoc (A). Ileum gene expression: Kruskal-Wallis test 
for sglt1 (P=0.035) and cd36 (P=0.000). Mann-Whitney U test for sglt1: 1 VS 2 U(15)= 9, 
P=0.029; 1 VS 3 U(14)= 7, P=0.026. Mann-Whitney U test for cd36: 1 VS 3 U(14)=0, P=0.001; 
2 VS 3 U(15)= 0, P=0.000. One-way ANOVA, glut2 F(2,19)=6.4, P<0.01 (B). Jejunum gene 
expression: Kruskal-Wallis test for cd36 (P=0.001) and fatp4 (P=0.016). Mann-Whitney U 
test for cd36: 1 VS 3 U(14)=0, P=0.001; 2 VS 3 U(15)= 0, P=0.000. Mann-Whitney U test for 
fatp4: 1 VS 3 U(15)=0, P=0.000. One-way ANOVA, lat4 F(2,20)=3.6, P<0.05 followed by 
Bonferroni’s post-hoc (C).   
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Statistical output related to Figure 3 (Effect of LAB on tissue weights and on the expression 
of genes involved in the catabolism and anabolism of adipose tissue) 
Tissue weights normalized by 100g of body weight: one-way ANOVA, sWAT F(2,22)=8.3, 
P<0.01; stomach F(2,22)=3.4, P=0.051; Intestine F(2,20)=4, P<0.05; eWAT F(2,21)=12.7, P<0.001; 
all followed by Bonferroni’s post-hoc (A). eWAT gene expression (anabolism): Kruskal-
Wallis test for acc (P=0.007). Mann-Whitney U test for acc: 1 VS 2 U(15)= 4, P=0.008; 2 VS 
3 U(15)= 1, P=0.002. One-way ANOVA, ob F(2,21)=12.6, P<0.001; cd68 F(2,21)=3.5, P<0.05; 
both followed by Bonferroni’s post-hoc (C). Plasma leptin: one-way ANOVA, F(2,22)=3.3, 
P=0.056 (D). sWAT gene expression: one-way ANOVA, ob F(2,21)=8.2, P<0.01 followed by 
Bonferroni’s post-hoc. Kruskal-Wallis test for fasn (P=0.001) and glut4 (P=0.032). Mann-
Whitney U test for fasn: 1 VS 2 U(15)= 1, P=0.001; 1 VS 3 U(14)= 0, P=0.001. Mann-Whitney 
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Rationale Bovine whey protein has been demonstrated to exert a positive effect on 
energy balance, lipid metabolism and nutrient absorption. Additionally, it affects gut 
microbiota configuration. Thus, whey protein is considered as good dietary candidate 
to prevent or ameliorate metabolic diseases, such as obesity. However, the relationship 
that links energy balance, metabolism and intestinal microbial population mediated by 
whey protein intake remains poorly understood. 
 
Objectives In this study we investigated the beneficial effects attributed to whey 
protein in the context of high-fat diet (HFD) in mice at two different ages, with short 
or longer durations of whey protein supplementation. 
Here, a 5-week dietary intervention with HFD in combination with either whey protein 
isolate (WPI) or the control non-whey milk protein casein (CAS) was performed using 
5-week or 10-week-old C57BL/6J mice. Notably, the younger mice had no prior 
history of ingestion of WPI, while older mice did.  
 
Results 5-week-old HFD-WPI-fed mice showed a decrease in weight gain and changes 
in the expression of genes within the epidydimal white adipose tissue including those 
encoding leptin, inflammatory marker CD68, fasting-induced adipose factor FIAF and 
enzymes involved in fatty acids catabolism, relative to HFD-CAS-fed mice. 
Differences in β-diversity and higher proportions of Lactobacillus murinus, and 
related functions, were evident within the gut microbiota of HFD-WPI mice. However, 
none of these changes were observed in mice that started the HFD dietary intervention 
at 10-weeks-old, with an extended period of WPI supplementation. 
 
Conclusions These results suggest that the effect of whey protein on mouse body 
weight, adipose tissue and intestinal parameters depends on diet duration and stage of 
life during which the diet is provided. In some instances, WPI influences gut 
microbiota composition and functional potential, which might orchestrate observed 





Bovine whey protein is a milk protein present in the liquid that results from cheese 
production, called whey. Whey protein includes subcategories of proteins present in 
different quantities, such as α-lactalbumin (~25%), β-lactoglobulin (~65%), bovine 
serum albumin (~8 %), lactoperoxidase (0·25–0·5 %), lactoferrin (~1%) and minor 
proteins such as immunogloblulins (<1%) (Morr & Ha 1993). Because of the specific 
amino acid composition including branched chain amino acids, intake of these proteins 
has been shown to bring about several health benefits. Notably, a diet supplemented 
with whey protein has been found to modulate appetite, and ileal expression and 
plasma levels of satiety hormones such as insulin, ghrelin, cholecystokinin and 
glucagon-like peptide 1 (Chungchunlam et al 2015, McAllan et al 2012, Pal et al 
2014). Additionally, in several studies in which whey protein constituted the main 
protein source of a high-fat diet (HFD), this protein ameliorated the impairment of 
glucose tolerance, and reduced the increase in body weight and adiposity compared to 
other dietary proteins, such  as casein (CAS, a non-whey milk protein which is the 
main component of cheese), soy, meat and fish proteins (Madsen et al 2017, McAllan 
et al 2013, Pilvi et al 2007). Whey protein also influences lipid metabolism in 
adipocytes, including plasma release of triacylglycerol (TAG), and reduces intestinal 
fat absorption (McAllan et al 2013, Pal et al 2010, Stanstrup et al 2014). For these 
reasons, whey protein has been chosen as a good candidate for dietary interventions 
aiming to prevent or ameliorate metabolic diseases such as obesity.  
 
Obesity is a complex and multifactorial disease characterised by an excess of adiposity 
due to an imbalance between energy intake and energy expenditure (De Lorenzo et al 
2016). According to the World Health Organization, in 2016, 1.9 billion adults 
worldwide were overweight or obese of which 650 million had obesity. It is well 
known that metabolic disorders are linked with other metabolic diseases, such as 
cardiovascular diseases, diabetes, adipose tissue dysfunction, as well as a dysbiosis of 
the intestinal microbial population (Carding et al 2015). The gut microbiota plays an 
important role in the modulation of the host metabolism and in energy harvesting 
through fermentation of fibres and proteins from food that were not digested and 
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absorbed within the small intestine. Some studies have shown that low-fat diet (i.e., 
LFD) and HFD containing whey protein isolate (WPI) have similar impacts on the gut 
microbiota, increasing the abundance of the families Bifidobacteriaceae and 
Lactobacillaceae, and Bifidobacterium spp. and Lactobacillus spp.. However, these 
studies were performed with in vitro gastrointestinal digestion models or 16S rRNA 
compositional metagenomic approaches and, thus, there are no studies describing in 
detail which species and which microbial functions are influenced by the presence of 
WPI in the diet (McAllan et al 2014, Sanchez-Moya et al 2017, Sprong et al 2010). 
Other factors that considerably shape the gut microbiota in humans in early stage of 
life of the individual are modality of delivery and genetics, which influence the 
microbial colonization in the perinatal and early-postnatal period. The microbiota 
evolves and becomes more similar to an adult microbial configuration by the end of 
3-5 years of life. From this stage, the gut microbiota becomes relatively stable 
throughout life, but factors such as diet, antibiotic treatment, lifestyle and bacterial 
infections can strongly affect and deviate the gut microbiota stability. In turn, this can 
have an impact on host metabolism and host physiology (O'Toole & Jeffery 2015, 
Rodriguez et al 2015). In contrast to the human case, the link between age and 
microbiota in rodents is still poorly understood. A recent study carried out in rodents, 
particularly in healthy Sprague Dawley rats, revealed a significant change in the 
composition of their microbiota from 3 weeks to 2 years of age, with consequences on 
the microbial fermentative capacity and thus, host metabolism regulation (Flemer et 
al 2017). Notably, we have shown that WPI intake (20% energy) starting from early 
adolescence and continuing for 8 week period reduces weight gain and adiposity 
(McAllan et al 2013), but extending intake into 21 weeks (and hence as mice get 
older), there is an impairment of the effects of WPI (McAllan et al 2014). These data 
suggested a potential interplay between duration of WPI and HFD intake on 
parameters related to energy balance that appear to be sensitive to the animal’s age. 
Untangling the relative importance of each for energy balance regulation is difficult to 
achieve because duration of the diet intake and age go together, instead one can focus 
on how different dietary component interplay with age by fixing one dietary 
component and changing another, and then assess the influence on energy balance. 
This would provide the basis for development of better interventions for prevention of 
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weight gain and development of obesity in individuals at risk as they grow from young 
to older age. 
In the present work we aimed to investigate the relationship between WPI-
supplemented diet duration, age, microbiome and host energy balance, using 5-week 
and 10-week-old C57BL/6J mice. To assess these interactions, we fixed HFD to a 
limited period (5 weeks) in young and older mice. We have previously shown that 
feeding high (30% and 40% by energy) WPI as part of a 45% energy HFD to 
adolescent mice was shown to reduce weight gain, with animals attaining a lean 
phenotype but where the microbial composition was distinct to LFD fed mice 
(McAllan et al 2014). This led to our first hypothesis that WPI intake as part of LFD 
during adolescence would bring about the microbial and endocrine changes necessary 
to impede weight gain resulting from a subsequent switch to HFD in older mice but 
whilst continuing to ingest WPI. Because microbial changes in the gut occurs early 
life, and it was not clear at what stage in adolescence the change in microbial 
composition occurs in relation to WPI intake, we also assessed the impact of WPI as 
part of a HFD much earlier on in adolescence without pre-intervention with LFD 
containing WPI. To this end, we focus mainly on the effects of a HFD containing a 
standard amount of WPI (20% energy) on body weight, energy intake, plasma 
hormones, metabolites and genes encoding nutrient transporters, lipid metabolism 
enzymes and hormones in the ileum and in the adipose tissue in mice at  two different 
stages of life (i.e., adolescence, from week 4 to week 8-9 of life, and early adulthood, 
from week 9 to 17-18 of life) (Brust et al 2015). In addition, using a high-throughput 
shotgun metagenomic approach, we performed a gut microbiota analysis on faecal 
samples. Unlike the 16S rRNA gene sequencing approach, shotgun metagenomics 
allows a more detailed view of the microbial composition and genes and metabolic 
pathways related to the microbial community (Quince et al 2017a). Specifically, we 
performed a first experiment with 5 week-diet duration (i.e., 5w) in which 5-week-old 
mice were fed a HFD, containing WPI (HFD-WPI) or the control CAS (HFD-CAS) 
as the protein source. In parallel, we performed a second experiment with 10 week-
diet duration (i.e., 10w), in which 5-week-old mice were fed LFD-CAS or LFD-WPI 
for 5 weeks and, when they were 10-weeks old, their diet was switched to HFD-CAS 
or HFD-WPI for a further 5 weeks. The control groups were maintained on LFD-CAS 
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or WPI for the entirety of the experiment (Fig. 3.1a). The above experimental design 
allowed us to fix the HFD feeding duration to 5 weeks in both experiments in younger 
and older mice, and focus on the potential interplay of the effects of WPI duration and 
age (shorter duration in younger mice in experiment 1 versus longer duration as mice 
age in experiment 2). 
 
We predicted that: (i) giving WPI in LFD during a pre-HFD period (i.e., second 
experiment 10w) would prevent/ameliorate the metabolic syndrome outcomes that 
would occur after switching to HFD and extending the WPI supplementation; (ii) 
energy balance, adipose tissue metabolism, gut microbiota and nutrient absorption 
would exhibit differences due to the dietary intervention carried out at two different 






The in vivo experiments were approved by the University College Cork Animal 
Experimentation Ethics Committee (2015/007) and were licenced under the European 
Directive 2010/63/EU. Eighty C57BL/6J 3-week-old male mice were purchased 
commercially (Harlan; UK) and were housed 4 per cage on a 12 h light/dark cycle. 
The mice had ad libitum access to food and water throughout the study unless 
otherwise stated. During the initial 2 weeks of acclimatisation period, mice were 
provided with a diet containing 10% low fat diet and 20 % casein (LFD-CAS; 
#D12450B; Research Diets, USA; % by values of energy). Subsequently, weight 
matched mice received different diets varying only in protein quality or fat content 
(Research Diets, USA): (1) LFD-CAS, (2) 10% fat and 20 % whey protein isolate 
(LFD-WPI; #D1208/601), (3) 45% fat and 20% casein (HFD-CAS; #D12451) and (4) 
45% fat and 20% whey protein isolate (HFD-WPI; #D11040501). The composition of 
each diet is detailed in the Table 3.T1. 
Two experiments were done: 
Experiment in which mice started the HFD dietary intervention at 5-week-old (5w): 
5-week-old mice were provided HFD-CAS or HFD-WPI (4 cages per group, each with 
4 animals) and LFD-CAS or LFD-WPI (controls; 2 cages per group, each with 4 
animals) for 5 weeks. After 5 weeks of dietary intervention, only the 10-week-old 
animals fed with HFD (groups 1 and 2) were euthanized (Fig. 3.1a).  
Experiment in which mice started the HFD dietary intervention at 10-week-old (10w): 
5-week-old mice were provided LFD-CAS or LFD-WPI for 5 weeks and switched to 
HFD-CAS or HFD-WPI for further 5 weeks (4 cages per group and 4 animals per 
cage). The controls were the same animals as the experiment 5w, i.e., mice fed with 
LFD-CAS or LFD-WPI (2 cages per group, each with 4 animals) for 10 weeks. At the 
end of the dietary intervention, all the 15-week-old animals (groups 3,4,5, and 6) from 
the four groups (i.e., HFD-CAS, HFD-WPI, LFD-CAS and LFD-WPI) were 
euthanized (Fig. 3.1a). 
In both experiments body weight was measured weekly, as well as the food intake per 
cage and was converted in energy (using the energy density HFD=19.79 KJ/g and 
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LFD=16.11 KJ/g of the rodent diets; Research Diets, USA). Notably, in the results are 
reported energy intake data for HFD-fed mice and not for LFD-fed mice because the 
latter groups had a sample size of 2, thus too small to carry out appropriate statistical 
analysis. For this reason, we omitted energy intake data for LFD-fed mice. 
The faecal samples were collected from individual mice the day before euthanasia and 
these were stored at -80˚C for subsequent analysis. In both experiments, mice were 
fasted for 8h commencing at 22.00 in the dark phase, then anaesthetized (100mg/Kg 
Ketamine and 10 mg/Kg Xylazine). Mice were euthanized by cervical dislocation and 
blood samples and tissues were collected. Tissues weight and/or length was recorded, 






















RNA Extraction and Gene Expression Analysis 
Total RNA was extracted from the ileum and liver (approximately 30 mg of tissue per 
each sample) using RNeasy Minikit and QIAshredder columns (Qiagen), and from 
epididymal white adipose tissue (eWAT) and subcutaneous white adipose tissue 
(sWAT) using QIAzol Lysis Reagent (Qiagen). The extracted RNAs were treated with 
DNase (Qiagen, Ireland). Complementary DNA was synthetized from 600ng total 
RNA using SuperscriptTM II Reverse Transcriptase kit (Life Technologies, Ireland), 
and subjected to Real-Time PCR (Roche, Ireland) using SYBR Green Select Master 
Mix (Roche, UK) as detailed before (McAllan et al 2015). The gene expression was 
calculated using 2-ΔΔCp and normalised against the reference gene β-actin (intestine 
and adipose tissue) and Gapdh (liver), and presented as a ratio versus average of HFD-
CAS 5w. The sequence of the primers is detailed in Table 3.ST1. RNA extraction and 
gene expression analysis were carried out in HFD-CAS and HFD-WPI-fed mice in 
both experiments (i.e., 5w and 10w), but not in the LFD control groups. 
 
Leptin, glucose, insulin and triglyceride levels 
Plasma leptin and glucose levels were determined using Mouse Leptin ELISA kit 
(Crystal Chem, USA) and Mouse Glucose Assay (Crystal Chem, USA) respectively. 
Mouse Insulin ELISA Kits, Ultra-Sensitive Assay (Crystal Chem, USA) was used to 
determine the plasma insulin level.  
The weights of liver and previously dried caecum content samples were recorded, and 
the samples were homogenised in 1,5 mL of %NP40/ddH2O solution. After two 
repeated steps of heating (80-100°C for 3-5 min) and cool down (15 minutes at RT), 
all the samples were centrifuged at maximum speed. The supernatant, containing the 
lipids, was collected and diluted 1:10. Triacylglycerol (TAG) level in the plasma, in 
the liver extract and in the caecum content extract it was measured using Triglyceride 
Quantification Assay Kit (abcam, UK). 






DNA extraction and library preparation 
Genomic DNA from faecal samples collected from HFD groups at the end of 
experiment 5w and 10w was purified according to the protocol for the standard Qiagen 
QiaAMP DNA Fast Stool Kit (Qiagen, Germany). Total DNA was accurately 
quantified with Qubit dsDNA HS Assay kit (Bio-Sciences, Dublin, Ireland). 
After DNA extraction, samples were processed for shotgun metagenomic sequencing 
using the Nextera XT DNA Library Prep Kit (Illumina, San Diego, CA, USA). After 
passing quality checks, libraries were prepared with Nextera XT DNA library prep 
kits (Illumina), the samples were sequenced on the Illumina MiSeq platform (2x250 
bp paired-end reads) in the Moorepark Teagasc sequencing facility, following standard 
Illumina sequencing protocols (Illumina 2013). DNA extraction and library 
preparation were carried out in HFD-CAS and HFD-WPI-fed mice in both 
experiments (i.e., 5w and 10w), but not in the LFD control groups. 
 
Bioinformatic analysis (shotgun metagenomic sequencing data) 
Metagenomic raw sequence reads were filtered on the basis of quality (removal all 
bases at the 3’ end with an average Phred score < 25 over a sliding window of 10 bp) 
and length (only reads with a minimum length of 180 bases were considered for further 
analysis) with PRINSEQ-lite 0.20.4 (Schmieder & Edwards 2011). After filtering, the 
sequences from the host, in our case the mouse, were eliminated. The mouse genome 
(Mus musculus (Mouse) GRCm38) downloaded from llumina iGenomes 
(https://support.illumina.com/sequencing/sequencing_software/igenome.htmL) was 
use as reference to remove host reads using BMTagger (Version 3.101) 
(Rotmistrovsky & Agarwala 2011). Paired-end reads were joined and filtered for 
duplicates using Picard tools 2.7.1, specifically FastqToSam and MarkDuplicates tools 
respectively (“Picard Toolkit.” 2019. Broad Institute, GitHub Repository. 
http://broadinstitute.github.io/picard/). Subsequently, the reads underwent another 
stage of quality filtering, sub-quality, using a modified version of the script 





script was used to delete reads with a Quality threshold value less than Q30. In 
addition, the reads shorter than 200 bp were also eliminated. 
The analysis of the microbial composition was carried out using the MetaPhlAn2 
species classifier (Segata et al 2012). Taxa with a relative abundance of <0.01% were 
categorized as "Other" for each classifier. Subsequently, the functions were assigned 
with HUMAnN2 tool (Franzosa et al 2018), based on ChocoPhlan and UniRef 
databases (Suzek et al 2007). The HUMAnN2 gene abundance table was regrouped 
by a mapping of GO terms for all categories of bacterial metabolism and dividing the 
functional table into two files (one stratified and one non-stratified). Metagenome 
assembly was performed using IDBA-UD (Peng et al 2012). 
 
Statistical analysis 
Power and coefficient of variation were calculated using data (body weight gain) from 
a previous study (McAllan et al 2015) and determined to be 8.8%. For a power of 80% 
and a significance level of 5%, this allows detection of a difference of 14% with a 
sample size of at least 8 mice per treatment. Body weight, cumulative weight gain and 
cumulative energy intake differences over both experiments 1 and 2 were analysed by 
a two-way repeated-measures ANOVA with Bonferroni’s post hoc pairwise 
comparisons. Statistical analysis of tissue weight, intestine weight/intestine length, 
gene expression, plasma leptin, insulin, glucose and TAG, and caecal and hepatic TAG 
data were performed using two-way ANOVA followed by pairwise comparison using 
Bonferroni’s post hoc test. Non-parametric data were compared by Kruskal-Wallis 
ANOVA followed by Mann-Whitney U test. Tissues weight was also evaluated using 
ANCOVA. Data were expressed as mean ± SEM and significance was set at P<0.05 
using SPSS software version 24 (IBM Corp). A complete description is detailed in 
“Supplementary Statistic” and figures 3.S4 and 3.S5. 
Bacterial and archaeal reads were retrieved from the output of MetaPhlAn2 for 
taxonomic profiling. Functional assignment was performed at the GO gene level. 
Statistical analyses were carried out with R (R version 3.4). Different R’s packages 
have been used (R Development Core Team 2016). To perform alpha-diversity 
analyses (Richness, Shannon Index and Simpson Index), as well as the 
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multidimensional scaling analysis (MDS) based on Bray-Curtis, the statistical package 
“vegan” version 2.3.0 (Oksanen et al 2015) was used. The Adonis function in “vegan” 
was used for PERMANOVA (permutational analysis of variance) analysis, and 
betadisper function for MDS figures. To compare alpha-diversity metrics among 
groups, ANOVA (aov) test was performed and it was adjusted with the Benjamini-
Hochberg method. Statistical differences between multiple samples in taxonomic and 
functional analyses were estimated by Kruskal-Wallis and False discovery rate (FDR). 
The Benjamini-Hochberg procedure was used to correct for multiple testing, and 
differences between two samples were estimated by Mann-Whitney test analysis and 
corrected with Family-wise error rate. The ggplot2 package (version 3.2.0) was used 
for data visualization (Wickham 2016).  
Statistical significance was established at P<0.05 (*), with other ranges, i.e. P<0.01 







HFD containing WPI increased energy intake but decreased body weight gain in 
younger mice 
During the first 5 weeks (5w, Fig. 3.1a), 5-week-old mice fed HFD-CAS significantly 
increased body weight starting from week 2 compared to the LFD-CAS (Fig. 3.1b). 
On the contrary, mice fed with HFD-WPI did not differ from their control group (i.e., 
LFD-WPI) for the duration of the experiment. HFD-WPI-fed mice exhibited 
significantly lower body weight, from week 3, and cumulative weight gain, from week 
1, compared to HFD-CAS-fed mice (Fig. 3.1b and 3.1c). During the experiment, not 
just HFD-CAS-fed mice, but also HFD-WPI-fed mice, had significantly higher 
cumulative body weight gain compared to LFD groups at every timepoint (Fig. 3.1c). 
The energy intake did not match the body weight and cumulative weight gain data: the 
HFD-WPI-fed mice showed an increase in the cumulative energy intake compared to 
CAS counterparts (week 5 timepoint, HFD-CAS vs HFD-WPI: 400.70 ± 12.27 KJ vs 
440.07 ± 6.90 KJ; Fig. 3.1d).  
 
In contrast, HFD containing WPI given to 10-week-old mice (10w, Fig. 3.1a) 
produced different outcomes with respect to energy balance compared to HFD-WPI 
feeding in younger individuals. LFD-fed mice supplemented with WPI or CAS had 
similar body weight trajectories until week 5, similar to our previous study (Fig. 3.1b) 
(Nilaweera et al 2017). When all the mice were 10-week-old, switching the diet to HF 
significantly increased body weight and cumulative weight gain of HFD-CAS group 
from week 7 compared to LFD-CAS control group (Fig. 3.1e and 3.1f). In this 
instance, the body weight trajectory of HFD-WPI-fed mice was similar to the LFD-
WPI-fed mice until week 9 (Fig. 3.1e), but their cumulative weight gain was higher 
starting from week 7 compared to LFD counterparts (Fig. 3.1f).  Unlike 5w mice, in 
10w mice no difference between HFD-CAS and HFD-WPI body weight trajectories 







Figure 3.1 Effect of HFD-WPI on body weight and energy intake in 5w vs 10w mice. (a) 
Mice were divided into 6 groups. 5-week-old mice (5w, groups 1 and 2) were fed a high-fat 
diet with control casein (HFD-CAS; 45% fat and 20% casein) or whey protein isolate (HFD-
WPI; 45% fat and 20% whey protein isolate). As controls for 5w, groups 5 and 6, respectively, 
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were fed a low-fat diet with casein (LFD-CAS; 10% fat and 20% casein) or whey protein 
isolate (LFD-WPI; 10% fat and 20% whey protein isolate). Groups 3 and 4 (10w) were initially 
fed with LFD-CAS and LFD-WPI respectively. After 5 weeks, when they were 10-week-old, 
the diet of these groups was switched from LF to HF, which lasted for other 5 weeks. The 
groups 5 and 6 (i.e., LFD-CAS and LFD-WPI) represented the control also for 10w. The 
present data show (b) body weight and (c) cumulative weight gain of 5w mice fed with HFD-
CAS, HFD-WPI, LFD-CAS and LFD-WPI. In panel (d) is indicated cumulative energy intake 
of 5w mice fed with HFD-CAS and HFD-WPI.  Data also show (e) body weight and (f) 
cumulative weight gain intake of 10w mice fed with HFD-CAS, HFD-WPI, LFD-CAS and 
LFD-WPI. In panel (g) is indicated cumulative energy of 10w mice fed with HFD-CAS and 
HFD-WPI. Statistical analysis: in figure (b) and (e) groups showing * (for HFD-CAS vs HFD-
WPI) and # (HFD-CAS vs LFD-CAS) are significant (*/# P<0.05 or **/## P<0.01 or ***/### 
P<0.001). In figure (e), the trends refer to HFD-WPI vs LFD-WPI. In figure 1 (c), (d), (f) and 
(g) groups showing * (for HFD-CAS vs HFD-WPI and LFD-CAS vs LFD-WPI) and # (HFD-
CAS vs LFD-CAS and HFD-WPI and LFD-WPI) are significant (*/# P<0.05 or **/## P<0.01 
or ***/### P<0.001). A complete statistical description is detailed in Methods and Materials 
and “Supplementary Statistics”. 
 
During 10w, in accordance 5w, the WPI groups fed with HFD showed a significant 
increase in the cumulative energy intake relative to CAS group (week 10 timepoint, 
HFD-CAS vs HFD-WPI: 774.85 ± 26.10 KJ vs 841.50 ± 16.68 KJ) (Fig. 3.1g). 
Clearly, this indicates that a loss of energy occurs during WPI supplementation.  
To investigate the aforementioned loss of energy, we quantified the level of lipids, 
more specifically triacyclglycerols, in the caecum, but did not observe any differences 
between CAS and WPI groups except in the 10w HFD-WPI group, which showed a 
trend towards a decrease compared to 10w HFD-CAS (Fig. 3.S1a and 3.S1b). In 
addition, 10w HFD groups showed a significantly higher amount of lipids in the 
caecum compared to 5w HFD groups (Fig. 3.S1a). This analysis did not yield an 
explanation for the discrepancy of energy between WPI and CAS groups, and the 
underlying cause remains unclear. 
 
Effect of HFD-WPI on organs and tissues at different ages 
Mice that received HFD-WPI at 5-week-old decreased the weight of adipose tissues 
(i.e., sWAT, eWAT and BAT) and increased liver and stomach weights, compared to 
the HFD-CAS group (Fig. 3.2a). No differences in caecum and small intestine weights 
were observed between the two groups (Fig. 3.2a). In addition, an organ/tissues 
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weights evaluation using ANCOVA (body weight as covariant) was also performed, 
which also yielded similar results (see supplementary statistics Fig. 3.S5b and 3.S5c).  
Details of tissue weight at this timepoint in the LFD-CAS and LFD-WPI have 
previously been detailed elsewhere (Nilaweera et al 2017). 
 
Prolonged WPI intake as part of LFD (10w mice) had no effect on organs and tissues 
weights (Fig. 3.2g). However, when WPI-fed mice and their controls were exposed to 
HFD at 10-week-old, they had increased eWAT and sWAT weights compared to LFD-
fed mice (Fig. 3.2g). While there was no difference observed in eWAT and BAT 
weight between HFD-CAS and HFD-WPI-fed mice, sWAT weight was significantly 
lower for 10w mice fed with HFD-WPI than those fed with HFD-CAS (Fig. 3.2g). No 
major changes were observed in stomach, caecum, small intestine and liver across the 
groups (Fig. 3.2g).  
The small intestine length (data not shown) and intestinal weight normalized to the 
length were similar across both 5w and 10w mice (Fig. 3.2b and 3.2h). 
 
From the organs weight data, we noticed that the weight of the liver was higher in 
mice fed a WPI (even if in 10w mice this difference did not achieve the significance). 
To investigate the possible reason behind this finding, we measured the level of gene 
expression of selected enzymes involved in hepatic fatty acids biosynthesis, namely 
acetyl-CoA carboxylase (Acc1), fatty acids synthase (Fasn), malonyl CoA-acyl carrier 
protein transacylase (Mcat) and acyl-CoA desaturase 1 (Scd1). To carry out this 
analysis, we solely focused on HFD-fed mice, both 5w and 10w. While no changes 
between HFD-CAS and HFD-WPI (both 5w and 10w) were observed in the gene 
expression of Acc1, Fasn and Mcat, the expression level of the gene Scd1 was lower 
in both HFD-WPI 5w and 10w compared to the CAS counterparts (Fig. S2a). SCD1 
takes part in TAG biosynthesis and animals with a deficiency in SCD1 have a lower 
rate of TAG biosynthesis (Flowers & Ntambi 2008). According to these results, we 
found that 5w mice showed a lower level of hepatic TAG in the presence of WPI. 
However, no differences in liver TAG were detected between 10w mice (Fig. S1c). 
This last result disagrees with Scd1 gene expression data. In addition, hepatic TAG of 
both 10w mice were similar to HFD-WPI 5w mice and lower than HFD-CAS 5w mice 
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(Fig. S1c). No statistical difference in hepatic TAG has been observed between LFD-
CAS and LFD-WPI fed mice (Fig. S1d). 
In summary, the reason why the liver is heavier during WPI supplementation is not 
because of a hepatic TAG accumulation. Thus, the underlying cause remains to be 
elucidated. 
 
Figure 3.2 HFD-WPI effect on tissues and organs weight, ileal gene expression and 
plasma metabolites and insulin in 5w vs 10w mice. Data show (a) the tissues and organs 
absolute weight, (b) intestine weight normalized by intestine length, (c) ileal gene expression 
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of hormones and nutrient transporters, plasma levels of (d) triacylglycerol (TAG), (e) glucose 
and (f) insulin of 5w mice fed with HFD-CAS and HFD-WPI. Also shown are (g) the tissues 
and organs absolute weight, (h) intestine weight normalized by intestine length, (i) ileal gene 
expression of hormones and nutrient transporters, plasma levels of (j) triacylglycerol (TAG), 
(k) glucose and (l) insulin of 10w mice fed with HFD-CAS and HFD-WPI. Abbreviation; 
eWAT; epididymal white adipose tissue, sWAT; subcutaneous white adipose tissue, BAT; 
brown adipose tissue, GLUT2; glucose transporter 2, CD36; cluster of differentiation 36, 
FATP4; fatty acid transporter 4, LAT4; L type amino acid transporter 4, SGLT1; sodium-
glucose transporter 1, SLCa19; methionine transporter, PYY; peptide YY, GCG; proglucagon, 
FIAF; fasting-inducing adipose factor. Statistical analysis: groups showing * (for HFD-CAS 
vs HFD-WPI) and # (HFD-CAS vs LFD-CAS and HFD-WPI and LFD-WPI) are significant 
(*/# P<0.05 or **/## P<0.01 or ***/### P<0.001). A complete statistical description is 
detailed in Methods and Materials and in figures 3.S4 and 3.S5. 
 
HFD-WPI does not influence ileal gene expression, glucose and insulin plasma 
levels  
Considering the differences observed in the body/organs weight and energy intake data 
across the different groups, we investigated further by measuring the ileal expression 
level of genes involved in the transport of nutrients and genes encoding for proteins 
involved in energy balance metabolism. We focused most of our analysis specifically 
on mice that received HFD-CAS and HFD-WPI at both ages (i.e., Fig. 3.1a groups 
1,2,3 and 4), as differences in mice fed with LFD-CAS or WPI have been previously 
investigated (McAllan et al 2013, McAllan et al 2014, McAllan et al 2015). 
WPI intake during 5w had no significant impact on the ileal expression of nutrient 
transporters and satiety hormones in HFD mice (Fig. 3.2c and 3.2i). In contrast, adults 
fed a HFD-WPI increased glucose transporter 2 (Glut2) expression compared to HFD-
CAS-fed mice (Fig. 3.2i). Furthermore, fatty acids transporter (Cd36) expression 
increased in the 10w HFD-CAS group compared to the 5w HFD-CAS group, without 
showing any differences between the WPI groups, and the gene encoding fatty acids 
transporter Fatp4 was significantly more expressed in both 10w groups, compared to 
the 5w groups (Fig. 3.S2b). No differences were detected in the amino acid 
transporters (i.e., Lat4 and Slc6a19) and the sodium-glucose transporter Sglt1 gene 
expression across all groups (Fig. 3.2c, 3.2i and 3.S2b). In addition, we observed an 
increase in the expression of anorexic hormone Peptide Tyrosine Tyrosine (Pyy) in 
10w HFD-CAS-fed mice relative to 5w HFD-CAS-fed mice, and an increase in Gcg 
(i.e., a gene that codes for the precursor of the satiety hormone GLP-1 in the intestinal 
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L cells of the ileum) in both 10w HFD groups, compared to 5w HFD groups. The 
expression of the Fasting-Induced Adipose Factor (Fiaf) remained unchanged (Fig. 
3.S2b).  
Although the expression of fatty acids transporters seems to be higher in older mice, 
no differences were observed in TAG levels in the plasma between 10w HFD-CAS 
and 5w HFD-CAS-fed mice and between LFD fed mice (Fig. 3.2d, 3.2j, 3.S1e and 
3.S1f). On the contrary, TAG levels in the plasma were higher in the 5w HFD-WPI 
group relative to the 10w counterpart (Fig 3.S1e).  
In addition, no changes were detected between CAS and WPI groups at both ages in 
glucose and insulin plasma level (Fig. 3.2e, 3.2f, 3.2k and 3.2l). However, 10w HFD-
WPI-fed mice showed a significant decrease in plasma glucose and an increase in 
plasma insulin relative to 5w HFD-WPI-fed mice. The plasma glucose levels were 
also lower in 10w HFD-CAS-fed mice compared to the 5w counterparts, but insulin 
remained unchanged between these two groups (Fig. 3.S1i and 3.S1j). According to 
our previous study (McAllan et al 2015), the two LFD groups had a similar plasma 
level of insulin (Fig. 3.S1j); however, in discordance with the study just mentioned, 
LFD-WPI-fed mice showed lower plasma glucose levels compared to LFD-CAS-fed 
(Fig. 3.S1h). 
These results suggest that the stage of life at which the mice start HFD-feeding has an 
influence on glucose and insulin levels and on the expression of genes involved in 
fatty acids transporters and genes coding for satiety hormones located in the distal part 
of the small intestine. In this context, the dietary protein typology did not particularly 
affect our measurements.  
 
HFD-WPI influences leptin and fat catabolism-related genes in younger mice 
A gene expression analysis was also carried out in the eWAT. Interestingly, we 
observed that Ob, Cd68 (i.e., genes that encode for leptin and for a protein expressed 
in the monocytes and macrophages, respectively) and Fiaf expressions were 
significantly lower in the 5w HFD-WPI-fed mice relative to the HFD-CAS control, 
but this difference was no longer observed between the two 10w groups (Fig. 3.3a, 
3.3e and 3.S2c). These findings were in accordance with body weight and cumulative 
weight gain data. Notably, the levels of plasma leptin data matched the Ob gene 
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expression levels between the 5w groups (Fig. 3.3b). In older mice, unlike the Ob gene 
expression data, the WPI groups showed a lower level of leptin compared to CAS 
groups, although this difference was less pronounced compared to the difference 
between HFD-CAS and HFD-WPI in younger mice (Fig. 3.3f). It is also important to 
highlight that, both Ob gene expression and plasma leptin levels were significantly 
higher in mice that began HFD-feeding at 10-week-old compared to mice that started 
the HFD intervention at 5-week-old (Fig. 3.S2c and 3.S1k). No differences in plasma 
leptin were detected between the LFD groups (Fig. 3.S1l). 
Analysis of the expression of genes involved in the catabolism within adipose tissue 
revealed an increase in Cpt1a and Ucp2 and a decrease in Hsl and Lpl expression in 
the 5w HFD-WPI-fed mice, relative to HFD-CAS-fed mice (Fig. 3.3c). Again, in older 
age, there were no differences detected between HFD-CAS and HFD-WPI-fed mice  
(Fig. 3.3g). No significant differences were detected in Ctp1b and Ucp3 expression 
(Fig. 3.3g and 3.S2d). 
Conversely, the anabolic gene Acc1 was expressed more in the HFD-WPI group 
compared to the HFD-CAS group during 10w, without any changes during 5w (Fig. 
3.3d and 3.3h). Only Fatp1 was more highly expressed in both HFD adolescent 
groups, compared to the HFD adult groups (Fig. 3.S2e). The expression of the anabolic 
gene Fasn and the transporter Cd36 remained unchanged. 
Altogether, the results showed the specific effect of whey protein within a HFD on 
leptin expression/plasma availability and on the expression of Cd68, Fiaf and some 
important genes involved in the catabolism of fatty acids in eWAT. However, these 
effects were only observed when the animals started the dietary intervention at 5-




Figure 3.3 Differential effect of HFD-WPI on eWAT gene expression and plasma leptin 
in 5w compared to 10w mice. Data show (a) expression of genes encoding for leptin (Ob), 
inflammation marker CD68 and the FIAF in the epididymal white adipose tissue (eWAT) and 
(b) plasma levels of leptin of 5w mice fed with HFD-CAS and HFD-WPI. Expression of genes 
encoding for (c) catabolic and (d) anabolic enzymes in the eWAT of 5w mice fed with HFD-
CAS and HFD-WPI were also investigated. Data also show (e) expression of genes encoding 
for leptin (Ob), inflammation marker CD68 and the FIAF in the eWAT, (f) plasma levels of 
leptin and expression of genes encoding for (g) catabolic and (h) anabolic enzymes in the 
eWAT of 10w mice fed with HFD-CAS and HFD-WPI. Abbreviation; OB; leptin, CD68; 
cluster of differentiation 68, CPT1a and b; carnitine palmitoyltransferase I, HSL; hormone-
sensitive lipase, UCP2 and 3; uncoupling protein, LPL; lipoprotein lipase, ACC; acetyl-CoA 
carboxylase, FATP1; fatty acid transporter 1, FASN; fatty acid synthase, CD36; cluster of 
differentiation 36. Statistical analysis: groups showing * (for HFD-CAS vs HFD-WPI) are 
significant (* P<0.05, ** P<0.01, *** P<0.001). A complete statistical description is detailed 
in Methods and Materials and figure 3.S4. 
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Younger mice fed with HFD-WPI have a higher proportion of Lactobacillus 
murinus within the gut 
Faecal DNA was subjected to shotgun metagenomic sequencing. The total number of 
reads per sample averaged 5,733,118 ± 1,768,632. These reads were used to 
investigate taxonomical and functional differences across the HFD-fed mice at 
different ages. At the family and species level, the taxonomical analysis of alpha-
diversity indexes (i.e., Simpson and Shannon) did not differ across the groups, 
although Richness index was higher in 5w HFD-WPI-fed mice compared to their CAS 
counterpart with no differences between the two 10w groups (Fig. 3.4a). The NMDS 
graph based on the dissimilarity matrix of Bray-Curtis showed clustering related to the 
type of diet. A clear separation between CAS and WPI groups was observed (Fig. 
3.4b, 3.4c and 3.S3b). At the family level, no significant differences were detected 
between HFD-CAS and HFD-WPI groups, either in 5w or in 10w (Fig. 3.4b), even if 
the two younger groups showed a more evident separation (R2=0.14, p=0.066 
PERMANOVA pairwise analysis) compared to the older individuals. However, at 
species level, a significant separation was noted between 5w HFD-CAS and HFD-
WPI (R2=0.147, p=0.036; PERMANOVA pairwise analysis), with no differences 
between the two 10w counterparts (Fig. 3.4c).  
 
A significantly higher proportion of the family Streptococcaceae and the 
corresponding genus and species Lactococcus and Lactococcus lactis were present in 
all groups fed with a diet containing CAS as the main protein source (Fig. 3.S3a and 
3.S3c). This is in accordance with our previous study, in which we demonstrated that 
the high abundance of this taxa in mice fed with CAS is due to the presence of L. lactis 
in the diet (Boscaini et al 2019) (Chapter 2). Bacteroides vulgatus was also more 
abundant in both CAS groups (Fig. 3.4d and 3.S3a). Interestingly, Lactobacillus 
murinus, was present in higher proportion in HFD-WPI fed mice compared to their 
CAS counterparts during 5w, with no difference in the abundance of this species 
between the 10w groups (Fig. 3.4d and 3.S3a). The relative abundance of L. murinus 
across the groups (represented in a taxa plot and as a percentage) is reported in figures 




Figure 3.4 Age- and duration-dependent effect of HFD-WPI on the gut microbiota 
taxonomy and function. Taxonomic (a) alpha-diversity at family and species level, measured 
with richness, Shannon and Simpson indexes, and beta-diversity, calculated using NMSD 
ordination, both (b) at family and (c) species level, of HFD-CAS and HFD-WPI-fed mice at 
both ages (5w and 10w). (d) Bar chart representing taxonomic differences at species level 
across the groups, using Kruskal Wallis method. (e) Functional beta-diversity calculated using 
NMSD ordination, and (f) bar chart representing differences in metabolic activities or 
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processes across the HFD-CAS and HFD-WPI-fed mice at both ages. Statistical analysis: 
groups showing * (for HFD-CAS vs HFD-WPI) and # (5w vs 10w) are significant (*/# P<0.05 
or **/## P<0.01 or ***/### P<0.001). A complete statistical description is detailed in Methods 
and Materials. 
 
In addition to the taxonomical data, functional analyses were carried out. Alpha-
diversity analysis performed with HUMAnN2 did not show changes across the groups 
(data not shown). As for the taxonomic data, a clear separation between CAS and WPI 
functions in the NMDS graph based on the dissimilarity matrix of Bray-Curtis beta-
diversity plot was observed (Fig. 3.4e and 3.S3d). HFD-WPI groups, at both ages, 
were significantly different compared to their CAS counterparts (5w: HFD-CAS vs 
HFD-WPI R2= 0.145, p=0.006; 10w: HFD-CAS vs HFD-WPI R2= 0.118, p=0.012; 
PERMANOVA pairwise analysis) (Fig. 3.4e). In addition, both WPI groups showed 
decreased metabolic FMN reductase, oxidoreductase and N5-carboxyethil-L-ornithine 
synthase activities (Fig. 3.4f). In contrast the membrane lipid biosynthetic process was 
decreased in 5w HFD-WPI-fed mice, relative to HFD-CAS-fed mice, with no 
difference between the 10w mice (Fig. 3.4f). 
In addition, we analysed in detail L. murinus -related functions that were significantly 
different across the groups. In total, we found 62 significantly different activities and 
functions across the groups (Fig. 3.5) and, among these, 49 functions were 
significantly higher in HFD-WPI-fed mice compared to HFD-CAS-fed mice during 
5w with no differences between the 10w groups. Several processes and functions, 
attributed to L. murinus, were found to be abundant within the younger HFD-WPI 
group, such as amino acids biosynthesis, sugars metabolism (including glycolysis and 
 fructose, mannose, lactose metabolism), vitamins metabolism (vitamin C catabolism 
and vitamin K2 biosynthesis), DNA and nucleic acid-related processes (including 
pentose phosphate pathway) and oxalate metabolism (Fig. 3.5). Altogether, these 
results suggest that the composition and the function of the intestinal bacterial 
population can be differently influenced based on the stage of life at which the dietary 









Figure 3.5 Differences in metabolic activities and processes of Lactobacillus murinus. 
Heat map showing significant differences in the increase of metabolic activities and processes 
abundance belonging to faecal Lactobacillus murinus in HFD-WPI, relative to HFD-CAS, in 
5w compared to 10w mice. Abbreviation # (in cell wall biosynthesis): UDP-N-Ac-L-Al-D-
Glu-2,6-DiPi-D-Al-D-A:P as UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-
diaminopimelyl-D-alanyl-D-alanine:undecaprenyl-phosphate transferase. Statistical analysis: 
groups showing * (for HFD-CAS vs HFD*-WPI) are significant (* p<0.05, ** p<0.01, *** 





There is an increasing emphasis on understanding the microbiota function and 
composition in response to diet (Hughes et al 2019). In particular, its modulation to a 
healthier configuration to ameliorate or prevent metabolic diseases, such as obesity, is 
of interest (Torres-Fuentes et al 2015, Torres-Fuentes et al 2017). Here, we have 
shown that a 5-week-diet intervention with HFD-WPI, compared to HFD-CAS, in 
mice that started the HFD intervention at 5-week-old, reduced weight gain and 
adiposity, changed eWAT catabolism and leptin production, with an increase in 
Lactobacillus murinus abundance and related functions within the gut. In contrast, 
none of these changes was observed in mice that underwent the same diet intervention 
starting from 10-week-old and an extended period of WPI supplementation. These 
results suggest that the efficacy of this dietary intervention is age-dependent and, based 
on age, the interplay with diet duration and the quality of response is different. Thus, 
this is in accordance with our second hypothesis. 
 
It has previously been shown that the presence of WPI as the protein component of a 
HFD caused a reduction in weight gain in rodents (McAllan et al 2013, McAllan et al 
2014, Pilvi et al 2008). With the present paper, we confirmed a reduction in weight 
gain and adiposity in mice starting a 5-week HFD-WPI dietary intervention at 5-week-
old. When the same dietary intervention was started at 10-week-old, the body weight 
trajectory and the cumulative weight gain of HFD-WPI-fed mice were not statistically 
significantly different, compared to their CAS counterparts. It is worth noting that, 
while total weight gain was not significant, sWAT weight was significantly lower in 
HFD-WPI compared to their CAS fed counterparts. Notably, WPI administration in 
LFD at 5-week-old did not prevent an increase in weight gain after the switch to HFD 
at 10-week-old. This finding goes against our first hypothesis.  
 
In contrast with previous studies in rodents that showed a satiety effect due to WPI-
enriched diets as being the mechanism of action responsible for reduced weight gain 
(Hall et al 2003, Pezeshki et al 2015, Zhou et al 2011), here we found an increase in 
energy intake, both in HFD and LFD-fed mice, suggesting a loss of energy during WPI 
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supplementation. Notably, we also found a discrepancy between body weight and 
energy intake in our previous study, in which we were investigating the metabolic and 
gut microbial differences in mice fed with HFD containing alpha-lactalbumin, a 
specific whey protein, compared to CAS counterparts (Boscaini et al 2019) (Chapter 
2). To investigate the loss of energy that occurred between WPI and CAS groups, we 
measured the level of TAG in the caecum. Variation of fat, specifically free fatty acids, 
cholesterol and TAG, in faeces is an indication of intestinal function and fat absorption 
changes under certain conditions (Kraus et al 2015, Mataki et al 2007). No differences 
were detected in the TAG levels between WPI and CAS-fed mice, but we cannot 
exclude that free fatty acids or cholesterol can be involved in the afore-mentioned loss 
of energy.  
Surprisingly, during organ weight data analysis, we observed that the liver was heavier 
in the presence of WPI within the diet. Since we did not observe either an accumulation 
of hepatic TAG or an overexpression of genes involved in fatty acids biosynthesis in 
the liver of WPI-fed mice, we could not explain the higher weight of the liver in these 
mice. Perhaps, this phenomenon is due to inflammation or an accumulation of other 
macromolecule such as glycogen or cholesterol or vitamins (Bhattacharya 2015, Li et 
al 2016). Future investigation, using histological and transcriptomics approaches, will 
be required to fully elucidate the effect of WPI on liver weight. 
In previous studies from our group it was observed that a LFD enriched in WPI 
changed the gene expression of some ileal nutrient transporters and satiety-control 
hormones, such as FATP4, methionine transporter and PYY (McAllan et al 2013, 
Nilaweera et al 2017). In the present study, we showed that, with the exception of 
Glut2 in 10w, WPI provided in presence of HFD decreases the capacity to regulate the 
expression of ileal nutrient transporters and satiety hormones. Instead, some of the 
analysed genes (i.e., Cd36, Fatp4, Pyy, Gcg) underwent increased expression in 10w 
relative to 5w mice. In accordance with these data, plasma levels of TAG, glucose and 
insulin also remained unchanged between WPI and CAS across the groups, but they 
showed some variations with age. This is in line with other studies testing TAG, 
glucose and insulin during HFD-WPI administration (McAllan et al 2013, Pilvi et al 
2007). The fact that nutrient transporter expression and plasma metabolites are 
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different between mice at different ages might be because they started the HFD dietary 
intervention at different stages of life with different duration of WPI intake. 
Consequently, we suggest that the decreased weight gain and adiposity observed in 
the presence of WPI-enriched HFD at younger age is not controlled or modulated by 
a differential nutrient absorption mechanism within the small intestine.  
 
Our data suggest that decreases in weight gain and adiposity in younger mice fed a 
HFD-WPI might be linked with eWAT catabolism. Cpt1a and Ucp2 are genes coding 
respectively for a mitochondrial enzyme that catalyses the rate-limiting step of fatty 
acids β-oxidation and a mitochondrial membrane protein that dissipates metabolic 
energy with prevention of oxidative stress accumulation (Bäckhed et al 2007, Horvath 
et al 2003, Pierelli et al 2017, Warfel et al 2017). While these two genes were 
expressed more in mice fed a HFD-WPI when younger, Hsl and Lpl genes, together 
with the gene coding for LPL-fasting induced inhibitor FIAF (also involved in 
triglyceride metabolism), were expressed less in the same group, compared to 5w mice 
fed with HFD-CAS. HSL is an intracellular neutral lipase responsible for the 
hydrolysis of TAG, diacylglycerols, monoacylglycerols and cholesteryl-esters 
(Haemmerle et al 2006, Shen et al 2011). LPL is an enzyme that hydrolyses TAG and 
controls the kinetics and transport of the majority lipoproteins in the plasma (Wang & 
Eckel 2009). This suggests that WPI modulates the expression of key genes involved 
in adiposity control and that play a role in metabolic syndrome development, thereby 
accelerating eWAT fatty acids catabolism and ameliorating adiposity and HFD-
induced obesity phenotype. 
In 5w mice fed with HFD-WPI, the level of expression of the eWAT Ob gene, together 
with the plasma level of the satiety hormone produced by this gene, leptin, were lower 
compared to the CAS counterparts. Notably, plasma leptin, but not Ob expression, was 
also lower in adult HFD-WPI-fed mice compared to the CAS controls. Also in the 
presence of LFD, WPI have been shown to reduce plasma levels of leptin (McAllan et 
al 2014), however we found no differences in circulating leptin between LFD-WPI 
and LFD-CAS, after 10 weeks of dietary intervention. As is well established for HFD-
induced obese mice and obese humans, leptin signalling to the brain is disrupted and, 
consequently, its level in periphery is higher than in the healthy status (Zhou & Rui 
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2013). WPI, not only by influencing fatty acids catabolism, but also possibly by 
lowering both plasma leptin and Ob gene expression, positively modulate adiposity in 
mice and this effect seems to be more powerful in the presence of HFD than LFD. 
Notably, our data suggest that a reduction in plasma leptin in HFD-WPI-fed mice is 
directly due to a reduction in Ob gene expression, rather than a reduction in adipose 
mass. Low Cd68 expression in eWAT, an inflammatory marker, gives a first insight 
regarding a low inflammatory state within the adipose tissue in the presence of HFD-
WPI, which is usually very high in mice and humans with obesity (Stolarczyk 2017).  
 
Aside from eWAT catabolism and leptin production, the gut microbiota composition 
and function showed changes between 5w HFD-WPI- and HFD-CAS-fed mice, that 
were no longer observed between 10w HFD groups. Specifically, the most important 
difference lay at species-level, where the species Lactobacillus murinus showed an 
increased abundance in younger HFD-WPI-fed mice relative to the CAS controls. L. 
murinus can attenuate allergic responses in mice with food allergy-induced dysbiosis 
within the gut microbiota and its high proportions in the gut are correlated with a lower 
degree of necrotizing enterocolitis, suggesting a protective role in the intestine (Huang 
et al 2016, Isani et al 2018). In addition, a recent study showed that there was a high 
proportion of L. murinus in the gut of mice that underwent calorie restriction, which 
was also linked with anti-inflammatory effects. In the same study, it was also 
demonstrated that L. murinus reduced intestinal permeability and systemic 
inflammatory markers in old microbiota-colonized gnotobiotic mice (Pan et al 2018).  
 
In the present study, L. murinus levels within the gut of younger HFD-WPI-fed mice 
were linked to changes in the functional profile, such as upregulation of amino acids, 
fatty acids and cell wall biosynthesis functions, together with functions related to 
transport, translation, DNA, nucleotides, sugar metabolism and general cellular 
function. This can be explained by the fact that WPI stimulates the growth of gut L. 
murinus, thus all the bacterial functions related to growth, cell division and survival 
are upregulated. Additionally, oxalate, bile acid and vitamin metabolism were found 




Oxalate is a toxic compound found in fruit, vegetables, grains and nuts. Excessive 
concentration of oxalate can cause problems in the gastrointestinal tract and 
exceptionally kidney failure. Recently, probiotic bacteria belonging to 
Bifidobacterium and Lactobacillus have been studied for their potential to degrade 
oxalate. A direct correlation between the oral administration of probiotic bacteria and 
the reduction of urinary oxalate excretion has been observed in rats and humans 
(Noonan & Savage 1999, Turroni et al 2007).  
Gut bacterial vitamin and bile acids metabolism are among the most important 
examples of gut bacteria-host metabolism interaction. In particular, it was recently 
shown that HFD causes a serious alteration of the bile acid pool, that may contribute 
to obesity morbidity and development (Lin et al 2019). Accordingly, in this study, we 
observed a significant increase in L. murinus-related choloylglycine hydrolase activity 
in younger mice fed with HFD-WPI. Cholylglycine hydrolase activity is related to the 
bile salt hydrolase enzyme (BSH), which is commonly produced by Lactobacillus spp. 
to promote bile acids biotransformation (Urdaneta & Casadesús 2017). This process, 
in turn, plays an important role in regulating host lipid and cholesterol, glucose, and 
energy metabolism, drug metabolism, and the modulation of immune response (Joyce 
et al 2014, Li & Chiang 2014). Thus, the anti-obesity effect exerted by WPI might be 
mediated by an increase in L. murinus and its bile acids biotransformation activity. In 
light of this, in the future, will be insightful to perform a detailed analysis on bile acids 
and gut microbiota upon WPI consumption. 
This work builds upon a decade of our research where we have tried to understand the 
energy balance related effects of WPI, which have led to the finding that this protein 
can reduce adiposity and body weight without relying on energy intake. Here, we have 
shown that early nutritional intervention with whey protein alters the composition of 
the gut microbiota and adiposity, where the effects of the catabolic response in the 
tissue were evident, suggesting a potential functional relationship between changes in 
the gut and the adipose tissue, which is not seen in later stage of the mouse life despite 
prolonged protein intake. It is interesting that preterm babies fed whey protein gain 
weight but this effect is lost in term babies (Berger et al 1979). More recently, it has 
been shown that babies aged 28 day fed formula with a higher proportion of whey 
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protein consume more of the formula but gain less weight (gain per intake) than babies 
fed low amounts of the protein (Fleddermann et al 2014). 
Taken together our findings show that WPI exerts a possible prebiotic effect within 
the gut thanks to its ability to promote L. murinus particularly at a young age. 
Consequently, we propose that the role of WPI, during HFD administration, in the 
amelioration of weight gain and regulation of adipose tissue metabolism might be 
directly linked to modulation of the gut microbiota. Future work is planned, which 















Genes Forward primer (5'-3') Reverse primer (5'-3')
Acetyl-CoA carboxylase (Acc1) 5'-cagtgctatgctgagattgagg-3' 5'-acacagccagggtcaagtg-3'
Fatty acid transporter 1 (Fatp1) 5'-ccggtgtggtggctgctcttctc-3' 5'-gctgccatctccccgccataaatg-3'
Fatty acid synthase (Fasn ) 5'-gctgctgttggaagtcagc-3' 5'-agtgttcgttcctcggagtg-3'
Lipoprotein lipase (Lpl ) 5'-tgtctaactgccacttcaaccac-3' 5'-gggcacccaactctcatacattc-3'
Cluster of differentiation 36 (CD36 ) 5'-ttgaaaagtctcggacattgag-3' 5'-tcagatccgaacacagcgta-3'
Leptin (Ob ) 5'-ccccgcaccgctggaagtac-3' 5'-atgtgccctgaaatgcggtatg-3'
Cluster of differentiation 68 (CD68) 5'-cacttcgggccatgtttctcttg-3' 5'-aggggctggtaggttgattgtcgtc-3'
Carnitine palmitoyltransferase 1a (Cpt1a ) 5'-gactccgctcgctcattc-3' 5'-tctgccatcttgagtggtga-3'
Carnitine palmitoyltransferase 1b (Cpt1b ) 5'-gagtgactggtgggaagaatatg-3' 5'-gctgcttgcacatttgtgtt-3'
Hormone-sensitive lipase (Hsl ) 5'-ctattcagggacagaggcag-3' 5'-cgatgtggtcttttggggc-3'
Uncoupling protein 2 (Ucp2 ) 5'-ccatttcctgcaccccgatttacttcc-3' 5'-gctgggctggggatgaagatgaag-3'
Uncoupling protein 3 (Ucp3 ) 5'-acaggcccacacggtccagaacc-3' 5'-cccatcaggtcagtgcaaaacagagg-3'
Angioprotein-like 4 (Fiaf ) 5'-gctcattggcttgactcccaac-3' 5'-aaaagtccactgtgccgctc-3'
Glucose transporter 2 (Glut2 ) 5'-tcctacttggcctatctgctgtgc-3' 5'-tgccctgacttcctcttccaac-3'
Fatty acid transporter 4 (Fatp4 ) 5'-tggcgtttcatccgggtcttcatc-3' 5'-gcaaacagcaggggcaccgtcttc-3'
L-type amino acid transporter 4 (Lat4 ) 5’cccgcttcctgttgttggtgctaac3’ 5’ggggcttcttctcaggctttcaag 3’
Sodium-glucose co-transporter 1 (Sglt1 ) 5’-gagccccgcggttactgc-3’ 5’-cctgcggctgctcctgtg-3’
System B(0) neutral amino acid transporter 1 (Slc6a19 ) 5’gtgtggcgcttcccctacctatg-3’ 5’ cctctgaccgatggcaaactcc-3’
Peptide YY (Pyy ) 5'-ggacgcctaccctgccaaacca-3' 5'-agtgccctcttcttaaaccaaaca-3'
Proglucagon (Cgc ) 5'-agggacctttaccagtgatgtga-3' 5'-acgagatgttgtgaagatggttgt-3'
Malonyl CoA-acyl carrier protein transacylase (Mcat ) 5'-cagtgtgggagagtttgctg-3' 5'-ccttcaccgcatacagacc-3'
Stearoyl-CoA desaturase (Scd1) 5'-ttccctcctgcaagctctac-3' 5'-cagagcgctggtcatgtagt-3'
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh ) 5'-aagagggatgctgcccttac-3' 5'-ccattttgtctacgggacga-3'




Figure 3.S1 Plasma metabolites and hormones, and TAG in the caecum and in the liver. 
Data show triacylglycerol (TAG) level in the caecum (a) between HFD groups in 5w vs 10w 
and (b) between LFD-CAS and LFD-WPI groups. TAG level in the liver (c) between HFD 
groups in 5w vs 10w and (d) between LFD-CAS and LFD-WPI groups. Plasma levels of TAG 
(e) between HFD groups in 5w vs 10w and (f) between LFD-CAS and LFD-WPI groups. 
Plasma levels of glucose (g) between HFD groups in 5w vs 10w and (h) between LFD-CAS 
and LFD-WPI groups. Plasma levels of insulin (i) between HFD groups in 5w vs 10w and (j) 
between LFD-CAS and LFD-WPI groups. Plasma levels of leptin (k) between HFD groups in 
5w vs 10w and (l) between LFD-CAS and LFD-WPI groups. Statistical analysis: groups 
showing * (for HFD-CAS vs HFD-WPI) and # (HFD-CAS 5w vs HFD-CAS 10w and HFD-
WPI 5w vs HFD-WPI 10w) are significant (*/# P<0.05 or **/## P<0.01 or ***/### P<0.001). 





















Figure 3.S2 Hepatic, Ileal and eWAT gene expression. Data show (a) expression of genes 
coding for enzymes involved in fatty acids biosynthesis within the liver, (b) ileal gene 
expression of hormones and nutrient transporters, (c) expression of genes coding for leptin, 
inflammation marker CD68 and the FIAF, (d) catabolic and (e) anabolic enzymes in the 
eWAT. Abbreviations: ACC1; acetyl-CoA carboxylase 1, FASN; fatty acids synthase; 
MCAT, malonyl CoA-acyl carrier protein transacylase; SCD1, stearyl-CoA desaturase; other 
figure descriptions in figures 2 and 3. Statistical analysis: groups showing * (for HFD-CAS 
vs HFD-WPI) and # (HFD-CAS 5w vs HFD-CAS 10w and HFD-WPI 5w vs HFD-WPI 10w). 




Figure 3.S3 Effect of HFD-WPI in the gut 
microbiota of 5w vs 10w mice. (a) Taxaplot 
showing families and species within the 
faecal samples of 5w and 10w mice fed with 
HFD-CAS and HFD-WPI. Also reported (b) 
taxonomic beta-diversity, calculated using 
NMSD ordination, both at family (R2=0.146, 
pValue=0.001) and species level (R2=0.181, 
pValue=0.001), (c) bar charts representing 
taxonomic differences at family, genus and 
species level across the HFD groups (5w and 
10w), using Kruskal Wallis method. The last 
graph shows (d) functional beta-diversity 
(R2=0.174, pValue=0.001) calculated using 
NMSD ordination, across the HFD groups 
(5w and 10w). (e) Relative abundance (%) of 
the species Lactobacillus murinus across the 
groups, using shotgun metagenomic analysis 
approach. Statistical analysis: groups 
showing * (for HFD-CAS vs HFD-WPI) and 
# (HFD-CAS 5w vs HFD-CAS 10w and 
HFD-WPI 5w vs HFD-WPI 10w) are 
significant (*/# P<0.05 or **/## P<0.01 or 
***/### P<0.001 or ****/#### p<0.0001). A 
complete statistical description is detailed in 







Figure 3.S4 Statistical analysis details. Complete statistical description organs and tissues 
weight data (a) in 5w and (b)(c) in 10w. Complete statistical description of (d)(e) hormones 
and metabolites data, and gene expression data. Mann Whitney U test: 1= HFD-CAS 5w; 2= 
HFD-WPI 5w; 3 = HFD-CAS 10w, 4 = HFD-WPI 10w. 
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Figure 3.S5 Hormones and metabolites statistics, and tissue/organs weight ANCOVA. 
Complete statistical description of (a) hormones and metabolites data in LFD-fed mice and 
















Body weight in experiment 5w (0-5 weeks): F(5;215) = 436.71, p < 0.001 for the effect 
of the time, F(1;43) = 6.14, p < 0.05 for the effect of the diet fat content, F(1;43) = 2.38, p 
> 0.05 for the effect of the protein type, F(5;215) = 21.43 , p < 0.001 for the effect of the 
time x diet fat content interaction, F(5;215) = 2.54, p > 0.05 for the effect of the time x 
diet protein type interaction, F(5;215) = 3.12, p < 0.05 for the effect of the time x diet fat 
content x diet protein type interaction. 
Body weight in experiment 10w (0-10 weeks): F(10;430) = 339.36, p < 0.001 for the 
effect of the time, F(1;43) = 3.21, p > 0.05 for the effect of the diet fat content, F(1;43) = 
0.15, p > 0.05 for the effect of the protein type, F(10;430) = 30.83 , p < 0.001 for the 
effect of the time x diet fat content interaction, F(10;430) = 0.53, p > 0.05 for the effect 
of the time x diet protein type interaction, F(10;430) = 3.11, 0.07 < p > 0.05 for the effect 
of the time x diet fat content x diet protein type interaction. 
Cumulative Weight Gain experiment 5w (0-5 weeks): F(4;172) = 340.66, p < 0.001 for 
the effect of the time, F(1;43) = 33.29, p < 0.001 for the effect of the diet fat content, 
F(1;43) = 4.13, p < 0.05 for the effect of the protein type, F(4;172) = 12.55 , p < 0.001 for 
the effect of the time x diet fat content interaction, F(4;172) = 1.36, p > 0.05 for the effect 
of the time x diet protein type interaction, F(4;172) = 2.55 p > 0.05 for the effect of the 
time x diet fat content x diet protein type interaction. 
Cumulative Weight Gain experiment 10w (0-10 weeks): F(9;396) = 285.36, p < 0.001 
for the effect of the time, F(1;44) = 16.91, p < 0.001 for the effect of the diet fat content, 
F(1;44) = 0.026, p > 0.05 for the effect of the protein type, F(9;396) = 37.85, p < 0.001 for 
the effect of the time x diet fat content interaction, F(9;396) = 0.66, p > 0.05 for the effect 
of the time x diet protein type interaction, F(9;396) = 4.61 p < 0.05 for the effect of the 
time x diet fat content x diet protein type interaction. 
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Cumulative Energy Intake/mouse experiment 5w (0-5 weeks): F(9;72) = 6615.09, p < 
0.001 for the effect of the time, F(1;8) = 8.09, p < 0.05 for the effect of the protein type,  
F(9;72) = 20.71, p < 0.01 for the effect of the time x diet protein type interaction. 
Cumulative Energy Intake/mouse experiment 10w (0-10 weeks): F(4;32) = 3575.00, p 
< 0.001 for the effect of the time, F(1;8) = 11.36, p < 0.05 for the effect of the protein 
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Rationale Whey protein isolate (WPI) is considered a dietary solution to obesity. 
However, the exact mechanism of WPI action is still poorly understood but is probably 
connected to its beneficial effect on energy balance, adiposity and metabolism. More 
recently its ability to modulate the gut microbiota has received increasing attention. 
 
Objectives Here, we used a microbiota depletion, by antibiotic cocktail (ABX) 
administration, to investigate if the gut microbiota mediates the physiological and 
metabolic changes observed during high-fat diet (HFD)-WPI consumption. To 
facilitate this, C57BL/6 mice received a HFD containing WPI (HFD-WPI) or the 
control non-whey milk protein casein (HFD-CAS) for 5 weeks or 10 weeks.  
 
Results HFD-fed mice supplemented with WPI showed reduced body weight gain, 
adiposity, Ob gene expression level in the epidydimal adipose tissue (eWAT) and 
plasma leptin relative to HFD-CAS-fed mice, after 5- or 10-weeks intervention both 
with or without ABX treatment. Following 10-weeks intervention, ABX and WPI had 
an additive effect in lowering adiposity and leptin availability. HFD-WPI-fed mice 
showed a decrease in the expression of genes encoding pro-inflammatory markers 
(MCP-1, TNFα and CD68) within the ileum and eWAT, compared to HFD-CAS-fed 
mice, which did not show alterations following microbiota depletion. Additionally, 
WPI supplementation decreased HFD-induced intestinal permeability disruption in the 
distal ileum; an effect that was reversed by chronic ABX treatment.  
 
Conclusions WPI reverses the effects of HFD on metabolic and physiological 
functions through mainly microbiota-independent mechanisms. In addition, we 
demonstrate a protective effect of WPI on HFD-induced inflammation and ileal 





Obesity is characterized by a long-term disruption of energy balance, which results in 
an excessive accumulation of fat mass. There are several health issues that arise in 
obesity, such as cardiovascular diseases, metabolic and endocrine dysfunction of 
adipose tissue, alterations of gastrointestinal physiology, dysregulation of 
hypothalamic satiety-related circuits and a state of chronic low-grade inflammation 
that can lead to insulin resistance (Cercato & Fonseca 2019, Gregor & Hotamisligil 
2011, Longo et al 2019, Teixeira et al 2012, Timper & Brüning 2017). In addition, the 
diversity, composition and function of the gut microbiota is altered in obese subjects, 
as well as the abundance of several metabolites produced by the intestinal microbial 
population, which are important for maintaining good health of the host (Canfora et al 
2019a, Sun et al 2018). Specifically, microbial metabolites can communicate with 
different organs, such as adipose tissue, liver and brain, regulating important metabolic 
and behavioural functions (Torres-Fuentes et al 2017, Wang et al 2018a). Moreover, 
HFD-fed mice are characterized by increased intestinal permeability, followed by an 
increase in plasma endotoxemia (i.e., increase in plasma levels of lipopolysaccharide, 
LPS) and expression of pro-inflammatory cytokines (Araújo et al 2017, Cani et al 
2007). This causes an exacerbation of the pathogenesis of HFD-induced obesity. 
The obesity problem is continuously growing in our modern society; thus, a 
considerable scientific effort is required to find strategies to prevent/ameliorate/treat 
this condition. Currently, pharmacotherapy, surgery and dietary therapies are the most 
widely used approaches (Ruban et al 2019). 
 
Bovine whey protein has recently been identified as a dietary candidate for the 
improvement of obesity-related physiological changes, because of its distinct 
properties. This protein is present in the liquified compartment (i.e., whey) that can be 
separated after casein curd formation during cheese production. Whey protein contains 
different protein components, such as β-lactoglobulin, α-lactalbumin, bovine serum 
albumin, lactoferrin, lactoperoxidase and glycomacropeptide (Morr & Ha 1993). In 
several human and rodent studies, whey protein has been shown to attenuate appetite 
as well as modulate insulin and some gastrointestinal hormones production, such as 
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cholecystokinin (CCK), peptide YY (PYY) and ghrelin, compared to casein (Hall et al 
2003, McAllan et al 2015, Pal & Ellis 2010a, Veldhorst et al 2009a). These findings 
were observed in lean individuals and mice fed with a low-fat diet (LFD). In the 
presence of a high-fat diet (HFD), the effect of whey protein on satiety seems to be 
less evident. However, compared to casein, whey protein supplementation results in a 
decrease in body weight gain, adiposity and leptin levels, together with an increase in 
fatty acid β-oxidation and glucose tolerance (Bergia et al 2018, Boscaini et al 2020, 
McAllan et al 2014, Pilvi et al 2007, Pilvi et al 2008, Shertzer et al 2011) (see Chapter 
3).  
 
In rodents and in vitro, we and others have shown that whey protein isolate (WPI) 
significantly alters the composition of the gut microbiota (Boscaini et al 2020, 
McAllan et al 2014, Sanchez-Moya et al 2017, Sprong et al 2010) (see Chapter 3). In 
the presence of HFD, these effects are accompanied by a decrease in body weight and 
adiposity, leptin availability and a change in the expression of genes involved in 
adipose tissue metabolism (Boscaini et al 2020) (see Chapter 3). These results suggest 
a possible link between the gut microbiota and metabolic and physiological 
modifications.  
Moreover, it was shown that the milk protein CAS ameliorated intestinal barrier 
function on diabetes-prone rats and bovine milk has been associated with a decreased 
gut permeability and improved inflammation and microbial dysbiosis in HFD-induced 
obese mice (Boudry et al 2017, Visser et al 2010). However, the effect of WPI on gut 
permeability during HFD-induced obesity is currently not fully understood. 
 
In light of these findings, we hypothesized that, in the presence of HFD, WPI may 
exert beneficial effects on body weight gain, adiposity and metabolic-related changes 
through the modulation of the gut microbiota. To test this, we depleted the gut 
microbiota using an antibiotic cocktail (ABX) and examined the impact on measures 
of body weight, immunometabolism, gut permeability, gut microbiota composition 






Seventy-four three-week-old C57BL/6J male specific pathogen free mice were 
purchased commercially (Envigo; UK) and were housed 3 per cage on a 12 h light/dark 
cycle with humidity maintained at 45-60% and temperature between 19-21°C. Mice 
had ad libitum access to food and water throughout the study. During the initial 2 
weeks of acclimatization, mice were provided with a diet containing 10% (low) fat and 
20% casein (LFD-CAS; #D12450Bi) (all % values by energy). Then, weight-matched 
cages were assigned to one of the 8 experimental groups (Fig. 4.1). Because of the 
importance of the timing on the ability of WPI to exert its anti-obesity effects (Boscaini 
et al 2020) (see Chapter 3), we sought to compare some of the readouts during different 
intervention windows. Mice were provided with a 45% high-fat diet containing 20% 
casein (HFD-CAS; #D12451i) and with a 45% high-fat diet containing 20% whey 
protein isolate (HFD-WPI; #D11040501) for 5 weeks (short-term intervention) or 10 
weeks (long-term intervention). The diets were OpenSource and were made by 
Research Diets (diets composition details, Table 4.T1). Since the start of the dietary 
interventions, groups 2, 4, 6 and 8 were given a cocktail of the following antibiotics 
(ABX) in drinking water: ampicillin (1 g/L), neomycin (0.5 g/L) and vancomycin 
(0.35 g/L) (Cani et al 2008, Rabot et al 2016, Thackray et al 2018). Mice were carefully 
monitored for signs of dehydration upon ABX administration and drinking water 
consumption was recorded every 2-3 days (data not shown). All ABX were obtained 
from Discovery Fine Chemicals and given for 5 or 10 weeks, as indicated in figure 
4.1.  
The in vivo experiments were approved by the University College Cork Animal 












Figure 4.1 Experimental design. 5-week-old mice were fed a high-fat diet with control casein 
(HFD-CAS; 45% fat and 20% casein) or whey protein isolate (HFD-WPI; 45% fat and 20% 
whey protein isolate) for 5 (until they are 10-week old; groups 1-4) or 10 weeks (until they are 
15-week old, groups 5-8). Groups 2, 4, 6 and 8 were provided with an antibiotic cocktail 
(ABX; ampicillin (1 g/L), neomycin (0.5 g/L) and vancomycin (0.35 g/L)) in drinking water 
for 5 or 10 weeks. The other groups (i.e., 1, 3, 5 and 7), which did not undergo ABX treatment, 
were considered as controls. At the end of the experiment, both at 5 and 10 weeks timepoints, 
several measurements were carried out. Number of mice: group 1=9, group 2=9, group 3=9, 
group 4=9, group 5=9, group 6=12, group 7=8, group 8=9. 
Table 4.T1 Composition of the experimental diets. 
   LFD-CAS    HFD-CAS    HFD-WPI
Ingredients gm Kcal gm Kcal gm Kcal
Casein 200 800 200 800 0 0
Whey Protein 0 0 0 0 200 800
L-Cysteine 3 12 3 12 3 12
Corn Starch 315 1260 72,8 291 72,8 291
Maltodextrin 10 35 140 100 400 100 400
Sucrose 350 1400 172,8 691 172,8 691
Cellulose, BW200 50 0 50 0 50 0
Soybean Oil 25 225 25 225 25 225
Lard* 20 180 177,5 1598 177,5 1598
Mineral Mix S10026 10 0 10 0 10 0
DiCalcium Phosphate 13 0 13 0 13 0
Calcium Carbonate 5,5 0 5,5 0 5,5 0
Potassium Citrate, 1 H2O 16,5 0 16,5 0 16,5 0
Vitamin Mix V10001 10 40 10 40 10 40
Choline Bitartrate 2 0 2 0 2 0
Total 1055 4057 858,1 4057 858,1 4057
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Body weight and food intake measures 
Body weight, as well as food intake, were measured weekly. Unexpectedly, the 
texture of the diets was soft and crumbly, which skewed the energy intake data. In 
addition, HFD-WPI diet had a softer consistency than HFD-CAS diet. Metabolic 
cages allowing precise measurement of food consumption were not available for 
this study. We, thus, decided to omit these data from our results since we could not 
guarantee data accuracy.  
 
Post-mortem tissue collection 
Following 5 (groups 1-4) and 10 weeks (groups 5-8) of dietary/ABX interventions, 
mice were euthanized for tissue collection. The day before euthanasia, faecal 
samples were collected and stored at -80˚C. Then, mice were fasted for 12h 
commencing at 19.00 in the dark phase. Mice were euthanized by decapitation and 
organs and adipose tissues i.e., epidydimal white adipose tissue (eWAT), 
subcutaneous white adipose tissue (sWAT), brown adipose tissue (BAT), 
retroperitoneal adipose tissue (rAT) and mesenteric adipose tissue (mAT) were 
collected, snap frozen in liquid nitrogen or dry ice and stored at -80˚C for 
subsequent analysis. Cervical blood samples were collected in tubes with EDTA 
and centrifuged for 10 minutes at 3000 xg; the supernatant (plasma) was stored at -
80˚C. The length of the gut (i.e., whole small intestine and colon) and the weight 
of all tissues/organs collected were recorded on fresh tissues before snap freezing. 
The weight of adipose tissues and organs are reported as absolute values. 
 
Ex vivo intestinal permeability  
Freshly isolated distal ileum and colon segments (length= 1-2 cm) were emptied of 
luminal contents with PBS and placed in Krebs solution (1.2 mM NaH2PO4, 117 mM 
NaCl, 4.8 mM KCl, 1.2 mM MgCl2, 25mM NaHCO3, 11 mM CaCl2 and 10 mM 
glucose). The samples were mounted into the Ussing chamber apparatus (Harvard 
Apparatus, exposed tissue area of 0.12 cm2) as previously described (Golubeva et al 
2017). To assess intestinal epithelial permeability to macromolecules, 4 KDa FITC-
dextran (Sigma-Aldrich) was added to the luminal chamber at a final concentration of 
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2.5 mg/mL; 200-μL samples were collected from the serosal chamber after 1 h and 
every 30 min for the following 2 h. The volume in the serosal chamber was replenished 
with fresh Krebs. To avoid the potential impact of Na+/glucose co-transporter on 
paracellular permeability in distal ileum samples (Turner 2000), glucose in the luminal 
chamber was replaced with 10 mM mannitol. FITC absorbance was measured at 485-
nm excitation/535-nm emission wavelength through fluorometric analysis using a 
multi-mode plate reader (Victor 3, Perkin Elmer). FITC flux at each timepoint was 
then calculated as an increment in fluorescence intensity vs baseline fluorescence in 
the serosal compartment and presented in ng/mL. Total flux was presented as 
μg/h/cm2. 
 
RNA extraction and gene expression analysis 
Total RNA was extracted from distal ileum (using RNeasy Minikit and QIAshredder 
columns (Qiagen)) and eWAT and hypothalamic tissues (RNeasy Minikit and QIAzol 
Lysis Reagent (Qiagen)), according to manufacturer’s recommendations. Extracted 
RNA was treated with RNAse-free DNAse (Qiagen) for complete DNA removal and 
quantified with Nanodrop (ThermoFisher Scientific). Complementary DNA was 
synthetized from 600 ng total RNA using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems), and subjected to Real-Time PCR (Roche) using SYBR 
Green Select Master Mix (Roche) as detailed before (McAllan et al 2015). Relative 
gene expression values were calculated using 2-ΔΔCt equation, normalized against the 
reference gene Actb and presented as a ratio versus pooled average of all the 
experimental groups. The sequences of the primers are detailed in Table 4.TS1. 
 
Leptin, insulin and inflammatory markers levels in plasma 
Plasma leptin and insulin were measured using Mouse Metabolic Kit, Multi-Spot 
Assay System (Meso Scale Discovery) following the instructions provided within the 
kit. Plasma MCP-1, TNF-α and IL6 were measured using U-PLEX Biomarker Group 
1 (ms) Assay, SECTOR Multiplex Assay (Meso Scale Discovery). The plates from 





Caecum metabolomics was performed in experimental groups that underwent 10 
weeks of dietary and ABX intervention (35 samples in total). Caecal water was 
prepared by homogenising caecal content (approx. 100 mg) with 400 µL of sterile 
water for 5 min using a bead beater. Samples were centrifuged at 16,000 xg for 30 min, 
after which supernatants were filtered through 0.22 µm column filters (Costar). Two 
separate mass spectrometry methods were used to measure metabolites in each sample. 
1) A broad profiling of caecal extracts was performed using the LC-MS method.  The 
analysis was carried out using a UPLC system (Vanquish, Thermo Fisher Scientific) 
coupled with a high-resolution quadrupole-orbitrap mass spectrometer (Q Exactive™ 
HF Hybrid Quadrupole-Orbitrap, Thermo Fisher Scientific). An electrospray 
ionization interface was used as ionization source. Analysis was performed in negative 
and positive ionization mode. A QC sample was analysed in MS/MS mode for 
identification of compounds. The UPLC was performed using a slightly modified 
version of the protocol described by Catalin et al 
(https://www.waters.com/waters/library.htm?locale=en_US&lid=134636355). Data 
were processed using Compound Discoverer 3.0 (ThermoFisher Scientific). 
2) Gas chromatography–mass spectrometry (GC-MS) was used to analyse short and 
long chain fatty acids (SCFA, LCFA) in caecal extracts. Samples were acidified with 
hydrochloric acid (for SCFA) or derivatized using methyl chloroformate (for LCFA). 
The raw GC-MS data was processed by software developed by MS-Omics and 
collaborators (PARAFAC2 model). 
 
Faecal bacteria quantification 
Faecal samples were weighted, homogenised and processed using mechanical 
(TissueLyser, Qiagen) and chemical lysis. Genomic DNA was extracted purified 
according to the protocol for the standard QIAmp PowerFaecal Pro DNA Kit (Qiagen). 
Total DNA was quantified with Qubit dsDNA HS Assay kit (Bio-Sciences). 
Subsequently, 16S rDNA gene of standards and samples was amplified and quantified 
using Real-Time PCR. In particular, to create the standards, 2μL of extracted bacterial 
DNA from each HFD-CAS and HFD-WPI non-treated sample that underwent 5-week 
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intervention were pooled. The pool represented the standard n=1, 100% of bacteria, 
concentration (1:1). Starting from standard 1, 4 more standards were creating by 1:10 
serial dilution in water. The last standard (n=6) contained water only (0% of bacteria) 
(total number of standards=6). 
Standards and DNA samples from all 8 experimental groups were subjected to Real-
Time PCR (Roche) using SYBR Green Select Master Mix (Roche) as detailed before 
(McAllan et al 2015) to amplify the 16S rDNA region (primer forward - 5' 
ACTCCTACGGGAGGCAGCAGT 3'- and primer reverse - 5' 
ATTACCGCGGCTGCTGGC 3’-). Ct values for standards and samples were 
obtained.   
A standard curve was generated by plotting the Ct values for the standards versus 
bacterial % of each standard. A lineal regression of the standard curve was performed 
to obtain an estimation of 16S rDNA copy numbers of each standard. 
16S rDNA copy numbers for faecal samples were calculated by interpolating Ct values 
in the standard curve and corrected considering the dilution factor of the sample. Then, 
16S rDNA copy numbers per mg of faeces (16S copies / mg faeces) were calculated. 
At the end, the % of 16S copies/mg of faeces were calculated versus pooled average 
of HFD-CAS copies/mg of faeces. Notably, HFD-CAS 5w contained the highest 
concentration of 16S copies, thus we considered it as 100%. 
 
DNA extraction, library preparation and 16S metagenomic sequencing 
Faecal samples from all experimental groups were homogenised and processed using 
mechanical (TissueLyser, Qiagen) and chemical lysis. Genomic DNA was extracted 
purified according to the protocol for the standard QIAmp PowerFaecal Pro DNA Kit 
(Qiagen). Total DNA was quantified with Qubit dsDNA HS Assay kit (Bio-Sciences). 
After DNA extraction, the 16S rRNA gene (V3-V4 region) was amplified with 
universal primers (PCR1 forward and reverse primer as to the Illumina 16S 
Metagenomic Protocol). Subsequently, amplicons from each sample were pooled in 
equimolar amounts and sequenced with Illumina Miseq platform (2 × 250 bp pairedend 
reads; V3 sequencing chemistry; Illumina). Negative controls were used for the 
Operative Taxonomic Unit (OTUs) table clean up with the objective of removing 
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contaminant sequences from the samples, as explained below. Sequencing run variable 
was taken into consideration in the multivariate models explaining alpha- and beta-




The Illumina reads were filtered on the basis of quality (removal of low quality 
nucleotides at the 3' end, and remove the 20 nt windows with a low average quality) 
and length (removal of sequences with less than 200 pb) with PRINSEQ-Lite v0.20.4 
(Schmieder & Edwards 2011), and the paired-end reads with a minimum overlap of 
20 bp were joined using Fastq-Join (Aronesty 2013). A second filtering step with 
PRINSEQ-Lite was performed at this point, ensuring a mean quality score of the reads 
of Q25 and a length range between 400-540 bp, approximately the length of the 16S 
rRNA amplicon. In addition, the sequences of dereplicates and unique sequences and 
chimeras were eliminated using GOLD database (https://gold.jgi.doe.gov) through the 
closed-reference Usearch v8.0 algorithm (Edgar 2010). The resulting sequences were 
clustered with 97% identity to obtain OTUs using UPARSE-OTU algorithm with 
Usearch v8.0 algorithm (Edgar 2010). The taxonomic assignment of these OTUs was 
obtained against the Ribosomal Database Project (Cole et al 2007). Negative controls 
were evaluated to identify contaminants. OTUs present both in samples and negative 
controls were removed. 
 
Statistical Analysis 
Data were analysed in SPSS software version 24 (IBM Corp.). All datasets were 
checked for the normality with Shapiro-Wilk test and homogeneity of variance with 
Levene’s test. Outliers were removed following Grubbs’ test (significance level = 
0.05). 
Changes in body weight gain and FITC permeability overtime were analysed by a two-
way repeated-measures ANOVA (diet and ABX as independent factors and time as a 
repeated-measure factor) followed by Bonferroni’s post hoc pairwise comparisons at 
each timepoint. Tissue and organ weights, intestinal length, gene expression, plasma 
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leptin, insulin, inflammatory markers and lipopolysaccharide binding protein levels, 
and total FITC flux data were compared with two-way analysis of variance (ANOVA) 
followed by pairwise comparison using Bonferroni’s post hoc test. Non-parametric 
data were compared with Kruskal-Wallis test followed by Mann-Whitney U test. 
Caecum metabolomics pairwise comparisons were performed with independent 
Student’s t test and expressed as Log2 ratios. Benjamin Hochberg (BH) procedure with 
false discovery rate (FDR) set at 0.05 was used to correct p values for multiple 
comparisons. p<0.05 was deemed significant in all cases. Data are expressed as mean 
+ SEM. 
A complete description of statistical analysis is detailed in “Supplementary Statistic” 
and figures 4.S5, 4.S6 and 4.S7. 
 
All statistical analyses of the gut microbiota data were performed with R version 3.6.0. 
Normality of the data was evaluated with Shapiro-Wilk test. Microbiota and study 
variables were included in the estimation of alpha-diversity richness (Shannon, 
Simpson and total Richness indexes) by the Vegan and Phyloseq R packages 
(McMurdie & Holmes 2013). Therefore, potential differences in richness of factors 
included in the study were estimated by repeated measures ANOVA. Statistically 
significant differences in beta-diversity were assessed by PERmutational Multivariate 
Analyses Of Variance (PERMANOVA) using a Bray-Curtis dissimilarity measure. 
Specific differences between groups were assessed by post hoc comparisons with 
Adonis pairwise comparisons. Principal Coordinates Analysis (PCoA) plots based on 
Bray-Curtis dissimilarity measure were used to visualize beta-diversity plot (Bray & 
Curtis 1957). Differences in taxa abundance for experimental groups were analysed 
by non-parametric Kruskal-Wallis test and Pairwise Wilcoxon Rank Sum tests for 






HFD-fed mice treated with antibiotics further reduced body weight gain and 
fat depots upon WPI supplementation 
Two experimental cohorts were included in this study: short-term (5 weeks) and long-
term (10 weeks) administration of WPI and ABX cocktail in HFD-fed mice.  
In both cohorts, the analysis of body weight gain revealed a significant effect of WPI 
and ABX administration on weight gain in HFD-fed mice (protein type, F(1;32) = 5.25, 
p=0.029; ABX treatment, F(1;32) = 11.44, p=0.002 in 5 weeks cohort and protein type, 
F(1;34) = 6.44, p=0.016; ABX treatment, F(1;34) = 4.54, p=0.04 in 10 weeks cohort). 
HFD-WPI, HFD-CAS+ABX and HFD-WPI+ABX mice showed a marked reduction 
of body weight gain compared to HFD-CAS group. These effects were significant as 
early as 1 week following the commencement of treatments (Fig. 4.2a-b), and the 
difference between HFD-CAS and other groups gradually increased throughout the 
intervention (Fig. 4.2a-b). Interestingly, in the long-term administration cohort, HFD-
WPI+ABX group demonstrated the slowest trajectory of weight gain. At 9 and 10 
weeks of intervention, HFD-WPI+ABX had a significantly lower body weight gain 
compared to HFD-CAS+ABX counterparts (p=0.048 for 9 weeks and p=0.027 for 10 
weeks).  
 
In agreement with body weight gain data, WPI and ABX administration substantially 
decreased the accumulation of adipose tissue in all major fat depots. The absolute 
weights of eWAT, sWAT, rAT and mAT were significantly lower in HFD-WPI and 
HFD-CAS+ABX groups compared with HFD-CAS group (Fig. 4.2c-d). The only 
exemption was BAT, which was marginally reduced by ABX in HFD-CAS diet only 
following 5 weeks of treatment, and by WPI following 10 weeks of intervention (Fig. 
4.2c-d). In the long-term administration cohort, HFD-WPI+ABX group showed a 
further reduction in adipose tissue weights compared to HFD-WPI counterparts, 
demonstrating a robust anti-obesity effect across all fat depots (Fig. 4.2d). 
Furthermore, HFD-WPI+ABX group displayed the lowest fat depots gain, which was 
significantly lower compared to HFD-CAS+ABX group (Fig. 4.2d). These data 
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suggest an additive effect of WPI and ABX co-administration against adiposity 
associated with HFD consumption. 
 
With regard to organ metrics, ABX administration for 5 weeks increased caecum 
weight (both full and empty), and decreased spleen, stomach and liver weights in both 
CAS and WPI groups. In addition, the presence of WPI in the diet caused an increase 
in liver weight, as well as in small intestine length (Fig. 4.S1a and 4.S1c).  
Following long-term administration of ABX, only caecum weight was significantly 
increased by ABX treatment with no major changes in other organs. Notably, an 
increase in caecum weight following administration of ABX is a hallmark of 
successful microbiota depletion in rodents. 
Similar to 5-week intervention cohort, HFD-WPI and HFD-WPI+ABX mice showed 
an increase in liver weight relative to CAS counterparts (Fig. 4.S1b). No major 
differences were detected in small intestine and colon lengths (Fig. 4.1Sd). 
 
Since we were unable to collect reliable energy intake data, we analysed the expression 
of genes encoding neuropeptides involved in satiety control in the hypothalamus.  
These included anorexigenic peptides (proopiomelanocortin, POMC and cocaine and 
amphetamine regulated transcript, CARTPT), orexigenic peptide neuropeptide Y 
(NPY), as well as glucocorticoid receptor and corticotropin-releasing hormone (GR 
and CRH). Overall, no robust effects in gene expression were observed in either WPI 
or ABX treated groups in comparison to HFD-CAS-fed mice and the fold change in 
expression between the groups was small across most of the significant differences 
detected (Table 4.TS2).  
 
In summary, we have shown that both a WPI consumption and microbiota depletion 
with ABX equally ameliorate HFD-induced weight gain and adiposity during either 5- 
or 10-week intervention. Following long-term 10-week administration, ABX and WPI 
presence showed an additive effect against adiposity. We next looked at a selected 
range of pathophysiological markers associated with obesity in order to understand the 








Figure 4.2 Body weight gain and adiposity. The present data show body weight gain (a) at 5 and 
(b) 10 weeks timepoints and different kinds of absolute adipose tissue weight (c) at 5 and (d) 10 
weeks timepoints of mice fed with HFD-CAS and HFD-WPI, both controls and ABX-treated. 
Abbreviation; eWAT; epididymal white adipose tissue, sWAT; subcutaneous white adipose tissue, 
BAT; brown adipose tissue, rAT; retroperitoneal adipose tissue, mAT; mesenteric adipose tissue. 
Statistical analysis: (a, b) groups showing * (for HFD-CAS vs HFD-CAS+ABX), # (HFD-CAS vs 
HFD-WPI) and § (for HFD-CAS+ABX vs HFD-WPI+ABX) are significant. (c, d) groups showing 
* (for HFD-CAS vs HFD-CAS+ABX and HFD-WPI vs HFD-WPI+ABX) and # (for HFD-CAS vs 
HFD-WPI and HFD-CAS+ABX vs HFD-WPI+ABX) are significant (*/#/§ P<0.05 or **/##/§§ 
P<0.01 or ***/###/§§§ P<0.001). A complete statistical description is detailed in Methods and 







HFD-fed mice treated with antibiotics further reduced plasma leptin availability 
production upon WPI supplementation 
It is well known that HFD-induced obesity leads to a dysregulation in the production 
of energy balance- and metabolism-related hormones (Sidhu et al 2000, Ye 2013). In 
this context, we first measured plasma levels and eWAT gene expression of leptin. 
Leptin plasma levels agreed with Ob (i.e., gene that encodes for leptin) gene 
expression, and both were matching body weight and adiposity data. At 5 weeks, leptin 
gene expression and plasma levels were significantly lower in HFD-WPI compared to 
the HFD-CAS group, with no differences between HFD-WPI and the ABX-treated 
groups (Fig. 4.3a and 4.3e). 
 
Figure 4.3 Adipokines, insulin and leptin. Data show plasma levels of (a) leptin and (b) 
insulin at 5 weeks timepoint and plasma levels of (c) leptin and (d) insulin at 10 weeks 
timepoint. Data also show (e) Ob and (f) Adipoq expression within the eWAT at 5 weeks 
timepoint and (g) Ob and (h) Adipoq expression within the eWAT at 10 weeks timepoint. All 
the data were measured in mice fed with HFD-CAS and HFD-WPI, both controls and ABX-
treated. Abbreviation; eWAT; epididymal white adipose tissue, Ob; leptin, Adipoq; 
adiponectin. Groups showing * (for HFD-CAS vs HFD-CAS+ABX and HFD-WPI vs HFD-
170 
 
WPI+ABX) and # (for HFD-CAS vs HFD-WPI and HFD-CAS+ABX vs HFD-WPI+ABX) 
are significant (*/# P<0.05 or **/## P<0.01 or ***/### P<0.001). A complete statistical 
description is detailed in Methods and Materials and figures 4.S6 and 4.S7. 
 
 
Similarly, 10 weeks, both HFD-WPI and HFD-CAS+ABX groups showed lower 
leptin gene expression and plasma levels compared to the HFD-CAS group. In 
addition, leptin levels in the HFD-WPI+ABX group showed a further significant 
reduction compared to HFD-WPI and HFD-CAS+ABX groups (Fig. 4.3c and 4.3g). 
This suggests an additive effect of ABX and WPI towards reducing leptin levels in 
HFD-associated obesity. 
 
In obesity, while leptin production increases, the level of adiponectin decreases. The 
leptin/adiponectin ratio is considered as a biomarker of WAT dysfunction (Frühbeck 
et al 2019). Therefore, we assessed the encoding Adipoq gene expression levels in the 
eWAT. Apart from a reduction in the HFD-WPI group compared to HFD-CAS group 
at 5 weeks, no changes in Adipoq expression was observed across the groups (Fig. 4.3f 
and 4.3h). 
 
To further investigate the impact of WPI and gut microbiota depletion on leptin 
signalling, we measured the expression of a gene that encodes for hypothalamic 
suppressor of cytokine signalling 3 (i.e., Socs3). Socs3 is a protein involved in leptin 
signalling within the hypothalamus and is overexpressed under HFD feeding. It acts 
by binding leptin receptor and inhibiting downstream the signalling cascade. Rodents 
with Socs3 deletion in proopiomelanocortin (POMC) neurons are resistant to diet-
induced obesity and have lower levels of circulating leptin (Bian et al 2013, McEwen 
et al 2016, Mori et al 2004). On the other hand, Socs3 upregulation promotes 
hypothalamic leptin resistance (Reed et al 2010). Here we observed that ABX-treated 
groups, both at 5 and at 10 weeks, had a lower hypothalamic Socs3 expression relative 
to their non-treated counterparts (Table 4.TS2). This is a first indication that, in the 
presence of HFD, gut microbiota depletion, and not protein quality within the diet, 




Plasma levels of fasting insulin were similar across all groups at both timepoints, 
except in HFD-CAS+ABX group at 10 weeks, which showed a lower insulin level 
compared to HFD-CAS group (Fig. 4.3b and 4.3d). 
 
In summary, we have shown that WPI and ABX administration had both ameliorated 
an increase in leptin production induced by HFD consumption, without impacting on 
insulin and adiponectin levels. Similar to body weight and adiposity results, ABX and 
WPI showed an additive effect towards reducing leptin production in 10 week-
administration cohort. In addition, gut microbiota depletion, and not WPI 
supplementation, seems to have a stronger impact on leptin signalling responsiveness 
within the hypothalamus. 
 
Whey protein and antibiotics administration decreased the gene expression levels 
of pro-inflammatory cytokines  
Obesity is also characterized by chronic low-grade inflammation, which, in turn, 
exacerbates the metabolic syndrome dysfunctions (Ellulu et al 2017). Here we 
measured the plasma levels of selected pro-inflammatory markers along with their 
gene expression levels in different tissues.  
At 5 weeks, plasma levels of monocyte chemoattractant protein 1 (MCP-1) did not 
show major differences across groups, except a decrease in the HFD-WPI+ABX group 
compared to HFD-CAS+ABX group (Fig. 4.4a). Plasma levels of tumour necrosis 
factor α (TNFα) was lower both in HFD-CAS+ABX group and HFD-WPI group 
relative to HFD-CAS mice (Fig. 4.4b). 
At 10 weeks, plasma MCP-1 was substantially decreased in HFD-WPI group 
compared to HFD-CAS group; intriguingly, the effect of WPI was no longer seen 
under ABX co-administration (Fig. 4.4c). No differences in plasma TNFα were 






Figure 4.4 Pro-inflammatory cytokines levels. Data show plasma levels of (a) MCP1 and 
(b) TNFα at 5 weeks timepoint and plasma levels of (c) MCP1 and (d) TNFα at 10 weeks 
timepoint. Data also show (e) Mcp1 and (f) Il1β ileal expression at 5 weeks timepoint and (g) 
Mcp1 and (h) Il1β ileal expression at 10 weeks timepoint. In addition, it is reported (i) Mcp1 
and (j) Tnfα expression within the eWAT at 5 weeks timepoint and (k) Mcp1 and (l) Tnfα 
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expression within the eWAT at 10 weeks timepoint. The final graph shows the expression of 
Cd68 within the eWAT at (m) 5 and (n) 10 weeks timepoint. All the data were measured in 
mice fed with HFD-CAS and HFD-WPI, both controls and ABX-treated. Abbreviation; 
eWAT; epididymal white adipose tissue, MCP1; monocyte chemoattractant protein 1, TNFα; 
tumor necrosis factor alpha, IL1β; interleukin 1 beta, CD68; cluster of differentiation 68. 
Groups showing * (for HFD-CAS vs HFD-CAS+ABX and HFD-WPI vs HFD-WPI+ABX) 
and # (for HFD-CAS vs HFD-WPI and HFD-CAS+ABX vs HFD-WPI+ABX) are significant 
(*/# P<0.05 or **/## P<0.01 or ***/### P<0.001). A complete statistical description is 
detailed in Methods and Materials and figures 4.S6 and 4.S7. 
 
 
The analysis of cytokine gene expression in the distal ileum showed that Mcp-1 
expression levels were markedly reduced by WPI and ABX administration, both in 5-
week and 10-week experimental cohorts (Fig. 4.4e and 4.4g). No differences between 
two ABX-treated groups were observed. In contrast, interleukin 1β (Il1β) gene 
expression was higher in WPI-fed mice compared to CAS-fed mice at 5 weeks, without 
showing differences across groups after long-term intervention (Fig. 4.4f and 4.4h). 
 
In the eWAT, the changes in Mcp-1 expression showed a similar pattern as in the ileum 
both at 5 and 10 weeks. HFD-WPI and HFD-CAS+ABX groups displayed lower levels 
of Mcp-1 gene expression. Furthermore, at 10 weeks Mcp-1 was less expressed in 
HFD-WPI+ABX group relative to the CAS counterpart (Fig. 4.4i and 4.4k). At 5 
weeks, Tnfα and cluster of differentiation 68 (Cd68) gene expression levels were lower 
in HFD-CAS+ABX and HFD-WPI groups compared HFD-CAS group and was higher 
in HFD-WPI+ABX mice compared to CAS counterparts (Fig. 4.4j and 4.4m). At 10 
weeks, both genes were less expressed in HFD-CAS+ABX and HFD-WPI groups 
compared HFD-CAS group. Cd68 expression level was lower in HFD-WPI+ABX 
mice compared to HFD-CAS+ABX mice (Fig. 4.4l and 4.4n). 
 
In conclusion, these data suggest that microbiota depletion attenuated HFD-induced 
inflammation within the ileum and eWAT, but not in the plasma. The presence of WPI 
had a protective effect towards HFD-induced inflammation in the ileum and eWAT as 





Gut microbiota depletion reversed the protective effect of WPI on HFD-induced 
ileal permeability alteration  
To investigate if the lower inflammation during ABX and WPI intervention could be 
related to intestinal barrier function, we measured the ex vivo permeability of ileal and 
colonic epithelium to macromolecules (4 KDa FITC) using Ussing chambers 
(Chelakkot et al 2018).  
 
 
Figure 4.5: Intestinal permeability. Data show (a) ileal FITC paracellular permeability at 
60, 90 and 120 min and (b) the total FITC flux that passed through the ileal epithelium over 2 
hours, at 5 weeks timepoint. Data also show (c) ileal FITC paracellular permeability at 60, 90 
and 120 min and (d) the total FITC flux that passed through the ileal epithelium over 2 hours, 
at 10 weeks timepoint. The final graph shows the plasma level of LBP (e) 5 and (f) 10 weeks 
timepoint. All the data were measured in mice fed with HFD-CAS and HFD-WPI, both 
controls and ABX-treated. Abbreviation; FITC; fluorescein isothiocyanate, LBP; 
lipopolysaccharide binding protein. Statistical analysis: (a, c) groups showing # (HFD-CAS 
vs HFD-WPI) and & (for HFD-WPI vs HFD-WPI+ABX) are significant. (b, d, e, f) groups 
showing * (for HFD-CAS vs HFD-CAS+ABX and HFD-WPI vs HFD-WPI+ABX) and # (for 
HFD-CAS vs HFD-WPI and HFD-CAS+ABX vs HFD-WPI+ABX) are significant (*/#/& 
P<0.05 or **/##/&& P<0.01 or ***/###/&&& P<0.001). A complete statistical description is 
detailed in Methods and Materials, “Supplementary Statistics” and figures 4.S6 and 4.S7. 
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In the distal ileum, ABX administration damaged the integrity of the barrier function. 
At 5 weeks, both ABX-treated groups showed a strong trend towards increased FITC 
flux compared to non-treated counterparts (pairwise post-hoc comparisons not 
significant due to high between-animal variability in ABX groups) (Fig. 4.5a, 4.5b, 
4.S6 and 4.S7). 
At 10 weeks, the increase in ileal permeability in HFD-WPI+ABX group compared to 
HFD-WPI group was even more dramatic. In addition, FITC flux in HFD-CAS group 
was much higher than HFD-WPI group and was similar to HFD-CAS+ABX and HFD-
WPI+ABX groups (Fig. 4.5c and 4.5d).  
 
In the colon, the FITC flux was lower in HFD-CAS+ABX group compared to HFD-
CAS group at 5 weeks timepoint, and in HFD-WPI+ABX group relative to HFD-WPI 
group at 10 weeks timepoint (Fig. 4.S2 a and 4.S2d). No effect of WPI compared to 
CAS in HFD and HFD-ABX mice was observed at both timepoints.  
 
Disruption of gut permeability can cause an increase of lipopolysaccharide (LPS) in 
the bloodstream. LPS is produced by Gram-negative bacteria and can further boost a 
pro-inflammatory response (Fuke et al 2019). We could not measure plasma LPS since 
a sterile environment for blood collection as unavailable. Instead, we measured the 
plasma levels of lipopolysaccharide binding protein (LBP), which is also considered 
as a marker of ‘leaky’ gut under various pathological conditions (Vreugdenhil et al 
2000). However, despite the robust changes in small intestinal FITC flux, no 
prominent changes in plasma levels of LBP were detected across the groups (Fig. 4.5e 
and 4.5f). 
 
No robust effects in the ileal gene expression of tight junctions (i.e., Tjp1: tight 
junction protein 1, F11: junctional adhesion molecule A, Cldn1: claudin 1, Ocln: 
occludin) were observed in either WPI or ABX treated groups in comparison to HFD-
CAS-fed mice and the fold change in expression between the groups was mainly small 





In conclusion, both HFD and ABX treatment had a negative impact on the epithelial 
barrier function in the small intestine, causing an increased macromolecular 
permeability in distal ileum. Here, for the first time, we showed a protective role 
exerted by WPI supplementation on intestinal barrier, effectively preventing the HFD-
induced increase in ileal permeability. This effect was reversed by ABX 
administration, suggesting that WPI acts through the gut microbiota to exert a 
protective role on HFD-induced ileal permeability alteration. 
 
WPI effect on the gut microbiota composition in ABX-treated and non-treated 
mice 
Next, using a 16S rRNA-based metagenomic approach, we analysed the composition 
of faecal gut microbiota to investigate the impact of 5- and 10-week ABX treatment 
and WPI intervention on taxonomic changes across the groups. 
After filtration and trimming, the reads per sample averaged 109095.5±16343.35. As 
expected, the alpha-diversity measured with three different indexes (i.e., Richness, 
Shannon and Simpson) was dramatically reduced in ABX-treated mice compared to 
non-treated mice after both 5 and 10 weeks of intervention (Fig. 4.6a and 4.6b). The 
successful depletion of microbiota by the selected ABX cocktail was further confirmed 
by a robust decrease in the bacterial DNA load in the faeces of ABX-treated mice 
(calculated as a number of 16S copies per mg of faecal matter, Fig. 4.S2e). As for the 
diet effect, Richness and Simpson indexes showed a decrease and increase, 
respectively, in alpha-diversity of HFD-WPI group relative to HFD-CAS counterparts, 
with no changes in Shannon index at 5 weeks (Fig. 4.6a). At 10 weeks, Richness and 
Shannon indexes showed a decrease in alpha-diversity of HFD-WPI group compared 
to HFD-CAS group, with no difference in Simpson index (Fig. 4.6b). Notably, across 
all of the indexes at both timepoints (except Simpson at 10 weeks), the alpha-diversity 
of HFD-WPI+ABX group was consistently higher than HFD-CAS+ABX counterparts 
(Fig. 4.6a and 4.6b). This was observed while the bacterial 16S gene quantification in 
HFD-WPI+ABX group was much lower than in HFD-CAS+ABX group (0.01% vs 






Figure 4.6: Gut microbiota analysis: alpha- and beta-diversity. Taxonomic alpha-
diversity, measured with richness, Shannon and Simpson indexes at (a) 5 and (b) 10 weeks 
timepoints. Beta-diversity of the all groups, calculated using PCoA ordination at (c) 5 and (d) 
10 weeks timepoints. All the data were measured in mice fed with HFD-CAS and HFD-WPI, 
both controls and ABX-treated. Groups showing * (for control vs ABX-treated) and # (CAS 
vs WPI) are significant (*/# P<0.05 or **/## P<0.01 or ***/### P<0.001 or ****/#### 
P<0.0001). A complete statistical description is detailed in Methods and Materials. 
 
Principal component analysis (PCoA) plots showed a clear beta-diversity separation 
of ABX-treated compared to non-treated mice, at both timepoints (5 weeks: HFD-CAS 
vs HFD-CAS+ABX, R2=0.69, p=0.006; HFD-WPI vs HFD-WPI+ABX, R2=0.57, 
p=0.006; 10 weeks: HFD-CAS vs HFD-CAS+ABX, R2=0.71, p=0.006; HFD-WPI vs 
HFD-WPI+ABX, R2=0.59, p=0.006; PERMANOVA pairwise comparisons) (Fig. 
4.6c and 4.6d). In addition, at both timepoints, HFD-WPI+ABX showed a significant 
separation from HFD-CAS+ABX (5 weeks: HFD-WPI+ABX vs HFD-CAS+ABX, 
R2=0.26, p=0.012; 10 weeks: HFD-WPI+ABX vs HFD-CAS+ABX, R2=0.24, 
p=0.006; PERMANOVA pairwise comparisons).  
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A significant separation was observed also between non-treated HFD-WPI mice and 
HFD-CAS mice, both after 5 and 10 weeks of dietary intervention (5 weeks: HFD-
WPI vs HFD-CAS, R2=0.33, p=0.006; 10 weeks: HFD-WPI vs HFD-CAS, R2=0.32, 






Figure 4.7: Gut microbiota analysis: taxonomic differences at family level abundance. 
Heatmaps representing taxonomic pairwise differences in abundance at family level across the 
groups, using Kruskal Wallis method (a) at 5 and (b) 10 weeks timepoint. Notably, green and 
red colours represent an increase and a decrease, respectively, in relative abundance of a 
specific group (not in brackets) compared to another group (in brackets). White colour 
indicates no significant differences (NS) between the two groups. The shades of each colour 
correspond to different p values thresholds. In (b), the families that did not show differences 
at 5 weeks timepoint but that showed differences at 10 weeks timepoint are indicated with a 
grey background. All the data were measured in mice fed with HFD-CAS and HFD-WPI, both 
controls and ABX-treated. Groups showing * are significant (*P<0.05 or **P<0.01 or 















Figure 4.8: Gut microbiota analysis: taxonomic differences in genera abundance. Data 
show the heatmaps representing taxonomic pairwise differences in abundance at genus level 
across the groups, using Kruskal Wallis method (a) at 5 and (b) 10 weeks timepoint. Notably, 
green and red colours represent an increase and a decrease, respectively, in relative abundance 
of a specific group (not in brackets) compared to another group (in brackets). White colour 
indicates no differences between the two groups. The shades of each colour correspond to 
different p values thresholds. In (b), the genera that did not show differences at 5 weeks 
timepoint but that showed differences at 10 weeks timepoint are indicated with a grey 
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background. All the data were measured in mice fed with HFD-CAS and HFD-WPI, both 
controls and ABX-treated. Groups showing * are significant (*P<0.05 or **P<0.01 or 




Both short- and long-term administration of ABX clearly caused a marked disruption 
of the gut microbiota at all the taxonomic levels (i.e., phylum, family and genus) (Fig. 
4.S3a-f, 4.7a and 4.7b, and 4.8a and 4.8b). This was not surprising because the ABX 
cocktail used in this study was reported to effectively deplete gut microbiota in other 
studies (Cani et al 2008, Rabot et al 2016, Thackray et al 2018). Intriguingly, here we 
observed that taxonomic alterations due to ABX treatment differed depending on the 
protein quality of the diet (i.e., CAS or WPI) (Fig. 4.S3e and 4.S3f, 4.7a and 4.7b, and 
4.8a and 4.8b).  
 
WPI supplementation also had a significant impact on the relative abundance of 
bacterial taxa at different levels.  
At family level, HFD-WPI gut microbiome was characterized by an increase in 4 taxa 
(Bacteroidaceae, Deferribacteraceae, Rhodospirillaceae and Sutterellaceae), and a 
decrease in 7 taxa (among these we found Saccharibacteria, Clostridiaceae, 
Eubacteriaceae, Streptococcaceae and  Staphylococcaceae) at 5 weeks timepoint (Fig. 
4.7a and 4.S3a). However, after 10 weeks of intervention, 31 families were more 
abundant (among these Sutterellaceae and Aerococcaceae) and 3 families were less 
abundant (Coriobacteriaceae, Streptococcaceae and Anaeroplasmataceae) in HFD-
WPI mice compared to HFD-CAS mice (Fig. 4.7b and 4.S3b). 
At genus level, 4 (Parabacteroides, Bacteroides, Mucispirillum and Allobaculum) and 
17 (among these Anaerotruncus, Butirycoccus, Roseburia, Anaerofustis, 
Clostridium_sensu_stricto, Turicibacter and Streptococcus) genera were increased 
and decreased, respectively, in HFD-WPI mice compared to HFD-CAS mice at 5 
weeks timepoint (Fig. 4.8a and 4.S3c). Instead, the abundance of 3 (Lactobacillus, 
Allobaculum and Parvibacter) and 74 (among these Bacteroides, Roseburia, 
Anaerofustis, Anaeroplasma, Akkermasia, Clostridium_XVIII, 
Clostridium_sensu_stricto and Streptococcus) genera were higher and lower, 
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respectively, in HFD-WPI group relative to HFD-CAS group at 10 weeks timepoint 
(Fig. 4.8b and 4.S3d).  
Notably, at every level, a greater number of taxa were changed in abundance between 
the groups after 10 weeks of intervention with respect to 5 weeks. 
 
In conclusion, ABX treatment caused a dramatic decrease in alpha-diversity and 
profoundly affected beta-diversity together with a significant change in the 
taxonomical composition of the gut microbiota after 5 and 10 weeks of intervention.  
In non-treated groups, supplementation of WPI in HFD significantly affected alpha- 
and beta-diversity as well as taxonomical structure of the intestinal microbiota. 
 
WPI supplementation and ABX treatment affect metabolites within the caecum 
Considering the importance of gut microbial-derived metabolites in regulating host 
metabolism to maintain good health, we carried out a broad profiling of the metabolites 
present in the caecum in mice that underwent 10 weeks of dietary intervention and 
ABX-treatment. The 10 week-treatment timepoint was selected because we observed 
more marked differences in body weight gain, adiposity, inflammation and gut 
permeability across the groups. The analysis showed a wide variety of metabolites to 
be affected by ABX-treatment and/or protein quality. For this reason, we grouped the 
data in different heatmaps that show metabolome changes caused by ABX treatment 
only, protein quality only and a combined effect of ABX treatment and protein quality. 
The ABX treatment brought about a corresponding effect in the presence of CAS and 
WPI, with respect to CAS and WPI non-treated mice, in the change in the abundance 
of 50 metabolites belonging to different categories such as SCFAs, amino acids, 
sugars, amino acids metabolism components and vitamins (Fig. 4.9a). It was 
particularly notable that the concentration of four SCFAs (i.e., 2-methyl propanoic 
acid, acetic acid, 3-methyl-butanoic acid and butanoic acid), as well as three 
tryptophan metabolism-related metabolites (i.e., 3-indolepropionic acid, 3-(4-
hydroxyphenyl)propionic acid and glutaric acid) were decreased during ABX 
treatment (Fig. 4.9a). 
The presence of WPI within HFD, both in ABX-treated and non-treated mice, caused 
an increase in the abundance of five amino acids (i.e., glycine, tryptophan, serine, 
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proline and lysine), two modified amino acids (i.e., N6-Acetyl-L-lysine and prolyl-
leucine), the tryptophan metabolism-related skatole, vitamin B1 as well as an increase 
in the nucleoside 7-methylguanine (Fig. 4.9b).  
 
Previously, we noted that both ABX-treated groups and HFD-WPI group were 
characterized by lower body weight gain, adiposity and inflammation with respect to 
HFD-CAS group. Thus, in those groups, we searched for metabolites that were 
changed in a similar way. We observed that the amino acids threonine and asparagine, 
cis aconitic acid (from tricarboxylic acid cycle, TCA) and 3-indoleacrylic acid (from 
tryptophan metabolism) were more abundant in both ABX-treated groups, relative to 
non-treated groups, and also in HFD-WPI-fed mice (ABX treated and non-treated), 
relative to their CAS counterparts (Fig. 4.S4a). In addition, in the same groups (except 
in HFD-WPI+ABX compared to HFD-CAS+ABX), a decrease in 2-oxindole (from 
tryptophan metabolism), 2,3-pyridinecarboxylic acid and quinolinic acid (from 
kynurenine pathway) was detected (Fig. 4.S4a). 
 
In conclusion, here we showed that the metabolic profile of caecal content can be 
affected by both ABX treatment and protein quality. In addition, a similar change in 
the abundance of seven well known metabolites (i.e., specific amino acids, TCA 
metabolites and tryptophan-related metabolites) were found in mice that showed lower 





Figure 4.9: Metabolites changes in the caecum at 10 weeks timepoint. The heatmaps show 
metabolites measured within the caecum content, where the changes observed across the 
groups are related to (a) ABX treatment and (b) protein quality. Notably, orange and blue 
colours represent an increase and a decrease, respectively, in abundance of group 1 compared 
to group 2 (below in each heatmap: Group 1 vs Group 2). On the left side of the heatmaps are 
indicated the categories in which the metabolites belong to. Abbreviations: 7-M-3-me-6-(3-
o)-3,3a,4,7,8,8a-h-2H-cy[b]furan-2-one; 7-Methyl-3-methylene-6-(3-oxobutyl)-
3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one. Groups showing * are significant (* 
P<0.05 or ** P<0.01 or *** P<0.001) and $ indicates a trend (0.05< P >0.07). A complete 






Recently, there has been a growing interest in deciphering the mechanism 
underpinning the anti-obesity actions of WPI. We previously observed that WPI given 
as part of HFD caused a decrease in body weight gain and adiposity, modulating lipid 
metabolism-related enzyme expression, as well as gut microbiota composition and 
function in adolescent mice, relative to HFD-CAS mice (Boscaini et al 2020) (see 
Chapter 3). These observations led to the hypothesis that the anti-obesity effects of 
WPI could be, at least in part, mediated by the growth of beneficial bacterial taxa in 
the gut. Thus, we hypothesised that a gut microbiota depletion with a broad-spectrum 
ABX would reduce or neutralize the positive effects exerted by WPI on body weight 
and metabolic outcomes during HFD feeding. However, the data generated do not 
support this hypothesis. This is possibly due to the fact that microbiota depletion per 
se will have a robust anti-obesity effect in HFD-fed mice. Indeed, we showed that 
HFD-CAS+ABX administration resulted in a reduction of body weight gain, adiposity, 
leptin availability and inflammation, both after short- and long-term intervention (Fig. 
4.1 and 4.2). Not surprisingly, we did not observe significant differences between 
HFD-WPI and HFD-WPI+ABX groups either. In light of this, it is hard to disentangle 
the effects of WPI with or without microbiota depletion on body weight. To this end, 
we investigated whether WPI utilises the gut microbiota to protect the host from HFD-
induced obesity. However, we did observe an additive effect of WPI and ABX 
treatment towards adiposity and leptin availability following long-term intervention. 
These findings suggest that WPI might exploit other mechanisms, independent of gut 
microbiota, to protect the host from HFD-induced obesity. 
 
Several studies have demonstrated that HFD consumption affects the composition of 
the gut microbiota along with an increase in metabolic syndrome-related derangements 
(i.e., body weight gain, dysfunction of adipose tissue, dysregulation of energy balance, 
leptin and insulin resistance) and low-grade inflammation (Davis 2016, Ellulu et al 
2017, Uranga & Keller 2019). It was shown that microbiota depletion through ABX 
administration during HFD feeding reduced glucose intolerance, body weight gain, fat 
mass development, inflammation, and macrophage infiltration within the adipose 
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tissue (Cani et al 2008). Similarly, germ-free mice were resistant to HFD-induced 
metabolic dysfunction such as insulin resistance, inflammation, glucose tolerance and 
hypercholesterolemia (Rabot et al 2010). These evidences suggest the importance of 
the gut microbiome in the pathogenesis of obesity. Accordingly, in the present study, 
we observed a decrease in metabolic syndrome-related outcomes, such as body weight 
gain, adiposity, gene expression of inflammatory markers and leptin availability, in 
HFD-CAS+ABX mice relative to HFD-CAS non-treated counterparts, at both 
timepoints. On the contrary, no one of these differences was observed between HFD-
WPI+ABX mice and HFD-WPI non-treated mice after 5 weeks of intervention. After 
10 weeks of HFD-WPI feeding, ABX-treated group showed less adiposity and lower 
leptin level than non-treated groups, without showing differences in body weight gain 
and inflammation outcomes. In general, these results highlighted the independent 
action exerted by WPI and ABX during HFD-feeding. 
 
Next, we reported the marked anti-obesity effects of WPI in HFD-fed mice. At both 5 
and 10 weeks of dietary intervention, a standard percentage (20%) of WPI contained 
in 45% fat HFD caused a decrease in body weight gain, adiposity and leptin levels 
compared to HFD-CAS-fed mice. Similar findings were observed in a previous study 
conducted in our group in which mice were fed with the aforementioned diet for 5 
weeks (from 5 weeks-old until 10 weeks-old), 8 weeks (from 8 weeks-old until 16 
weeks-old) and for 21 weeks (from 6 weeks-old until 27 weeks-old) (Boscaini et al 
2020, McAllan et al 2013, McAllan et al 2014) (see Chapter 3).  
 
In addition, in this study, we acquired novel insights relating to the effect of WPI on 
inflammation and intestinal permeability. Previously, two in vitro studies have 
highlighted the anti-inflammatory and anti-oxidant features of a modified form of WPI 
(i.e., hydrolysate) on endothelial cells (Da Silva et al 2017, Piccolomini et al 2012). In 
rodents, a specific component of WPI, namely alpha-lactalbumin (LAB), exerted a 
positive effect on inflammation in the presence of HFD. In particular, LAB affected 
TNFα, IL6 and MCP-1 gene expression within the adipose tissue and colon as well as 
their serum levels (Gao et al 2018, Li et al 2019a). Here, we found that WPI reduced 
the inflammatory response associated with HFD. In particular, WPI caused a decrease 
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in MCP1 plasma levels (at 10 weeks timepoint only) and a decrease in adipose tissue 
and ileal expression of Mcp-1 (both at 5 and 10 weeks), and adipose tissue expression 
of Tnfα and Cd68 genes. These observations suggest the anti-inflammatory action of 
WPI on the intestinal and adipose tissues (both at 5 and 10 weeks). A lower expression 
of Cd68 suggests that a decreased inflammation within the adipose tissue might be due 
to a decrease in macrophages infiltration. 
 
With respect to intestinal permeability, we demonstrate what is to our knowledge for 
the first time that supplementation with WPI effectively protects the gut from the 
impairment of the epithelial barrier function associated with HFD-induced obesity. 
Indeed, HFD consumption, as well as ABX treatment, have been previously shown to 
compromise intestinal epithelial permeability (Lendrum et al 2016, Murakami et al 
2016). In agreement with these reports, we observed an increased epithelial 
permeability in the small intestine (distal ileum) of ABX-treated mice. The effect was 
more robust following 10 week of ABX administration. In addition, we also observed 
an increase in ileal permeability in HFD-CAS-fed mice at the 10-week timepoint, 
compared to the 5-week, indicating intestinal permeability perturbation overtime. 
Maintenance of epithelial integrity in the gut is critically important for the health. The 
phenomenon of “leaky” gut has been tightly associated with gastrointestinal disorders, 
such as inflammatory bowel syndrome, and has also been recently extended to 
metabolic and psychiatric diseases (Chakaroun et al 2020, Kelly et al 2015, Michielan 
& D'Incà 2015). Here, we observed that the presence of WPI prevented epithelial 
barrier disruption and decreased the gene expression of the inflammatory marker 
MCP-1 in the small intestine. These data suggest that WPI might have a positive effect 
on intestinal health and function. For this reason, supplementation of WPI can be 
considered as an adjunctive dietary therapeutic approach in inflammatory bowel 
diseases (IBD). In support of this idea, 2-month whey protein administration improved 
intestinal permeability (measured as lactulose mannitol excretion ratio in urine) and 
morphology in Crohn’s disease patients (Benjamin et al 2012).  
Notably, after a long-term intervention, ABX cancelled the beneficial effect of WPI 
on gut permeability. This suggests that WPI protects form HFD-induced ileal 
permeability alteration through the gut microbiota. In accordance with this finding, in 
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the present study, we observed a decrease in plasma MCP-1 in the presence of WPI in 
HFD-fed mice and this change was abolished during gut microbiota depletion. This 
might suggest that also the action of WPI on systemic inflammation (and not anti-
inflammatory cytokines expression at the tissue-level) is gut microbiota-mediated. In 
the future, a deeper analysis of systemic inflammation is required to confirm this first 
evidence of gut microbiota-dependent effects of WPI as part of HFD on gut 
permeability and systemic inflammation. Additionally, a more specific investigation 
focused on targeting the specific members of the gut microbiota involved in WPI 
action will be required. 
 
Notably, the presence of WPI within HFD had a significant effect on the gut microbiota 
composition. In accordance with our previous study (Boscaini et al 2020) (see Chapter 
3), HFD-WPI and HFD-CAS groups showed significant differences in beta-diversity 
and the relative abundance of multiple bacterial taxa at the phylum, family and genus 
levels after 5 weeks or 10 weeks of dietary intervention. Notably, different duration of 
the dietary intervention, from adolescence to adulthood, had a differential impact on 
the microbiota composition. Previously, it was shown that WPI caused an increase in 
the relative abundance of Lactobacillus and Bifidobacterium spp. and a decrease in 
Clostridium compared to HFD-CAS-fed rodents (McAllan et al 2014, Sprong et al 
2010). Here, we found an increase in Lactobacillus only after 10 weeks of dietary 
intervention, without finding any differences in Bifidobacterium proportions.  
Both after 5 and 10 weeks, in HFD-WPI groups we found an increase in 
Deferribacteres at phylum level, an increase in Sutterellaceae and a decrease in 
Streptococcaceae at family level, and an increase in Allobaculum and a decrease in 
Anaerotruncus, Saccharibacteria_genera_incertae_sedis, Intestimonias, Roseburia, 
Anaerofusits, Anaeroplasma, Lefsonia, Clostridium_sensu_stricto, Turicibacter and 
Streptococcus at genus level. This is to our knowledge the first evidence of an increase 
in Allobaculum in the presence of HFD-WPI. Notably, in figure 4.S3c and 4.S3d is 
clearly Allobaculum much more present in the presence of WPI compared to CAS in 
non-treated mice.  A decrease in Allobaculum was found in obesity-prone mice fed 
with HFD and an increase of this genera has been linked with a reduction in body 
weight in obese mice (Huazano-García et al 2017, Qiao et al 2014, Ravussin et al 
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2012). Furthermore, unlike our previous results (Boscaini et al 2020) (see Chapter 3), 
here we observed a decrease in alpha-diversity in HFD-WPI vs HFD-CAS group. 
However, it is worth noting that direct comparison of data between both studies is 
challenging due to the different approaches to gut microbiota analysis utilised (shotgun 
metagenomics vs 16s rRNA-based sequencing). 
Here, we also observed some differences between the ABX groups after 10 weeks 
intervention. For instance, HFD-WPI+ABX mice showed a lower adiposity and leptin 
level compared to HFD-CAS-ABX mice. This suggests an additive effect of WPI and 
ABX treatment on those parameters. Differences between these two groups were also 
found within the gut microbiota. The HFD-WPI+ABX group showed a higher alpha-
diversity, differences in beta-diversity, lower faecal bacterial load and an increase in 
relative abundance of multiple taxa at phylum, family and genus level, compared to 
HFD-CAS+ABX group. These intriguing observations clearly indicate that protein 
quality impacts on body weight-related parameters and gut microbiota despite the very 
low microbial abundance caused by 10-week ABX exposure.  
 
In the presence of WPI, both in ABX-treated and non-treated mice, several amino acids 
were more abundant in the caecal content, such as tryptophan, N6-acetyl-L-lysine and 
prolyl-leucine. The two latter ones are modified amino acids containing branched-
chain amino acids (BCAAs). This is in line with the fact that whey protein is naturally 
enriched in essential BCAAs, which are very important for muscle repair, recovery 
and protein synthesis (Gorissen et al 2018). In addition, WPI has a higher proportion 
of tryptophan compared to other dietary proteins. Particularly, LAB contained in WPI 
has a very high percentage of tryptophan. This amino acid is the precursor of serotonin, 
a neurotransmitter that acts in the brain modulating mood, cognitive function, appetite 
and sleep (Layman et al 2018a). A higher percentage of vitamin B1 was also found in 
the caecal content of WPI-fed mice. Several Lactobacillus spp. are vitamin B1-
producers, thus the higher relative abundance of Lactobacillus genus within the gut of 
HFD-WPI-fed mice (both ABX-treated and non-treated) can explain the vitamin B1-
related data observed (Yoshii et al 2019). Vitamin B1 is an essential dietary 
requirement for the host due to its role in conversion of ingested food by the host into 
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energy as well as in proper functioning of peripheric and central nervous system 
(Osiezagha et al 2013). 
 
In mice with lower body weight, adiposity and leptin levels (i.e., both ABX-treated 
groups and HFD-WPI non treated group), we observed a similar increase in threonine, 
asparagine, cis aconitic acid and 3-indoleacrylic acid, and a similar decrease in 2-
oxindole and quinolinic acid. Interestingly, 3-indoleacrylic acid is a tryptophan-
derivate indole which have been associated with suppression of inflammation 
(Wlodarska et al 2017). This suggests that the high abundance of tryptophan within 
WPI might contribute at least in part the anti-inflammatory action observed within the 
intestine.  
Conversely, the kynurenine pathway-derivate quinolinic acid has been shown to have 
neurotoxic effect and its brain levels are high in patients with depression (Bansal et al 
2019, Gheorghe et al 2019, Myint et al 2012). Altogether, the caecum metabolomics 
readouts suggest an influence of WPI presence within the diet on amino acid content, 
especially on tryptophan and some tryptophan metabolites derivates produced by the 
gut bacteria which are involved in inflammation and brain health. 
 
In conclusion, we have further delved into the molecular mechanism of WPI anti-
obesity effects. We have shown that the protective effects of WPI dietary 
supplementation on body weight, adiposity and leptin levels in HFD-fed mice persist 
in the conditions of gut microbiota depletion with ABX cocktail. However, ABX 
administration per se had a strong anti-obesity effect with similar effect size. 
Therefore, in the current experimental design, it is impossible to conclude whether 
WPI exploits microbiota to protect the host from HFD-induced obesity. However, the 
additive effect of WPI and ABX on adiposity and leptin production suggest that WPI 
has a gut microbiota-independent protective effect against HFD-induced obesity. 
In the future, it would be worth to repeat the same study but in the presence of normal 
chow or low-fat diet to have a complete picture on the relation between WPI effects 
and microbiota. Alternatively, other gut microbiota-related strategies (such as a direct 
intervention on Lactobacillus genus or faecal microbiota transplantation) can be 
applied to avoid the strong effect of ABX. 
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Moreover, we have shown that supplementation of WPI reduced HFD-induced pro-
inflammatory cytokines plasma level and gene expression in the ileum and adipose 
tissue as well as ileal barrier disruption. In particular, the effects observed for ileal 
permeability and plasma level of MCP-1 seem to be mediated by the gut microbiota. 
These data together further support the potential of WPI as an anti-obesity agent. 















Genes Forward primer (5'-3') Reverse primer (5'-3')
β-actin (ActB ) 5'-gtggtacgaccagaggcatac-3' 5'-aaggccaaccgtgaaaagat-3'
Interleukin 1 β (Il1β ) 5'-attgttgaacatcgccactg-3' 5'-aaatgagccccagtagcactt-3'
Monocyte chemoattractant protein 1 (Mcp1 or Ccl2 ) 5'-agccaactctcactgaagcc-3' 5'-atcctcttgtagctctccagcc-3'
Adiponectin (Adipoq ) 5'-ggagagaaaggagatgcaggt-3' 5'-ctttcctgccaggggttc-3'
Leptin (Ob ) 5'-ccccgcaccgctggaagtac-3' 5'-atgtgccctgaaatgcggtatg-3'
Cluster of differentiation 68 (CD68 ) 5'-cacttcgggccatgtttctcttg-3' 5'-aggggctggtaggttgattgtcgtc-3'
Tumor necrosis factor alpha (Tnf α) 5'-tcttctcattcctgcttgtgg-3' 5'-ggtctgggccatagaactga-3'
Proopiomelanocortin (Pomc ) 5'-agtgccaggacctcacca-3' 5'-cagcgagaggtcgagtttg-3'
Neuropeptide Y (Npy ) 5'-ccgctctgcgacactacat-3' 5'-tgtctcagggctggatctct-3'
Glucocorticoid receptor (Gr ) 5'-caaagattgcaggtatcctatgaa-3' 5'-tggctcttcagaccttctt-3'
Cocaine- and amphetamine-regulated transcript protein (Cartpt ) 5'-cgagaagaagtacggccagg-3' 5'-ctggcccctttcctcact-3'
Suppressor of cytokine signalling 3 (Socs3 ) 5'-aatacctttgacaagcggac-3' 5'-ccttcacacacccttttctc-3'
 Cannabinoid receptor type 1 (Cb1 ) 5'-gggcaaatttccttgtagca-3' 5'-ggctcaacgtgactgagaaa-3'
Corticotropin-releasing hormone (Crh ) 5'-caaatgctgcgtgctttc-3' 5'-ttgccttttccctttctcttc-3'
Tight junction protein (Tjp1 ) 5'-gttttgagagcaagccttctg-3' 5'-cagcatcagtttcgggtttt-3'
Junctional adhesion molecule 1 (F11 or Jam1 ) 5'-actccttgctgaatctgaacagt-3' 5'-ggacacaaagattgcgatcag-3'
Claudin 1 (Cldn1 ) 5'-agaacaaagaaagggactgcac-3' 5'-accaggaacgacgaggtct-3'
Occludin (Ocln ) 5'-gtccgtgaggccttttga-3' 5'-ggtgcataatgattgggtttg-3'
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Table 4.TS2 Hypothalamic gene expression across all experimental groups, after short- (5 
weeks) or long-term (10 weeks) intervention. Relative gene expression and standard error of 
the mean (SEM) are indicated. Abbreviation; Pomc; proopiomelanocortin, Cartpt; Cocaine- 
and amphetamine- regulated transcript, Npy; neuropeptide Y, Cb1; cannabinoid receptor 1, 
Crh; corticotropin-releasing hormone, Gr; glucocorticoid receptor, Socs3; suppressor of 
cytokine signalling 3. a: significant differences between HFD-CAS vs HFD-CAS+ABX; b: 
significant differences between HFD-WPI vs HFD-WPI+ABX; c: significant differences 
between HFD-CAS vs HFD-WPI; d: significant differences between HFD-CAS+ABX vs 
HFD-WPI+ABX. A complete statistical description is detailed in Methods and Materials and 
figures 4.S6 and 4.S7. 
 
5 weeks















Pomc 0,943 0,103 0,706 0,070       0,926  c   0,132 1,105 0,140
Cartpt 1,174 0,103    1,812  a 0,187 1,104 0,100      1,021   d  0,088
Npy 0,835 0,087    1,227  a 0,111 1,003 0,140      1,326   b 0,116
Cb1 1,202 0,043 1,447 0,153 1,081 0,096      1,055   d  0,111
Crh 0,914 0,085 1,056 0,126 1,333 0,224 1,529 0,230
Gr 0,926 0,049 0,777 0,056 1,033 0,063      0,958   d  0,057
Socs3 0,846 0,058   0,554  a 0,061 0,788 0,095 0,722 0,072
10 weeks
Pomc 0,878 0,077 1,304 0,144      1,043  c   0,111 1,082 0,114
Cartpt 0,612 0,034     0,790  a 0,052 0,642 0,078     0,962 b d 0,058
Npy 0,728 0,107 0,810 0,052 0,821 0,079     1,153 b d 0,189
Cb1 0,675 0,013    0,944  a 0,085 0,635 0,090   0,984 b 0,112
Crh 0,621 0,053 0,867 0,108 0,647 0,146   1,044 b 0,113
Gr 1,189 0,045 1,072 0,046    0,919  c  0,044 1,087 0,152
Socs3 1,446 0,113     1,082  a 0,064 1,632 0,238   0,911 b 0,054
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Table 4.ST3: Tight junctions gene expression across all experimental groups, after short- (5 
weeks) or long-term (10 weeks) intervention. Relative gene expression and standard error of 
the mean (SEM) are indicated. Abbreviation; Tjp1; tight junction protein 1, F11; Junctional 
adhesion molecule A, Cldn1; claudin 1, Ocln; occludin. a: significant differences between 
HFD-CAS vs HFD-CAS+ABX; b: significant differences between HFD-WPI vs HFD-
WPI+ABX; c: significant differences between HFD-CAS vs HFD-WPI; d: significant 
differences between HFD-CAS+ABX vs HFD-WPI+ABX. A complete statistical 



















Tjp1 1,147 0,070 1,118 0,043 0,874 c 0,072 0,714 d 0,069
F11 0,875 0,074 0,749 0,041 1,027 0,083 1,010 d 0,057
Cldn1 0,856 0,106 0,633 0,083 1,152 0,174 0,706 b 0,124
Ocln 0,771 0,092 0,843 0,060 0,877 0,107 1,134 b,d 0,070
10 weeks
Tjp1 0,890 0,072 1,178 0,098 0,996 c 0,083 1,103 0,067
F11 1,236 0,093 1,052 0,069 1,104 0,081 0,940 0,082
Cldn1 1,757 0,188 0,871 a 0,129 1,282 c 0,197 0,888 0,178





Figure 4.S1 Absolute organ/tissue weights and intestinal length. Data show tissue and organ 
absolute weights (a) at 5 and (b) 10 weeks timepoints. Data also show small intestinal and 
colonic length (c) at 5 and (d) 10 weeks timepoint. All the data were measured in mice fed 
with HFD-CAS and HFD-WPI, both controls and ABX-treated. Groups showing * (for HFD-
CAS vs HFD-CAS+ABX and HFD-WPI vs HFD-WPI+ABX) and # (for HFD-CAS vs HFD-
WPI and HFD-CAS+ABX vs HFD-WPI+ABX) are significant (*/# P<0.05 or **/## P<0.01 
or ***/### P<0.001). A complete statistical description is detailed in Methods and Materials 






Figure 4.S2 Colonic permeability and faecal bacterial quantification. Data show (a) colonic 
FITC paracellular permeability at 60, 90 and 120 min and (b) the total FITC flux that passed 
through the colonic epithelium over 2 hours, at 5 weeks timepoint. Data also show (c) colonic 
FITC paracellular permeability at 60, 90 and 120 min and (d) the total FITC flux that passed 
through the colonic epithelium over 2 hours, at 10 weeks timepoint. (e) % of bacterial yield 
calculated at % of 16S copies present in 1 mg of faeces at 5 and 10 weeks timepoints (bacterial 
yield average of HFD-CAS at 5 weeks was considered as 100%; bacterial yield of all the 
groups was normalized by bacterial yield average of HFD-CAS at 5 weeks). Statistical 
analysis: (a, c) groups showing * (for HFD-CAS vs HFD-CAS+ABX), § (for HFD-
CAS+ABX vs HFD-WPI+ABX) and & (for HFD-WPI vs HFD-WPI+ABX) are significant 
(*/§/& P<0.05 or **/§§/&& P<0.01 or ***/§§§/&&& P<0.001). A complete statistical 











Figure 4.S3 Gut microbiota analysis: further 
taxonomic differences across the groups. Taxaplot 
showing families (a) at 5 and (b) 10 weeks timepoints 
and genera at (c) 5 and (d) 10 weeks timepoints within 
the faecal samples. Data also show the heatmaps 
representing taxonomic pairwise differences in 
abundance at phylum level across the groups, using 
Kruskal Wallis method (e) at 5 and (f) 10 weeks 
timepoint. Notably, green and red colours represent an 
increase and a decrease, respectively, in relative 
abundance of a specific group (not in brackets) 
compared to another group (in brackets). White colour 
indicates no differences between the two groups. The 
shades of each colour correspond to different p values 
thresholds. In (b), the phyla that did not show 
differences at 5 weeks timepoint but that showed 
differences at 10 weeks timepoint are indicated with a 
grey background. All the data were measured in mice 
fed with HFD-CAS and HFD-WPI, both controls and 
ABX-treated. Groups showing * are significant 
(*P<0.05 or **P<0.01 or ***P<0.001 or 
****P<0.0001). A complete statistical description is 






Figure 4.S4 Further metabolites changes in the caecum at 10 weeks timepoint. The heatmaps show 
metabolites measured within the caecum content, where the changes observed across the groups are 
related to (a) both ABX treatment and protein quality. Also reported (b) an heatmaps with changes in 
one pairwise comparison. Notably, orange and blue colours represent an increase and a decrease, 
respectively, in abundance of group 1 compared to group 2 (below in each heatmap: Group1 vs Group 
2). On the left side of the heatmaps are indicated the categories in which the metabolites belong to. 
Abbreviations: (8aR,12S,12aR)-12-H-4-m-4,5,6,7,8,8a,12,12a-o-2H-3-b-2,9(1H)-d; (8aR,12S,12aR)-
12-Hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-2H-3-benzoxecine-2,9(1H)-dione. Groups 
showing * are significant (* P<0.05 or ** P<0.01 or *** P<0.001) and $ indicates a trend (0.05< P 







































Figure 4.S5 Two-way ANOVA - Organs and tissues weight statistics. Complete statistical 
description of organs and tissues absolute weight data (a) after 5 weeks and (b) 10 weeks of 





Figure 4.S6 Two-way ANOVA – Plasma analysis, gene expression (ileum, eWAT, 
Hypothalamus) and FITC flux statistics. Complete statistical description of plasma analysis, 
gene expression and FITC flux data (a) after 5 weeks and (b) 10 weeks of intervention.   
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Figure 4.S7 Non-parametric test Kruskal Wallis & Mann Whitney – Organs and tissues, 
plasma analysis, gene expression (ileum, eWAT, Hypothalamus) and FITC flux statistics. 
Complete statistical description (a) of organs and tissues absolute weight data and (b) plasma 
analysis, gene expression and FITC flux, after 5 weeks and 10 weeks of intervention. 1 vs 2 
for HFD-CAS+ABX vs HFD-WPI+ABX, 3 vs 4 for HFD-CAS vs HFD-CAS+ABX, 1 vs 3 




















Delta body weight 5 weeks: F(5;160) = 610.12, p < 0.001 for the effect of the time, F(1;32) = 11.44, 
p < 0.01 for the effect of the treatment, F(1;32) = 5.25, p < 0.05 for the effect of the protein type, 
F(1;32) = 3.93, p =0.056 for the effect of the treatment x protein type interaction,  F(5;160) = 12.15, 
p < 0.001 for the effect of the time x treatment  interaction, F(5;160) = 6.00, p < 0.01 for the 
effect of the time x protein type interaction, F(5;160) = 4.48 , p < 0.05 for the effect of the time 
x treatment x protein type interaction. 
 
Delta body weight 10 weeks: F(10;340) = 571.68, p < 0.001 for the effect of the time, F(1;34) = 
4.54, p < 0.05 for the effect of the treatment, F(1;34) = 6.44, p < 0.05 for the effect of the protein 
type, F(1;34) = 0.99, p = 0.33 for the effect of the treatment x protein type interaction,  F(10;340) 
= 6.96, p < 0.01 for the effect of the time x treatment  interaction, F(10;340) = 14.85, p < 0.001 
for the effect of the time x protein type interaction, F(10;340) = 1.42 , p = 0.25 for the effect of 
the time x treatment x protein type interaction. 
Serosal FITC concentration ileum 5 weeks: F(3;78) = 36.49, p < 0.001 for the effect of the 
minute passed, F(1;26) = 5.92, p < 0.05 for the effect of the treatment, F(1;26) = 0.30, p = 0.59 for 
the effect of the protein type, F(1;26) = 0.57, p = 0.46 for the effect of the treatment x protein 
type interaction,  F(3;78) = 7.75, p < 0.01  for the effect of the minutes passed x treatment 
interaction, F(3;78) = 0.25, p = 0.63 for the effect of the minutes passed x protein type 
interaction, F(3;78) = 0.61 , p = 0.45 for the effect of the minutes passed x treatment x protein 
type interaction. 
 
Serosal FITC concentration ileum 10 weeks: F(3;75) = 39.27, p < 0.001 for the effect of the 
minute passed, F(1;25) = 1.21, p = 0.28 for the effect of the treatment, F(1;25) = 1.43, p = 0.24 for 
the effect of the protein type, F(1;25) = 3.61, p = 0.07 for the effect of the treatment x protein 
type interaction,  F(3;75) = 1.01, p = 0.35  for the effect of the minutes passed x treatment 
interaction, F(3;75) = 2.99, p = 0.084 for the effect of the minutes passed x protein type 
interaction, F(3;75) = 2.28 , p = 0.13 for the effect of the minutes passed x treatment x protein 
type interaction. 
Serosal FITC concentration colon 5 weeks: F(3;90) = 62.16, p < 0.001 for the effect of the minute 
passed, F(1;30) = 1.71, p = 0.20 for the effect of the treatment, F(1;30) = 0.003, p = 0.95 for the 
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effect of the protein type, F(1;30) = 4.94, p < 0.05 for the effect of the treatment x protein type 
interaction,  F(3;90) = 2.24, p = 0.14  for the effect of the minutes passed x treatment interaction, 
F(3;90) = 0.51, p = 0.50 for the effect of the minutes passed x protein type interaction, F(3;90) = 
4.21 , p < 0.05 for the effect of the minutes passed x treatment x protein type interaction. 
Serosal FITC concentration colon 10 weeks: F(3;93) = 73.25, p < 0.001 for the effect of the 
minute passed, F(1;31) = 6.18, p < 0.05 for the effect of the treatment, F(1;31) = 0.059, p = 0.81 
for the effect of the protein type, F(1;31) = 0.15, p = 0.7 for the effect of the treatment x protein 
type interaction,  F(3;93) = 7.38, p < 0.01  for the effect of the minutes passed x treatment 
interaction, F(3;93) = 1.14, p = 0.31 for the effect of the minutes passed x protein type 










5.1 Overview and Summary 
In this thesis, I explored the multiple effects exerted by bovine WP (as a whole and 
specific WP, i.e., LAB) in the context of HFD-induced obesity in male mice 
(C57BL/6J) between 5-weeks and 15-weeks old. Additionally, I investigated the 
possibility of a relationship amongst various WP-related anti-obesity parameters, with 
a focus on those involved in controlling weight gain. 
 
Our data showed that HFD containing the specific WP, LAB, as the protein source 
altered energy balance and gut-related functions, such as intestinal nutrient absorption 
and gut microbiota composition (Chapter 2). Specifically, mice fed with HFD-LAB 
for 10 weeks had a similar body weight and energy expenditure compared to controls, 
HFD-CAS-fed mice, but showed an increase in cumulative energy intake. This energy 
imbalance suggested a loss of energy in the presence of LAB within the diet. In the 
small intestine, we observed a decrease in Glut2 and Cd36 (i.e., glucose and fatty acid 
transporters, respectively) expression within the ileum and a decrease and a trend 
towards an increase, respectively, in Cd36 and Lat4 (an essential amino acids 
transporter) expression within the jejunum of mice fed with HFD-LAB. These results 
suggested that, following LAB consumption, changes in gene expression of important 
intestinal nutrient transporters within the small intestine could be one of the causes of 
the energy mismatch observed in HFD-fed mice. The presence of LAB within HFD 
significantly affected the gut microbiota configuration. Beta-diversity of HFD-LAB-
fed mice showed a significant separation from HFD-CAS-fed mice and, at genus level, 
the relative abundances of Parabacteroides, Bifidobacterium, Parvibacter and 
Lactobacillus were significantly higher in the HFD-LAB group. Together these data 
highlight the specificity with which WP components act to alter different aspects of 
energy balance. 
 
In Chapter 3, we examined WPI as a whole and we focused on the effect of WPI given 
with HFD on energy balance, lipid metabolism and gut-related functions at two 
different stages of life (i.e., adolescence and early adulthood). A 5-week HFD-WPI 
dietary intervention carried out in younger mice (from 5 to 10-weeks old) caused a 
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decrease in body weight gain and adiposity. In addition, differences in enzymes 
involved in lipid catabolism were found. In particular, Cpt1a and Ucp2 expression 
increased and Hsl and Lpl expression decreased within the eWAT of adolescent HFD-
WPI-fed mice. These data suggest that the presence of WPI decreases adiposity, 
possibly through a modulation of lipid metabolism within the adipose tissue. In 
addition, WPI caused a reduction in plasma level of leptin and Ob expression (i.e., 
gene that codes for leptin) within eWAT in younger mice fed with WPI, which is a 
sign of attenuation of the metabolic syndrome caused by HFD. A decrease in Cd68 
expression within the eWAT in younger HFD-WPI-fed mice also suggests a lower 
macrophage recruitment in the adipose tissue. Through gut microbiota analysis, we 
observed a significant separation in beta-diversity at species level between HFD-WPI 
and HFD-CAS younger mice. Moreover, Lactobacillus murinus relative abundance 
and 49 L. murinus-related functions were more abundant in the HFD-WPI group.  
All these changes, observed after dietary intervention in younger mice, were not 
observed in mice that started the 5-week HFD-WPI dietary intervention at an older 
age (from 10- to 15-weeks old).  
These results suggest that WPI, when given as part of HFD, impacts differently on 
body weight, adipose tissue and gut microbiota, depending on the stage of life during 
which the diet is provided.  
 
Following on from the results found in Chapter 3, we next examined (Chapter 4) if 
WPI exerts a beneficial effect on HFD-induced metabolic and physiological 
dysregulations through the modulation of the gut microbiota. HFD-WPI or HFD-CAS-
fed mice were treated with ABX to deplete the gut microbiota for a short-(5 weeks) or 
long-term (10 weeks) intervention. HFD-WPI-fed mice, both ABX-treated and non-
treated, showed a reduction in body weight gain, adiposity, leptin availability and gene 
expression of selected pro-inflammatory markers (MCP-1, TNFα and CD68) within 
the eWAT and ileum, compared to non-treated HFD-CAS-fed mice. In particular, WPI 
and ABX had an additive effect in lowering adiposity and leptin production in HFD-
WPI+ABX mice that underwent long-term intervention. These data indicated that WPI 
acts on body weight and adipose-related functions in a gut microbiota-independent 
manner in HFD-fed mice. Conversely, WPI supplementation protected from HFD-
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induced ileal permeability disruption and high MCP-1 level in the plasma and these 
effects were abolished by ABX administration. These results suggest that WPI action 
on gut permeability and systemic inflammation required an intact gut microbiota. Gut 
microbiota composition and caecum metabolomic analysis showed differences 
between HFD-WPI and HFD-CAS-fed mice, both non-treated and, surprisingly, 
ABX-treated. In this regard, WPI modulated the gut microbiota differently compared 
to CAS, even in a microbiota depleted condition. 
Altogether, these results demonstrate that WPI beneficially modulates HFD-induced 





Figure 5.1 Summary of the findings of this thesis. Abbreviations: HFD, high-fat diet; LAB, alpha-lactalbumin; WPI, whey protein isolate; CAS, 




5.2 Whey protein: a dietary strategy to fight obesity 
Obesity has become a global healthcare challenge of the 21st century, with worldwide 
obesity levels increasing 4-fold in the past 20 years. Data from Irish Health Service 
Executive (HSE) show that only 37% of Irish population have a normal weight, 
whereas 37% are overweight and 23% obese (www.hse.ie). Other countries, such as 
USA, UK and Australia, show a similar situation, as reported by the World Health 
Organization (WHO) (www.who.int). The fact that more than half of the population 
in these countries is overweight or obese means that this condition represents the “new 
normal”. This phenomenon has a huge personal and financial cost because of the wide 
list of health complications that come together with obesity, which reduces the life 
expectancy, and, consequently, increases treatment and hospitalization costs. This 
highlights why we must be concerned and drive the scientific effort to overcome the 
problem. 
 
The most common approach adopted to lose body weight is through dietary strategies, 
which include a wide range of diet programs that allow the consumption of fewer 
calories compared to the calories expended. However, these approaches have yielded 
limited results because of the adaptions of energy balance-related mechanisms to 
counteract energy deficits, such as changes in hypothalamic neuropeptides that seek 
to drive food searching behavior and over-eating when food becomes available. In 
recent decades, studies have focused on the importance of macronutrients in the diet 
and changing their proportions to manipulate energy balance in a way that could 
overcome the calorie deficit. It has emerged that, in a situation of equal calorie intake, 
diets with a high content of protein are more efficient in decreasing body fat and 
increasing lean mass. However, this effect can be different depending on the protein 
source. In this regard, WP has been emerged as a good candidate because it is a rich 
source of essential amino acids, including BCAA, which are responsible for rapid 
digestibility and positive effects on metabolism and adiposity (Siddik & Shin 2019). 
This thesis focuses on the multi-organ effects of WP supplementation (present in a 
standard amount of 20% of energy) in mice under HFD-induced obesity condition. 
The implications of our findings will be discussed in this section. 
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5.2.1 Whey protein consumption impacts on energy balance, gut 
physiology and the gut microbiota during obesity 
It has been shown many times that WP exerts a potent satiety effect accompanied by 
an increase in plasmatic anorexigenic hormones and a decrease in plasmatic orexigenic 
hormones produced along the GIT, both in lean humans and rodents (Hall et al 2003, 
McAllan et al 2015, Pal & Ellis 2010a, Veldhorst et al 2009a). However, this is not 
the case for obese individuals or HFD-induced obese mice, despite WP action 
lowering body weight and adiposity. The studies in obese individuals have contrasting 
end points. In some clinical trials in obese individuals, WP supplementation shows a 
positive effect on satiety, whereas in others, WP either has no effect on satiety or has 
a short-term effect that then disappears after a long-term intervention (Bowen et al 
2006b, Mollahosseini et al 2017, Pal et al 2014, Wiessing et al 2015). In HFD-fed 
mice, WPI does not show a satiety effect but, as we observed in Chapter 3, WPI-fed 
mice show a higher energy intake compared to CAS counterparts (McAllan et al 2014, 
Tranberg et al 2013). We observed the same scenario in Chapter 2, where mice fed 
with HFD containing LAB (i.e., a whey protein component) showed a higher energy 
intake compared to HFD-CAS-fed mice, without showing any differences in body 
weight. This clearly suggest an energy loss in the presence of WP within HFD. In this 
thesis, we explored the energy loss by looking at the gene expression of different 
nutrient transporters within the small intestine. In Chapter 2, the presence of LAB 
within HFD showed a decrease in the gene expression in FAs and glucose transporters 
(CD36 and GLUT2) within the ileum and jejunum. This would explain, in part, the 
energy balance mismatch in these mice. However, in Chapter 3, in HFD-WPI-fed 
mice, we did not find relevant changes in the gene expression of ileal nutrient 
transporters or through the investigation of TAGs content in the caecum. Thus, the 
reason for the discrepancy between energy intake and body weight in HFD-fed mice 
supplemented with WPI or LAB remains unsolved. One possibility is that this relates 
to AA compositional differences between WPI and LAB, and how they are digested 
by the host and microorganisms and made available to the host. In the future, more 
investigations on caloric content within the faeces or a detailed analysis on energy 
expenditure such as body temperature, BAT functionality and energy dissipation are 
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required. It would also be useful to assess how an imposed change in the AA 
composition of the protein source affects the host. 
 
Furthermore, in Chapter 4, we showed that WPI can also protect from HFD-induced 
intestinal barrier disruption. Other studies reported the beneficial effect of WPI on 
intestinal repair, integrity and maturation in rodents and pigs (Boza et al 1996, Kotler 
et al 2013, Xiao et al 2016). However, these studies were not performed during HFD 
consumption. Thus, we showed for the first time WPI action on gut permeability that 
protects from HFD-induced derangements. Moreover, we observed that this effect is 
mediated by the gut microbiota, since the depletion of the gut microbiota though ABX 
treatment abolished the protective effect on ileal permeability during HFD 
consumption. However, more studies are required to confirm this evidence. Currently, 
the effect of WPI on the gut health in obese individuals remains unexplored. 
 
WP presence in the diet influences the gut microbiota composition. It was previously 
shown that WP feeding in rodents increases the abundance of Lactobacillus and 
Bifidobacterium genera (McAllan et al 2014, Sprong et al 2010). Accordingly, in 
Chapter 3, we observed an increase in abundance of Lactobacillus murinus in the gut 
of younger mice fed with HFD-WPI. In Chapter 4, we observed a significant increase 
in the relative abundance of Lactobacillus following 10-week HFD-WPI intervention 
in mice. Accordingly, HFD-WPI-fed mice showed a higher caecal concentration of 
vitamin-B1, which is produced by several Lactobacillus spp. (Yoshii et al 2019). 
However, both in Chapter 3 and 4, we did not observe significant differences in 
Bifidobacterium. In addition, in Chapter 4, we found that both 5-week and 10-week 
intervention with HFD-WPI provoked an increase in Allobaculum and a decrease in 
Anaerotruncus, Saccharibacteria_genera_incertae_sedis, Intestimonias, Roseburia, 
Anaerofusits, Anaeroplasma, Lefsonia, Clostridium_sensu_stricto, Turicibacter and 
Streptococcus at genus level. This is the first evidence of an increase in the relative 
abundance of Allobaculum in the presence of HFD-WPI.  
 
Moreover, in mice fed with HFD, some individual WP components were able to 
modulate the gut microbiota. In particular, Lf supplementation led to an increase in 
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the proportion of Bifidobacterium spp., and LAB supplementation caused an increase 
in relative abundance of Lachnospiraceae and Blautia (Li et al 2019a, Sun et al 2016). 
In Chapter 2, we observed that LAB caused an increase in Parabacteroides, 
Bifidobacterium, Parvibacter and Lactobacillus within the gut of HFD-fed mice.  
Together, these results show clearly that WP or single WP components can modulate 
the composition of the gut microbiota, promoting the growth of selected taxa. Since 
certain strains of Lactobacillus and Bifidobacterium are among the most important 
probiotics, WP consumption can be beneficial for HFD-induced gut microbiota 
alteration. Accordingly, a decrease in Allobaculum was found in obesity-prone mice 
fed with HFD and an increase of this genera has been linked with a reduction in body 
weight in obese mice (Huazano-García et al 2017, Qiao et al 2014, Ravussin et al 
2012). Variation between different studies might be due to animal strain, diet kind and 
duration, age and, very importantly, the gut microbiota analysis approach adopted.  
While there are few studies looking at the gut microbiota following WP intake related 
to exercise in humans (Cronin et al 2018, Moreno-Pérez et al 2018), studies that 
explore the impact of WP supplementation on the gut microbiota of obese/overweight 
people are not currently available. To better explore the relationship between WP 
intake, obesity and gut microbiota, evidence in humans are necessary.  
 
In light of the multiple effects on host physiology observed during WP administration, 
we sought to find a link between gut microbiota modulation and physiological 
outcomes during HFD-WPI administration. In Chapter 4, through a microbiota 
depletion with ABX cocktail, we observed that WPI action in lowering body weight, 
adiposity and leptin level seems to be independent from the modulation of the gut 
microbiota. Thus, we hypothesized that adipose tissue lipid metabolism, which might 
be the cause of lower adiposity (see paragraph 5.2.2), would not be affected by the 
microbiota manipulation. However, in the future, different strategies to better 
understand if the gut microbiota mediates WPI effects, such as experiments in GF mice 
or specific bacterial taxa manipulation (for example, for studies that involve WPI, it 
would interesting to target specifically Lactobacillus spp.) or FMT studies are 
required. Also, to have a complete picture of the effect of WPI during microbiota 
depletion, it would be worth carrying out a microbiota depletion experiment using the 
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same ABX cocktail in normal diet/LFD-fed mice supplemented with WPI. In this way, 
the direct effect of WPI on the gut microbiota, independently of HFD, can be 
investigated.  
 
5.2.2 Whey protein ameliorates HFD-induced adiposity via 
modulations of lipid metabolism 
From this thesis, and from previous studies carried out in rodents, the ability of WPI 
to decrease adiposity and body weight gain in a context of HFD feeding has been 
revealed (Abbas et al 1989, McAllan et al 2013, McAllan et al 2014, Pezeshki et al 
2015, Pilvi et al 2007, Pilvi et al 2008). In some of the cited studies, the decrease in 
fat mass was accompanied by an increase in the lean mass (enhancement of muscle 
protein synthesis). Notably, considerations of lean body mass were omitted from this 
thesis. Clinical studies that involve WP supplementation in overweight and obese 
humans on either a normal diet or an energy-restricted diet have been carried out (Baer 
et al 2011, Frestedt et al 2008a, McGregor & Poppitt 2013, Mojtahedi et al 2011). 
From those studies, it emerged that WP (both under WPI and WPC form) had a 
positive effect on reducing body weight and adiposity when supplemented at 
approximately 50g/day for at least six months. In particular, WP supplementation in 
obese humans had a strong impact on body fat loss, which is not always associated 
with body weight loss. Together, these findings in HFD-fed rodents and obese humans 
highlight the impact of WP on lipid accumulation and the way of action was 
demonstrated to be through a regulation of lipid metabolism. It was shown that an 
upregulation of Adrb3 expression, which codes for β-3 adrenergic receptor, occurs 
during WP supplementation in the eWAT of HFD-fed mice (Pilvi et al 2008). 
Catecholamines (adrenaline and noradrenaline) bind to this receptor and trigger the 
hydrolyzation of TAG stored within the adipocytes so that TAG can be mobilized as 
fuel for other organs. This suggests that WP might promote fat catabolism. In support 
of this evidence, in this thesis we have shown that WPI as part of a HFD given in 
younger mice decreased the gene expression of HSL, an enzyme involved in lipolysis, 
which can be regulated by the stimulation of the β-3 adrenergic receptor (Collins 
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2012). In parallel, we observed an increase in the gene expression of two genes 
involved in fatty acids β-oxidation (Cpt1a and Ucp2) in HFD-WPI-fed mice. These 
results indicated that different pathways (i.e., lipolysis and β-oxidation) involved in 
fat catabolism are affected by WP consumption. Moreover, a lower expression of Lpl 
was observed in the eWAT of HFD-WPI-fed mice. Given the importance of LPL for 
FAs uptake into adipocytes, it seems that WP suppresses fat gain by acting on adipose 
tissue lipid metabolism, both preventing the entrance of FAs into the adipocytes and 
enhancing fat storage mobilization. Moreover, it was shown that specific WP 
components could alone impact on fat metabolism. Unlike LAB, which had no impact 
on either eWAT or sWAT (Chapter 2), the WP component BSA was shown to reduce 
sWAT, where expression of genes involved in fat catabolism (i.e., Pparα, Cpt1b and 
Ucp3) were increased (McManus et al 2015b).  
Future work should focus on investigating the impact of lipid metabolism in other fat 
depots, such as mAT and rAT. In this regard, future studies are also required to 
investigate the impact of WPI on the browning of the WAT by looking at “browning 
markers” such as UCP1 and PGC-1α. 
In previous studies, it was shown that WP also has an impact on genes involved in 
lipid metabolism in other organs, such as muscle and the liver (Shi et al 2011, 
Tauriainen et al 2011). In the liver, WPI supplementation was associated with a 
suppression of hepatic accumulation of lipids in rodents and an improvement of 
hepatic steatosis in obese women (Bortolotti et al 2011, Hamad et al 2011, Shi et al 
2011). In this thesis, we did not focus on the impact of WPI on the liver, however, in 
Chapter 3, we observed a lower hepatic TAG concentration. Additionally, in both 
Chapter 3 and Chapter 4, we observed a significant increase in liver weight after WPI 
supplementation. Since WPI protects from lipid accumulation in the liver, the reason 
for our observation is still unknown. This unanswered question can be addressed in 
future studies through histological approaches and, perhaps, through metabolomics or 
transcriptomics analysis to better elucidate lipid metabolism-related pathways and 
pathways of another nature. 
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5.2.3 Whey protein: a possible solution for leptin resistance?  
Historically, leptin is the hormone considered to be the master regulator of satiety, 
aside from its role in regulating energy expenditure, metabolism and immune function 
(Park & Ahima 2015). Indeed, mice and humans carrying a mutation in either Ob gene 
(leptin production from the adipose tissue) or Db gene (leptin receptor within the 
brain) develop severe obesity. While for obese people with Db mutate there is no cure, 
leptin replacement therapy is very efficient for obese Ob deficient people. 
Unfortunately, the same therapy cannot be applied in common obesity (which covers 
the majority of cases) because the over production of leptin, which overstimulates 
leptin receptors, causes a desensitization (leptin resistance). For these reasons, the 
scientific community is looking for therapies that can increase leptin sensitivity or 
reduce leptin resistance. This last strategy would be ideal since people affected by non-
genetic obesity already have elevated leptin levels that can act on more sensitized 
receptors. In this context, results that emerged from this thesis are promising. 
In Chapter 3 and Chapter 4, WPI supplementation clearly showed a drastic 
neutralization of HFD-induced leptin production (both at gene expression level within 
the eWAT and at concentration level in the plasma). This observation is in agreement 
with other studies in rodents (McAllan et al 2013, McAllan et al 2014, Zapata et al 
2017b). Moreover, McAllan et al showed a decrease in the expression of the gene that 
codes for hypothalamic leptin receptor LepRb in HFD-WPI-fed mice, compared to 
HFD-CAS-fed mice. This suggests that WPI influences adipose leptin production, as 
well as the leptin receptor within the hypothalamus. Unlike LAB (Chapter 2), a 
beneficial effect on leptin production was also observed in HFD-induced obese mice 
supplemented with the WP components Lf and BSA (McManus et al 2015a, McManus 
et al 2015b). Notably, while WPI and BSA caused a decrease in adiposity together 
with leptin production, Lf acted on leptin levels without affecting adiposity. This 
suggests that changes in leptin production upon consumption of WP components are 
not always related to changes in adiposity. 
In Chapter 4, we further investigated the hypothalamic leptin receptor signaling 
pathway by measuring the gene expression of Socs3, which is involved in feedback 
inhibition on the leptin receptor and is a potential mediator of physiologic leptin 
resistance (Bjorbak et al 2000). However, no differences were found between HFD-
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WPI and HFD-CAS-fed mice, and thus a deeper investigation on the impact of WPI 
on leptin receptor functionality is necessary. This should include all the components 
of the LepRb cascade signaling, since they are all important regulators of LepRb 
functionality. Since these components are constantly activated and inactivated by post-
translational modifications, a proteomics analysis, rather than a gene expression 
analysis, would be ideal. Also, further investigations on the impact of WPI on leptin 
production and leptin resistance in humans are required. 
 
5.2.4 Whey protein and its anti-inflammatory effect 
 
Obesity is associated with chronic low-grade inflammation. This condition, over a 
longer term, triggers the development of obesity-related comorbidities, such as 
adipose tissue dysregulation, cardiovascular diseases and insulin resistance (Ellulu et 
al 2017, Lee et al 2013). Thus, finding dietary strategies that could ameliorate this 
inflammatory status would be useful to prevent the development of obesity-related 
conditions. Although several studies on obese individuals showed no differences in 
the circulatory inflammatory cytokines after WP administration, other studies showed 
a beneficial effect of WP components, such as Lf and immunoglobulins, during obesity 
(Brimelow et al 2017, Pal & Ellis 2010b, Pal & Ellis 2011). In HFD-induced obesity 
in rodents, WP supplementation showed a decrease in the adipose tissue inflammation 
but this intervention was coupled with aerobic exercise (Ahmadi-Kani Golzar et al 
2018). Among WP components, LAB has been shown to decrease HFD-induced 
inflammatory markers, such as TNFα, MCP-1 and IL6 in the adipose tissue, colon and 
in the serum, together with a decrease of LPS in the serum (Gao et al 2018, Li et al 
2019a). In Chapter 2, we did not carry out a detailed analysis of the anti-inflammatory 
properties of LAB contained in HFD. Our only measurement of relevance related to 
the level of gene expression of CD68, which is a marker of macrophage infiltration 
within the adipose tissue, without observing any differences compared to the HFD-
CAS control group. On the contrary, in Chapter 3 and 4, we observed a decrease in 
Cd68 gene expression in HFD-WPI-fed mice. In addition, in Chapter 4, we found a 
decrease in the gene expression of MCP-1 and TNFα in the adipose tissue. These 
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results suggest that WPI decreases the expression of pro-inflammatory cytokines in 
the adipose tissue, in parallel with a decrease in macrophage recruitment and 
infiltration in HFD-induced obese mice. In the future, histological analyses of the 
adipose tissues will be required to further confirm this finding. 
In Chapter 4, HFD-WPI-fed mice showed a decrease in gene expression and 
concentration of MCP-1 in the ileum and in the plasma, respectively. Notably, 
according to the positive effect of WPI on ileal permeability, WPI caused a decrease 
of MCP-1 concentration in the presence of HFD, but this effect is abolished by gut 
microbiota depletion.  
These findings might suggest that WPI decreases HFD-induced systemic 
inflammation through a protective effect on gut permeability and, potentially by gut 
microbiota modulation. Interestingly, our previously described data suggests that this 
mechanism of action of WPI is independent from the WPI effect on adiposity, fat 
metabolism control, and local tissue inflammation. 
Notably, in Chapter 4, we observed a higher caecal content of tryptophan and 3-
indoleacrylic acid, which is a tryptophan-derived indole associated with suppression 
of inflammation, in HFD-WPI-fed mice (Wlodarska et al 2017). Thus, the high 
tryptophan content in WP might contribute to ameliorating the inflammation caused 
by HFD. 
 
In the future, further studies to investigate the beneficial effects of WP on 
inflammation in obese individuals are required. Since the human studies mentioned in 
this section lasted for 12 weeks, it is necessary to carry out a WPI supplementation for 
longer periods. According to studies showing WPI efficacy in lowering adiposity, 
discussed in paragraph 5.2.2, WP supplementation should last at least 6 months. 
Ultimately, analyses on the inflammatory status should be coupled with analyses of 








5.2.5 Anti-obesity effects of whey protein: when and for how long? 
 
Previous studies in our lab focused on WPI administration in HFD and LFD, taking 
into account the duration of the dietary intervention. Both short-term (7-8 weeks) and 
long-term (15-21 weeks) dietary interventions have been carried out and, based on the 
diet’s macronutrient composition, WPI action can be different. In the presence of 
HFD, for example, WPI causes an improvement in insulin sensitivity only after a 
short-term dietary intervention and causes an alteration of the gut microbiota only after 
a long-term intervention. However, WPI given with HFD affects body weight gain, 
liver TAG and lean mass both after short- and long-term interventions (McAllan et al 
2013, McAllan et al 2014, McAllan et al 2015). In this thesis, we also consider the 
duration of WPI intervention, both in Chapter 3 and Chapter 4, keeping in both studies 
a WPI administration that lasted 5 and/or 10 weeks. In Chapter 4, we have seen that 
WPI caused lower body weight gain, adiposity, leptin availability and inflammation 
markers expression after both 5 and 10 weeks of administration. However, the efficacy 
of WPI in ameliorating systemic inflammation and gut permeability was significant 
only after 10 weeks of WPI administration. These results suggest that different 
durations of WPI intervention lead to different effects. 
Another factor that is worth considering is the age, or the stage of life, of the individual. 
In Chapter 3, we showed that 5-week HFD-WPI intervention brought about beneficial 
effects in adolescent mice but not in mice during early adulthood. However, this study 
is limited by the fact that early adult mice, before the intervention with HFD-WPI, 
were fed with LFD-WPI that had a different % of sucrose compared to HFD. Despite 
this, the study highlights when in life WP supplementation can be more effective. 
Future studies that will focus on the effect of HFD-WPI on adult rodents are planned 
in our lab. 
Thus, both duration and stage of life are two important parameters to consider during 
WP administration, to maximize the desired effect. Further work is needed to better 




5.3 Beyond obesity: other applications of whey protein 
In this thesis, we focused on the beneficial effects of WP during obesity. However, it 
has been shown that WP supplementation could help to ameliorate other pathological 
conditions, such as type 2 diabetes, cardiovascular diseases and inflammatory bowel 
diseases.  
Type 2 diabetes is a metabolic condition characterized by chronic hyperglycaemia. 
This is due to impaired insulin secretion and/or insulin resistance in peripheral organs 
(Olokoba et al 2012). Although, in this thesis, we did not find important differences in 
plasma insulin and glucose concentrations in the fasting condition between mice fed 
with HFD-WPI and HFD-CAS, several studies support a positive effect of WPI during 
diabetes. In rodents, it was shown that WP consumption causes a decrease of 
postprandial plasma glucose and fasting plasma insulin, which indicates an 
improvement in insulin sensitivity (Belobrajdic et al 2004, Kavadi et al 2017). In 
support of this evidence, in Chapter 3, WPI as part of a LFD (10% fat diet with 70% 
carbohydrates) was shown to reduce glucose levels in mice, and this could be related 
to changes in GLUT2 within the ileum (Nilaweera et al 2017). Similarly, in both 
healthy and diabetic humans, daily supplementation with WP had comparable effects 
to drugs used to manage hyperglycaemia in type 2 diabetes. Indeed, WP consumption 
lowered fasting insulin level. In postprandial analysis, humans consuming WP had a 
lower plasma glucose concentration and higher insulin, confirming an increase in 
insulin responsiveness (Frid et al 2005, McGregor & Poppitt 2013, Pal & Ellis 2010a, 
Pal et al 2010). It seems that this insulinotropic effect exerted by WP is due to its high 
BCAA and tryptophan content (Nilsson et al 2004, von Post-Skagegård et al 2006). 
These essential amino acids promote the release of satiety hormones within the gut, 
such as GLP-1, which is known to be an incretin hormone (Mignone et al 2015). 
Cardiovascular diseases include numerous pathological conditions of the 
cardiovascular system. They can be grouped into coronary-artery diseases, 
cerebrovascular diseases, peripheral artery diseases and aortic atherosclerosis 
(Benjamin et al 2018). Although, in this thesis, we did not investigate any 
cardiovascular-related parameters, WP has been demonstrated to have a beneficial 
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effect against cardiovascular-related conditions. WP consumption in hypertensive 
and/or overweight humans resulted in a postprandial decrease of both systolic and 
diastolic blood pressure (Pal & Ellis 2010a, Pal & Ellis 2010b). This anti-hypertensive 
effect exerted by WP seems to be mediated by the inhibition of angiotensin-converting 
enzyme (ACE), which catalyses the conversion of angiotensin 1 to angiotensin 2 and 
controls arterial vasoconstriction (FitzGerald & Meisel 1999). Moreover, long-term 
consumption of WP results in a significant decrease in the augmentation index (AI), 
which is an indicator of arterial stiffness (Pal & Ellis 2010b). Very often, AI is high in 
people with hypercholesterolemia (Wilkinson et al 2002). This effect might be linked 
with role of WP in lowering blood pressure (Blacher & Safar 2005).  
In this thesis, we provided further insight into the anti-inflammatory properties of WPI 
together with gut permeability protection. Thus, WP could be a beneficial dietary 
approach also for individuals affected by inflammatory bowel disease (IBD), which is 
a multifactorial immune disorder characterised by chronic relapsing inflammation of 
the intestine. IBD primarily consists of two different disorders: Crohn’s disease (CD) 
and ulcerative colitis (UC). Disrupted intestinal permeability and gut microbiota 
alteration are two common conditions found in IBD patients (Khan et al 2019, 
Michielan & D'Incà 2015). The causes of IBD are still not very well defined. However, 
it is believed that an impairment of the immune system, together with an imbalanced 
interaction between gut microbiota and intestinal epithelium, leads to the development 
of chronic intestinal inflammation when genetically susceptible hosts come across 
certain environmental factors (Kim & Cheon 2017, Podolsky 1991). Consumption of 
WP caused an increased secretion of faecal mucin and the abundances of Lactobacillus 
and Bifidobacterium in rats administered with the inflammatory colitis inductor 
dextran sulfate sodium (DSS). This was accompanied by a decrease in the gene 
expression of IL1β, calprotectin, and inducible nitric oxide synthase. In addition, WP 
diminished diarrhea symptoms and faecal blood loss (Sprong et al 2010). Similarly, 
low-temperature processed WPC supplementation increased mucin production, 
decreased intestinal lymphocyte infiltration and epithelial morphology distribution in 
DSS-induced colitis in BALB/c mice (Jayatilake et al 2014). These evidences suggest 
a protective and anti-inflammatory role exerted by WP within the intestine. 
Accordingly, a study carried out in humans with Crohn’s disease showed that WP 
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supplementation significantly decreased intestinal permeability and ameliorated 
intestinal morphology parameters, such as the villi ratio (Benjamin et al 2012).  
 
In conclusion, a dietary supplementation with WP can be beneficial for multiple 
diseases, thanks to their wide variety of multiorgan effects. The composition of WP, 
which is rich in essential AA, is one of the main driving forces of the multiple actions 
of WP. 
 
5.4 Whey protein and obesity: Future Directions 
Different experimental strategies can be employed to further investigate the beneficial 
effects of WP in obese individuals. More effort is required to seek the mechanism of 
action of WP, to identify one or more possible therapeutic targets. Moreover, the 
relationship between gut microbiota and WP consumption in the context of obesity 
needs to be better elucidated. This section describes different experimental approach 
that could help to identify new aspects of the role of WP consumption on counteracting 
the development of obesity. 
 
5.4.1 Dietary interventions 
Macronutrient quality within precast diet 
It is well known that the precast diet purchased to study obesity in rodents has 
limitations due to the very high fat contents (usually 40-45% and 60%), which do not 
always match with the fat content in human HFD. In addition, the percentage of 
sucrose of HFD compared to LFD/normal diet is different. This can lead to a 
misinterpretation of the effect of fat contained in HFD. Another, limitation of the 
precast diet is the quality of the macronutrients (i.e., fats, proteins and carbohydrates). 
To make precast diet more similar to a human diet, it is now possible to change the 
quality of the FA composition (i.e., saturated/mono-unsaturated/polyunsaturated FAs) 
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within the diet, and to vary the percentage of sucrose and protein (Hu et al 2018, 
Speakman 2019). 
To this end, the use of precast diets with different macronutrient compositions that 
better mimic human diets can be employed to confirm and better understand the effect 
of WPI in HFD-induced obese mice. In addition, experiments with a fixed percentage 
of sugar in both HFD and LFD/normal diet containing WPI are required. 
 
Use of isotope of carbon to measure energy expenditure 
The most common way to measure energy balance, i.e., the combined impact of energy 
intake and energy expenditure, in rodents is using metabolic cages. Some important 
metabolic parameters detected by these cages are: oxygen consumption (VO2) carbon 
dioxide production (VCO2), respiratory exchange ratio (RER, VO2/ VCO2) and 
locomotor activity (Speakman 2013). However, the energy expenditure measurement 
is general and it is not possible to precisely quantify the utilization (oxidation) of a 
specific macronutrient (MacAvoy et al 2006). 
A more detailed measurement of energy expenditure can be done by using 
macronutrients (fat or sugars) labeled with an isotope of carbon, 13C. Practically, mice 
are provided with a diet (LFD or HFD) supplemented with WPI and then a 
macronutrient that contains the carbon isotope can be administered to the mice. 
Through this method, it is possible to measure the oxidation efficiency of the specific 
macronutrient through the quantity of 13C in breath (contained in CO2) (Welch Jr. et 
al 2016). This would provide a better understanding of how WPI impacts on energy 
demand and metabolic rates. 
Whey protein-derived bioactive peptides and obesity 
Once in the stomach, dietary proteins are exposed to an acidic environment, which 
promote their denaturation. In this status, the proteins are more accessible to 
proteolytic enzymes. The high concentration of HCl in the stomach allows the 
autocatalytic activation of pepsinogen in the aspartic protease pepsin, which is active 
in a pH range of 1-5 (Lin et al 1992). Pepsin can hydrolyse the bonds between the 
aromatic amino acids phenylalanine, tryptophan and tyrosine, breaking down the 
proteins into peptides (four to nine amino acids) (Antonov et al 1974). The next step 
of the protein degradation process occurs in the first tract of the small intestine, the 
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duodenum, in which are released other proteolytic enzymes, together with bicarbonate, 
by the pancreas. The presence of bicarbonate allows an increase of the pH in the 
duodenum, creating a favorable environment for the action of pancreatic proteases. 
Trypsin, chymotrypsin, elastase and carboxypeptidases are initially secreted by the 
pancreas as inactive zymogens that, within the duodenum, are cleaved in their active 
form by enterokinases (Layer & Keller 1999). Trypsin and chymotrypsin cleave 
peptide bonds adjacent to lysine or arginine and hydrophobic amino acids, respectively 
(Ma et al 2005). Instead, elastase cleaves peptide bonds adjacent to alanine, glycine 
and serine and carboxypeptidases cleave one amino acid at a time from the carboxyl 
ends of peptide chains (Feher 2017). At the end of the protein digestion, the final 
products are compose of 30% free amino acids and 70% by oligopeptides (Matthews 
1971).  
Most of the peptides that come from bovine milk intestinal hydrolysis are considered 
“bioactive” because of their capability to exert a range of biological activities such as 
antihypertensive, antioxidative, antithrombotic, hypocholesterolemia, satiety and 
antimicrobial actions (Park & Nam 2015). In addition, whole WP and each WP 
component are the source of different kinds and quantities of bioactive peptides 
(Madureira et al 2010). Through a deep investigation of WP-derived bioactive 
peptides, it might be possible to better understand the anti-obesity effect attributable 
to WP.  
WP-derived bioactive peptides can be obtained by performing in vitro digestion and 
selected peptides can be directly injected in the small intestine (to avoid further 
digestion) of obese mice. In this way, the anti-obesity potential of each WP-derived 
bioactive peptide (or a combination of more bioactive peptides) can be assessed. This 
approach would prevent the interference of WP-derived bioactive peptide activity with 
food formulation. For instance, micronutrients, macronutrients, and other ingredients 
present in the food that contains WP could interfere with the digestion, absorption and 
activity of the bioactive peptides. 
It is worth noting that the gut microbiota can ferment proteins and peptides that escape 
from digestion (Diether & Willing 2019). Thus, the effect of specific WP-derived 
bioactive peptides on the gut microbiota can be studied and can be linked with the WP 
biopeptide-related biological function. 
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5.4.2 Microbiota-related experimental approaches 
Probiotics, prebiotics and synbiotics combined with WPI supplementation  
Probiotics are living bacteria that confer beneficial health effects on the host, when 
ingested in adequate amounts (Butel 2014). Several studies have demonstrated the 
wide range of effects exerted by different strains of probiotics in improving host 
immunity, metabolism and endocrine function (El Aidy et al 2015, Patterson et al 
2016). Several Lactobacillus and Bifidobacterium spp. are among the most common 
probiotics. As we showed in this thesis, these correspond to the genera that mainly 
increase in abundance within the gut in the presence of WP. To this end, administration 
of WPI or specific WP components can potentially amplify the beneficial effect 
exerted by specific probiotic strains on host metabolism and health.  
 
The same concept is valid for prebiotics, which are substrates that are selectively 
utilized by the host’s microorganisms and which confer a health benefit (Gibson et al 
2017). Dietary fibers represent the main class of prebiotics, which include inulin, 
fructooligosaccharides (FOS), galactooligosaccharides (GOS) and resistant starch. 
The consumption of prebiotics, which helps the growth of beneficial gut bacteria, has 
been associated with the improvement of obesity and associated co-morbidities, thanks 
to their influence on lipid metabolism, glycemic control and regulation of the secretion 
of satiety hormones (Parnell & Reimer 2012, Xavier-Santos et al 2020). As with 
probiotics, prebiotics, together with WP supplementation, could enhance or participate 
in the shaping of the gut microbiota. The co-administration of WP and prebiotics could 
be a strategy to improve WP’s efficacy in promoting health benefits. 
 
In general, the administration of probiotics, prebiotics or a combination of both (i.e., 
synbiotics) can be an adjunctive microbiota modulation-therapy to complement the 
WP effects on host metabolism, adiposity, immunity and intestinal health. These 
investigations should ideally be carried out both in preclinical and clinical studies.  
 
Faecal microbiota transplantation and WP supplementation 
Another way to investigate the relationship between microbiota, metabolic syndrome 
and WP supplementation could be through FMT. FMT consists of the transfer of 
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intestinal microbiota from one individual to another via oral administration of faecal 
material. This technique results in a donor-like microbiome in the GIT of the recipient, 
opening new strategies for the understanding of the host-microbiome relationship 
(Aron-Wisnewsky et al 2019, Lai et al 2018). Previously, it was demonstrated that GF 
mice colonized with an obesity-associated microbiota increased body fat and energy 
harvest compared to mice colonized with lean donor microbiota (Ley et al 2005b, 
Turnbaugh et al 2006a). Thus, we could potentially test the effects of WP 
supplementation in mice that develop metabolic syndrome not induced by HFD but 
through FMT of an obesity-associated microbiota. This can potentially be one strategy 
to study the effect of WPI in metabolic syndrome without using precast HFD.  
In addition, it is possible to further investigate the microbiota’s role in various clinical 
conditions via “humanization” of the rodent microbiota (FMT from human to rodents) 
(Staley et al 2017, Wrzosek et al 2018). This would provide mechanistic insights into 
the relationship between human microbiome and host. In our case, it would be very 
interesting to assess the effect of WP supplementation in rodents with metabolic 
syndrome caused by FMT from obese humans. However, whether FMT from obese 
human donors could cause the development of obesity in a lean rodent recipient 
remains to be elucidated. A study examined FMT from twin pairs of adult females, 
discordant for obesity, into GF mice. GF mice receiving FMT from the obese 
individuals caused a more evident increase in body weight and obesity-associated 
metabolic phenotypes. Co-housing mice with an “obese” microbiota with mice 
containing the lean co-twin’s microbiota prevented the development of increased body 
mass and obesity-associated metabolic phenotypes (Ridaura et al 2013). In a recent 
study, it was shown that FMT from human obese donors did not cause the development 
of obesity in the lean rodent recipient (Rodriguez et al 2019). Thus, it seems that FMT 
from obese subjects performed into mice reproduces the metabolic syndrome defects 
only in a GF condition. More studies are needed to elucidate this aspect.  
 
Germ-free models 
In this thesis, we studied the relationship between WPI supplementation and gut 
microbiota by depleting the gut microbiota using an ABX cocktail. This method is 
rapid, inexpensive, and rapidly accessible; however, the degree of depletion depends 
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on which antibiotic is employed. Thus, only specific taxa will be eliminated by specific 
antibiotics. Even treatments with ABX cocktails do not completely clear the entire gut 
microbiota. In addition, the systemic side effects of a chronic antibiotic treatment must 
be taken into account (Kennedy et al 2018).  
As an alternative, GF rodents can be used to study the host-microbiota relationship 
(Williams 2014). These rodents are generated via aseptic caesarean section (C-section) 
and are not exposed to microorganisms from birth and throughout the lifespan. GF 
mice differ with respect to development and physiology, relative to animals with 
commensal bacteria; for example, they are characterized by a lower body weight and 
have impaired intestinal function and immune system (Belkaid & Hand 2014, 
Jeppsson et al 1983, Savage et al 1981). Moreover, their metabolism is altered as well 
as their hormone signaling regulation (Kawase et al 2017, Weger et al 2019) 
GF mice can be a useful tool to confirm/further investigate the host-microbiota 
crosstalk upon WP supplementation. A limitation of GF mice is that they do not 
develop obesity upon HFD consumption. 
 
Additionally, gnotobiotic mice can be useful in the study of WP influence on specific 
gut microbiota taxa (Gordon & Pesti 1971). These mice are initially GF and are 
subsequently colonized with a few specific strains of bacteria of interest. For example, 
in our case, we could select specific strains belonging to Lactobacillus, 
Bifidobacterium or Allobaculum, since they were the genera that increased relative 
abundance following consumption of WP or WP components. In this way, it would be 
possible to investigate the communication between specific members of the gut 
microbiota and the host physiology, linked with nutrition.  
 
5.4.3 Other preclinical interventions 
Preclinical genetic models 
In this thesis, we have shown that WP possibly exerts its effect on body weight through 
the regulation of adipose tissue metabolism, in the presence of HFD. However, the 
precise molecular mechanism and all the specific enzymes involved remain to be 
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elucidated. As described in paragraph 5.2.1, WPI can influence the expression of 
several genes coding for enzymes or transporters involved in different pathways that 
characterize adipose tissue metabolism: lipolysis (such as Adrb3 and Hsl), fatty acids 
β-oxidation (such as Cpt1a and Ucp2) and lipid biogenesis (such as Lpl). 
First, the analysis of the protein production profile of these components is necessary 
to verify if WPI acts on the gene expression level and on protein production, or both. 
This can be done by performing Western blots or, to have a wider picture, through a 
proteomic analysis (Gulcicek et al 2005, Mahmood & Yang 2012). 
Second, to get further insight on the specific mechanism of action of WPI on adipose 
tissue metabolism, conditional mouse models can be employed. In conditional mice it 
is possible to perform a knockout or an inactivation of a specific gene of interest in a 
specific tissue. The knockout or the inactivation of a gene can be performed anytime, 
based on the study design and adopting different techniques (Bockamp et al 2008). In 
general, a transgenic DNA construct, equipped with all the elements necessary for 
gene expression, is inserted into a pronucleus or embryonic stem cells (which are 
subsequently injected into the blastocysts). Then, the inserted construct (present in 
every cell of the organism) will be activated in a selected way and during a selected 
time (Haruyama et al 2009). Recently, another technique has been developed, called 
“clustered regularly interspaced short palindromic repeats-Cas9” (CRISPR-Cas9), 
which has several advantages, such as reduced mutational experimentation, reduced 
cost and the ability to generate a homozygous mutant in the founder generation. The 
sensitivity of this system also allows researchers to investigate subtle genetic factors 
such as point mutations, and gene clusters, as well as allowing the specific targeting 
of the genomes rather than just total gene deletion or up-regulation (Hsu et al 2014, 
Young et al 2015). 
Conventional gene targeting strategies have been successfully applied to animal 
models for the study of lipid metabolism, lipid disorders and adipose tissue biology. 
For example, mouse models of conditional CD36, TNFα, UCP1, PPARγ, PGC-1β, 
APOE, SCAP (i.e., escort protein of SREBP) and many others, have been developed 
to study important pathways linked to atherosclerosis, lipid transport and 




Generating and using conditional transgenic mice for genes that might be important 
during WPI consumption could be a good strategy to precisely define mechanism of 
action of WPI within the host. Thus, the effect of WPI on inflammation and on 
intestinal physiology can be studied through this approach. 
 
Sex differences 
In healthy mice (of different strains) there are sex-dependent physiological 
differences. Indeed, it was shown that males and females have different regulation of 
energy metabolism and physiological parameters, such as body weight and leptin 
production, from weaning (Wang et al 2011). These sex differences are also 
accompanied by strain- and sex-specific differences in the gut microbiota and in the 
immune system (Baars et al 2018, Elderman et al 2018). In this thesis, we carried out 
all studies in male mice, and thus it would be necessary to validate/compare our 
findings in females. 
 
5.4.4 Human-targeted interventions 
Whey protein and anti-obesity drugs, drugs that induce weight gain and bariatric 
surgery 
Different drugs to control satiety-related hormones are available as a help for obese 
individuals. These drugs act on food intake and energy expenditure regulation. A few 
examples include: 
- Liraglutide: GLP-1 analogue that acts as GLP-1 receptor agonist (Mehta et al 
2017). 
- Natrexon/Bupropion: a combination between an opioid antagonist (Natrexon), 
that acts in the hypothalamic melanocortin, and an inhibitor of catecholamines 
uptake, that reduces dopaminergic tone and stimulates POMC neurons within 
the hypothalamus (Billes et al 2014).  
- Orlistat: inhibitor of pancreatic lipases (Drew et al 2007). 
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- Pioglitazone: activator of PPARs. It improves glycemic control and 
adiponectin production. In addition, it causes redistribution of lipid storage and 
a decrease in inflammation of the adipose tissue (Smith 2001). 
However, none of these drugs alone can cure obesity. Moreover, they are accompanied 
by collateral effects such as GIT disturbances and chronic usage of some of these drugs 
can lead to a “drug-resistance”, which can lead to weight re-gain. 
In light of WP potentialities described in this thesis, WP could be administered as a 
coadjutant of anti-obesity drugs. This may cause an additive effect of drug and WP 
that could potentially increase the beneficial effects on the individuals, especially if 
coupled with exercise and calorie restriction.  
 
Similarly, WP administration can be beneficial for patients that undergo bariatric 
surgery. Currently, bariatric surgery is the only long-term solution for obesity because 
of its action on body fat as well as metabolic changes. However, bariatric surgery can 
lead to malabsorption and/or gastric acid reduction that can cause nutrient deficiency. 
This can lead to further complications in the long-term (Cornejo-Pareja et al 2019). In 
addition, bariatric surgery can cause severe muscle loss (Davidson et al 2018). Thus, 
WP consumption can be tested as an approach to maintain lower body weight and 
further improve metabolic-related conditions, as well as to help prevent muscle loss in 
patients that underwent bariatric surgery. In support of this hypothesis, WP 
supplementation caused increased body weight loss in women with long-term weight 
regain following bariatric surgery (Lopes Gomes et al 2017). 
 
Moreover, different drugs may induce weight gain as a collateral effect. A few 
examples of these drugs are (Verhaegen & Van Gaal 2000, Wharton et al 2018): 
- Drugs for diabetes (i.e., thiazolidinediones and sulfonylureas); 
- Antipsychotic drugs (i.e., haloperidol, clozapine, risperidone, olanzapine, and 
lithium); 
- Antidepressant drugs (i.e., amitriptyline, imipramine, paroxetine, and 
sertraline); 
- Epilepsy drugs (i.e., valproate, carbamazepine, and gabapentin); 
- Corticosteroids drugs (i.e., prednisone); 
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- Antihypertensive drugs (i.e., metoprolol, propranolol). 
WP, consumed before or during administration of these drugs, might have a 
positive effect in preventing or ameliorating weight gain and, thus, reducing the 
side effects of the drugs. 
Whey protein, exercise and obesity 
As previously mentioned, the anti-obesity effects of WP are variable in different 
human studies (see paragraph 5.2). A possible way to improve the WP effect in obese 
individuals would be to couple WP consumption with exercise. It has been shown that 
physical activity exerts a large list of beneficial effects on health, such as decreased 
adiposity, improved cardiorespiratory function, improved metabolism and improved 
mental health (Vina et al 2012). In addition, both exercise and WP consumption 
promote muscle health and exercise performance, and decreased inflammation 
(Davies et al 2018, Ertek & Cicero 2012, Warburton et al 2006). Thus, the combined 
action of WP consumption and exercise might offer an efficient long-term solution for 
obesity. 
Whey protein and the microbiota-gut-brain axis 
WP consumption has been shown to have a beneficial effect on mental health, 
particularly on anxiety, stress, cognition and sleep (see paragraph 1.6.5). However, 
whether the WP effect on mood and behavior is linked with changes within the gut 
microbiome is still to be elucidated. Thus, clinical studies looking at the effect of WP 
on mental health and microbiota are now warranted. These examinations could be 
carried out in healthy people as well as in obese people (for whom mental health is 




5.5 Overall conclusions 
 
This thesis presents data showing that bovine whey protein (WPI) and its components 
modulate energy balance, adiposity, metabolism, intestinal physiology and the 
compositon of the gut microbiota. Therefore, we have demonstrated that this dietary 
milk protein source can reduce weight gain and adiposity, which have implications for 
ameliorating several disturbances linked with HFD-induced obesity in preclinical 
models. 
Initally, we have shown that the WP component LAB modulates energy balance 
partially through regulation of the gene expression of some important nutrient 
tranporters within the small intestine. Moreover, LAB presence within HFD promotes 
the growth of specific members of the gut microbial population, such as Lactobacillus 
and Bifidobacterium. 
Subsequently, we focused on the effect of whole WP (WPI) as part of HFD given at 
different ages and with different durations of the dietary intervention. We showed that 
WPI exerts several beneficial effects on HFD-induced body weight gain, leptin 
availability, adiposity and adipose tissue metabolism, gut health and inflammation. 
WPI impacts on gut microbiota diversity and composition, (in particular on 
Lactobacillus and Allobaculum taxa). Importantly, we demonstrated that WPI’s 
positive effects on gut permeability and systemic inflammation seems to be mediated 
by the gut microbiota. However, more investigation on the relationship between 
obesity, WP and gut microbiota are needed to reveal the precise mechanisms that 
underlie the WP anti-obesity effects.  
 
This thesis represents an appropriate starting point for a deeper investigation of the 
beneficial effects of consumption of specific macronutrients in individuals affected by 
metabolic syndrome and more research on the implications for clinical practice is now 
warranted. Importantly, WP is an attractive addition to obesity treatment as it is a 
natural dietary supplement, which would facilitate compliance with its administration. 
Overall, the work presented here may help to focus future studies exploring the weight 
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